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In gene expression, the GACKIX motif interacts with multiple activators to 
regulate diverse physiological processes including cellular growth, hematopoiesis, 
synaptic plasticity, and lipid homeostasis; thus, dysregulation of these complexes 
is also linked to many diseases from leukemia to Alzheimer’s disease. Chemical 
tools are sought to understand the individual roles of activator-GACKIX 
complexes in transcription. However, the confounding problem has been finding 
small molecules that are selective in their interactions towards GACKIX because 
this small motif is found in multiple eukaryotic coactivators including CBP, its 
homolog p300 and the mediator subunit, MED15. In this dissertation, the site-
directed strategy known as Tethering is applied to develop selective small 
molecule probes that target the KIX domain of one coactivator such as CBP versus 
p300.  
Tethering readily detects fragments with an intrinsic affinity for the target 
by amplifying the strength of these interactions via the formation of a covalent 
disulfide bond between a disulfide fragment and a cysteine-containing KIX target. 
Traditional liquid-chromatography mass spectrometry applied to Tethering 
xx 
 
screens ranked fragments by their ability to bind to the cysteine-containing KIX 
target. We developed a novel fluorescence polarization screen that streamlined the 
identification of small molecules inhibitors directed at the c-Myb and CREB- 
binding site of CBP KIX. More importantly, the FP Tethering screen has the 
potential to increase the applicability of Tethering to other important biological 
targets that would benefit from this approach.  
Tethering identified fragments that impacted the assembly or disassembly 
of activator binding partners with KIX. For example, KIX N627C tethered to 1-10 
disrupted MLL binding and enhanced the binding affinity of KIX for pKID by 2-
fold. By using mutants and tethered KIX complexes in transient state stopped-flow 
experiments, we showed that the stabilization of the ternary complex contributed 
to the positive cooperativity. In cells, 1-10 could be a useful probe to study the KIX 
interactions on CREB(pKID)-responsive genes because the 1-10-KIX N627C 
complex allosterically prolongs this interaction. The 1-10 disulfide was converted 
into a series of irreversible analogs that are compatible with the reducing 
environment in cells. This irreversible Tethering strategy demonstrated how 
fragments such as 1-10 selectivity have the potential to selectively target an 
engineered cysteine-containing KIX mutant of CBP in cellulo.  
In conclusion, I built upon the Tethering strategy to selectively target 
dynamic activator-GACKIX complexes with small molecules; these fragments 
along with other biochemical techniques demonstrated how KIX regulates its 




Chapter 1 Transcription is regulated by elaborate choreography between 
activators and coactivators.  
 
1.1 Introduction 
Transient, low affinity protein-protein interactions (PPIs) are primed for 
regulating biological processes by rapidly switching partners and engaging 
different pathways in response to environmental cues. Transcription is a process 
that depends heavily upon dynamic PPIs between activator and coactivators for 
proper gene expression. For instance, the KIX domain of the coactivators CBP and 
its homolog p300 recognizes over a dozen activators to regulate diverse 
physiological processes from development to cognitive function. Activators 
induce conformational changes within KIX that impact the functional binding at 
two intrinsic binding surfaces. This introductory chapter describes how 
activator∙coactivator KIX domain complexes regulate transcription and discusses 
approaches and challenges to understand their interactions and functions.  
1.2 What is transcription? 
Transcription is the first step to produce a protein and so it is essential for 
life. The definition of transcription is quite simple – the process by which DNA is 
converted into RNA.1 A transcription reaction in a test tube proceeds by incubating 
a DNA template, the appropriate nucleotide triphosphates, and a RNA 
polymerase enzyme if a simple, single polypeptide such as the bacteriophage T7 




and specificity for its own 23-base-pair (bp) promoter to initiate transcription 
(Figure 1-1A).2-4 
In cells transcription becomes far more complex. Cells have diverse sets of 
genes encoding proteins for opposing processes such as cellular growth and 
apoptosis, so specialized transcriptional networks restrict RNA polymerase to 
given genes in a spatial and temporal manner.5 Even simple, unicellular 
prokaryotes such as bacteria regulate transcription through subunits known as 
sigma factors (σ).6,7 These factors recognize distinct sets of promoter sequences to 
direct the formation of the multi-subunit RNA polymerase.1 Transcription 
proceeds once the four catalytic subunits of the RNA polymerase and the single 
regulatory σ factor assemble at a given promoter (Figure 1-1B).8 
In higher eukaryotes, such as humans, transcription is highly regulated 
through the organization of the genome and intricate protein networks. The 
human genome contains approximately three billion base pairs of DNA so stuffing 
almost two meters of DNA into the nucleus requires finesse.9,10 Therefore, 146 base 
pairs of DNA wrap around a core of histone octamers to form chromatin and the 
repeating chromatin units form nucleosomes.11,12 They condense further into 
euchromatin to produce transcriptionally inactive regions.13 Histone tails contain 
multiple post translational modification site (PTM) for phosphorylation, 
methylation, acetylation, ubiquitination and other chemical changes.14,15 These 
modifications act as a “histone code” to regulate the accessibility of DNA and 




transfer an acetyl group to lysine residues on histone tails which neutralize the 
positively-charged ɛ-amino group of lysine and weakens the histone-DNA 
interaction.20,21 These regions are indicative of transcriptional activity and vary 
across cell types.18 
At accessible core promoters, transcription initiation requires the 
preinitiation complex (PIC) including RNA polymerase II (PolII), and the general 
transcription factors (TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH).22-24 Initiation 
is the highly controlled, rate-limiting step for gene expression because PolII 
Figure 1-1 The activation of transcription is either simple or complex  (A) In a test tube purified 
bacteriophage T7 RNA polymerase recognizes its promoter on a DNA template and catalyzes the 
synthesis of complementary RNA. PDB ID: 1CEZ  (B) A model of how bacteria initiate transcription 
is shown with the assembly of sigma factor (blue), and RNA polymerase subunits (yellow). PDB 
ID: 4XLP  (C) In multicellular organisms such as humans, DNA is compacted into nucleosomes 
(grey) and chromatin remodeling complexes modify these regions. To activate transcription TF 
(red) bind to DNA and recruit coactivators (blue). The coactivators recruit the PolII machinery 




diffuses on and off the promoter resulting in pulses of mRNA production.25 Site-
specific transcription factors (TF) or activators promote active transcription by 
stabilizing the PIC at specific promoters.26,27 They bind to consensus sequences 
using a DNA-binding domain (DBD).28 However, TF don’t coordinate the 
assembly and stabilization of the PIC alone.26 They lure in coactivator(s) through 
a flexible or intrinsically disordered recognition motif known as the transcriptional 
activation domain (TAD) (Figure 1-1C).29-31 
1.3 Coactivator play pivotal roles in mediating transcription   
Coactivators link the requests of activators to the transcriptional machinery 
and they function as large dynamic and modular complexes.32,33 Some coactivators 
complexes associate as exchangeable subunits.34,35 Others connect multiple 
domains through flexible, intrinsically disordered linkers which permit them to 
independently interact with diverse TF.36,37 The individual interactions contribute 
to the overall function of the larger coactivator complex. Coactivators such as CBP 
and its homolog p300 coordinate interactions with over four hundred TFs.38,39 
These interactions are mediated through the five domains; nuclear coactivator 
binding domain (NCBD) or interferon-binding domain (IBid),40,41 CH1 (TAZ1),42,43 
CH2 (Bromo, PHD),44-46 CH3 (ZZ and TAZ2),47 and KIX (Figure 1-2).48 These master 
coactivators also contain a HAT domain which modifies both nucleosomes and 
other transcriptional regulators including itself.49-51 The CBP and p300 HAT 
domain autoregulatory loop competes with the substrate-binding site which 
requires hyperacetylation and structural changes to fully activate the HAT 
domain.51 Structural changes imparted by the loop contribute to active 
transcription because it causes CBP or p300 to dissociate from the Mediator 




promoter.52,53 The HAT domain regulates TF activity by altering protein or DNA 
interactions.54 With the KIX-related TFs, c-Myb and CREB acetylation within their 
TADs enhances their transactivation potential by increasing their affinity for 
CBP.55,56 In the case of TFs such as p53 and SREBP1a, acetylation prevents 
ubiquitination and subsequent degradation. 
CBP and its homolog p300 are pivotal for many cellular processes and 
consistent with their importance, the knock-out of CBP or p300 in mice is lethal.57-
59 They share 61% overall sequence identity and 80-90% homology across 
conserved domains.60 Due to their similarities CBP and p300 functions overlap 
acting as a buffer to make genetic networks more robust to cellular changes.61,62 
They also maintain distinct tissue-specific and cell-specific processes.63 From 
transfection-based cellular assays, most DNA-bound TFs stimulate transcription 
in the presence of either CBP or p300.63 Therefore, their divergent functions 
depend on specific cellular contexts such as temporal-spatial regulators, or 
Figure 1-2 The architecture of CBP/p300  The schematic shows the arrangements of the CBP and 





The core transcriptional players such as PolII and coactivator subunits are 
highly conserved across metazoans.66,67 This shows how accurate control over gene 
expression is vital for physiological processes.68 To control these processes a highly 
versatile motif diverges into different co-regulators and contributes to other 
transcriptional events. This can be seen with the GACKIX motif.  
1.4 What constitutes a KIX domain? 
The GACKIX motif is found in mammals, yeast, plants, arthropods, and 
nematodes and it can tightly and efficiently regulate PPIs.69 In the plant Arabidopsis 
thaliana, KIX domain proteins repress development and cell division through 
interactions with PEAPOD proteins and the RNA polymerase subunit B2.70 
Reduced expression of KIX8 and KIX9 genes results in higher crop yield due to 
increased leaf growth.71,72 In the fungi Saccharomyces cerevisiae and Candida species, 
the MED15/Gal11 subunit in the tail module of the Mediator complex contains a 
GACKIX motif that interacts with the pleiotropic drug resistance TF (Pdr1) to 
express genes in response to xenobiotics.73 The genes encode membrane-spanning 
efflux pumps to expel toxins. The pathogenic fungi Candida glabrata resists 
antibiotics such as azoles through constitutive Pdr1 activity.73 MED15/Gal11 KIX 
also participates in fatty acid metabolism. The TF Oaf1 recognizes fatty acids such 
as oleic acid, myristic acid, and lauric acid, which promotes its interaction with the 
MED15/Gal11 KIX domain to turn on fatty acid β-oxidation and peroxisomal 
genes.74  
In humans, the GACKIX motif is found in at least four transcriptional 
regulators (Figure 1-3A).75 The KIX domain of CBP (residues 586-672) and p300 




of TF through two intrinsic binding sites. These interactions regulate diverse 
processes which deserve a more in-depth discussion in section 1.6. The 
ARC105/MED15 KIX domain is similar to the yeast MED15/Gal11 domain and it 
also regulates metabolic responses.60,69 Finally, a domain within the human RecQ 
protein-like 5 (RecQL5) minimally resembles the other GACKIX motifs yet 
functions similarly to the Arabidopsis KIX8 and KIX9 domains - it interacts with 
PolII to repress transcription during DNA damage response.  
In terms of structure the GACKIX motif is small consisting of about 75 to 90 
amino acids, and it is modestly stable (the free energy of unfolding, ΔG0 of 3.5 – 
4.1 kcal∙mol-1 for CBP KIX) at physiological pH.76 The KIX domain of CBP is 
composed of three α-helices (α1 597-611; α2 623-640; α3 646-669) with an amino-
terminal 310 helix (G1 591-594). The carboxyl-terminus of α1 connects by a loop (L12) 
to a second 310 helix (G2 617-621). Core structural residues are highly conserved 
including W591, Y649 and the π-cation interaction between Y640 and R600 (Figure 
Figure 1-3 Comparison of GACKIX motifs  A) The amino acid sequences are aligned using Crustal 
Omega (EMBL-EBI) and then compared to the structure of CBP KIX with ESPript. B) In the box,
the conserved core residues are shown on CBP KIX with the orange spheres as Y649 and W591 and 
the red spheres for W640 and R600. To the right the full CBP KIX domain is shown as a grey-colored 
cartoon with its respective helices marked. Other available structures for GACKIX motifs share 
some of these core residues which are shown on the cartoon structures as spheres. PDB IDs: 2LXT 




1-3B).69 In the case of CBP, R600 is methylated by the coactivator-associated 
arginine methyltransferase 1 (CARM1) displacing activator∙KIX interactions.77,78 
R600 does not directly interact with activators so the methylation likely disrupts 
the structural integrity of the three-helix bundle.79 KIX adopts a molten globule 
state in vitro when this arginine is mutated to methionine.  
By altering certain residues, the GACKIX motif adjusts its binding partner 
preferences (Figure 1-4).80 ARC105/MED15 KIX binds specifically to the sterol 
response element binding proteins, SREBP1a and SREBP2 which activates genes 
required for fatty acid, triglyceride, and cholesterol biosynthesis.81-83 Within CBP 
KIX Y658 and K662 promote interactions between pKID and c-Myb, but the 
MED15 KIX domain lacks these residues rendering it unable to bind to them.81 The 
double mutant I64Y and D68K MED15 KIX can bind to c-Myb and pKID.81 
Figure 1-4 Distinct residue differences between GACKIX motifs  The cartoon schematic shows 
the structural alignment for the NMR solution structure of CBP KIX in complex with pKID against 
the ARC105/MED15 KIX domain. Within the box the residues shown as sticks are important for 
the pKID interaction with KIX. By mutating these residues within ARC105/MED15 KIX it regains 
some ability to bind to pKID. PDB ID: 2GUT represents the NMR solution structure for human 
ARC105/MED15 KIX. PDB ID: 1KDX represent the NMR solution structure for mouse CBP KIX in 




Therefore, MED15 KIX with similar structural and functional characteristics as 
CBP or p300 KIX adopts limited, but specific binding partners. The binding profile 
of these coactivator domains may confer important transcriptional functions since 
CBP and p300 KIX also interact with SREBPs.84,85  
The challenge is to understand how CBP KIX recognizes a broad range of 
activators with disparate sequences to control gene expression. KIX consists of two 
defined binding sites often referred to as the “MLL site” and “pKID/c-Myb site” 
from the prominent activators that bind to the respective sites. Insights into their 
biological functions comes from first understanding their molecular and 
biophysical characteristics. 
1.5 How do different TADs interact with the KIX domain of CBP? 
The KIX binding partners share a distinct feature – their interacting regions 
contain various degrees of intrinsically disordered regions (IDRs) with minimal 
sequence similarities (Figure 1-5).  
These TADs lack hydrophobic cores that would drive them into 
independently, stable structures. They are enriched in disorder-promoting (A, G, 
S, Q, P) and charged residues (D, E, K, R).86-89 In other words, IDRs are minimalists 
as well as manipulators. They exploit the folding process to direct the function of 
Figure 1-5 Alignment of TADs that interact with the KIX domain of CBP/p300  These KIX 
recognition sequences contain minimal similarities but conform to a generic motif of ɸ-X-X-ɸ-ɸ




their binding partner(s) as they adopt structures against any partner that contains 
complementary chemical and steric properties.  
Their recognition motifs make them highly selective in a complex cellular 
environment, yet they act as versatile regulators in a process known as 
“moonlighting”. This provides complexity to physiological processes.90 They 
regulate diverse functions depending upon the combinations of partners directed 
within a hub such as CBP or p300.28 
The IDR of TF rely upon their highly versatile binding schemes; these raise 
the nagging question of what advantages disorder provides to biological function? 
Of course, IDRs have fewer steric and orientation restraints than globular proteins 
so they adapt to extended and complex binding surfaces. However, the biological 
advantage of IDRs is more complex and likely varies with each PPI and its 
concomitant binding affinity and specificity. The TADs of CREB (pKID) and c-
Myb utilize a similar binding site around the α1 and α3 helices of KIX, yet their 
recognition of KIX occurs through distinct binding modes possibly reflecting their 
functions (Figure 1-6A). The phosphorylation of CREB (pKID) at the serine residue 
133 promotes its interaction by 20-fold over the unmodified form. KIX also 
preferentially binds to pKID over c-Myb by approximately 7-fold.91 The 
magnitude of gene expression correlates to the strength of activator-coactivator 
complexes and this case it discriminates between inducible (CREB-dependent) and 
constitutive (Myb-dependent) gene expression. 
The debate continues for what allows these IDRs to achieve functional 
binding affinity and specificity. Initially, they recognize partners by coupled 
folding and binding mechanisms. With an induced fit process, specific structural 
changes occur within the IDR that distinguish it from the bound versus the 




the disorder-to-order transition. This requires an initial favorable interaction 
between the IDR and its partner before it commits to the complex. The pKID TAD 
follows this process to form two α-helices around KIX.92 The pKID∙KIX complex 
initially forms weak hydrophobic contacts in a diffusional encounter complex 
followed by a folding intermediate where the αB of pKID remains partially 
unfolded (Figure 1-6B).93,94 Then the pKID∙ KIX complex stabilizes through 
complementary electrostatic and hydrophobic contacts in an enthalpy driven 
process.95,96 
Along with the coupled folding-after-binding process, the “fly casting” 
hypothesis purposes that the IDR flex out into a larger radius so they can rapidly 
initiate interactions by capturing their partners through complementary residues 
Figure 1-6 Schematic for the interactions of pKID and c-Myb with KIX  (A) The TADs pKID (blue 
with purple sphere for the phosphorylated serine) and c-Myb (green) share an overlapping site 
within KIX (grey surface structure) (B) pKID is significantly disordered in solution and binds to 
KIX through an encounter complex intermediate before fully folding into two helices to form a 
stable complex with KIX. (C) c-Myb is largely disordered, but rapidly forms partial helical 
structures in solution. c-Myb binds to KIX through both a conformational selection and induced fit 




on their flexible “fly lure”; the recognition motif within the IDR.97 Coarse-grained 
molecular dynamics simulation using the pKID-KIX interaction shows that 
association rate constants (kon) gradually increases with increasing disorder. The 
“fly casting” scheme is predicted to provide only 1.6-fold enhancement in the 
association rate97 because the complex depends on its interaction strength at the 
binding site. As the disorder increases the intermolecular interactions must 
compensate for the entropy cost from the folding process. With too much disorder 
the intermolecular interactions cannot overcome the folding cost. Therefore, a 
good quality fly lure adds to a complex’s affinity by not only decreasing the 
association rate, but by enhancing the dissociation rate to an extent.98  
Electrostatic “steering” can contribute significantly to kon and allows rates 
to exceed 107 M-1∙s-1.99 These interactions are important for the formation of 
activators and coactivator domain complexes. The basal association rate constant 
measured at infinite salt concentration shows how an IDR produces a productive 
complex depending only upon diffusion and collisions between proteins. For KIX 
its partners reach basal association rate constants up to 105 – 106 M-1∙s-1 following 
diffusion-limited processes.93,100-102 
With conformational selection, an IDR freely acquires bound-like structures 
which stabilize it upon colliding into its partner. The residual structures reduce 
the entropic cost. The complex formation depends on the concentration of the high 
energy bound-like conformer and conformational selection should accelerate the 
association, kon. However, an increase in kon concretely correlates to a reduction in 
the free energy of the rate-limiting transition state, not necessarily due to a pre-
formed conformer. Folding intermediates may increase kon as the complex 
proceeds to stabilize helical, bound-like states. Additional structural evidence is 




kon through a conformational selection process.  
An IDR may follow both mechanisms as seen with the c-Myb∙KIX 
interaction which depends upon both favorable enthalpy and entropy.96 The c-
Myb32 (residues 284-315) tends to form an overall 80% helical ensemble freely in 
solution. However, c-Myb has disproportionate regions of helicity. The amino 
terminal from residues 290-301 populates an estimated 70% helicity while the 
propensity for spontaneous helix formation for the carboxyl-terminal region (302-
310) is significantly smaller (~20%).100 While c-Myb binds extremely fast 
proceeding through a two-step mechanism without observable intermediates, the 
disorder-to-ordered transitions for c-Myb23mer are faster along the estimated 
helix-coil transitions nanosecond time range.103 Therefore, the helical ensembles 
transition more quickly than the rate at which c-Myb binds to KIX.100 Due to the 
large helical propensity for the amino-terminal segment, c-Myb likely binds to KIX 
through a conformational selection model with fast pre-equilibrium while the 
carboxyl terminal proceeds through an induced fit process (Figure 1-6C). Isolating 
the amino-terminal region of c-Myb shows that increasing its helicity correlates 
directly to an increase in kon.100  
Conflicting evidence argues for a purely induced-fit model.104 For instance, 
chemically stabilizing the helicity of a shorter c-Myb construct with 1,1,1-tri-
fluoro-ethanol (TFE) lowers koff and has no significant effect on the overall kon.105 
The additional electrostatic forces within the longer c-Myb construct may also 
contribute to the accelerated kon rate because the basal association rate constants 




(Figure 1-7).104,106 This represents how subtle changes within TF and other 
environmental conditions must be considered when comparing these complexes. 
General models remain consistent that c-Myb associates very quickly with KIX 
driven by the L302 that orients within a hydrophobic interface within KIX. 
Meanwhile the binding mechanism requires additional investigations to hash out 
this complex both in vitro and then in cellulo. 
The MLL TAD binds to KIX at a different site formed by the G2, α1 and α3 
helices. MLL (residues 2844-2857) is only 13% helical in solution by circular 
dichroism (CD), and it forms a helical structure with 15 residues in a complex with 
KIX.107 MLL induces a network of residues from the L12-G2- α3 interface to 
reposition the G2 helix and these structural changes promote energetically 
favorable hydrophobic contacts between KIX and MLL. Most notably F612 
contacts MLL while other critical residues such as L628, Y631, L664 (to a minor 
extent I611, and I660) are also important for binding MLL (Figure 1-8).108 As 
discussed with the c-Myb TADs, MLL constructs and changes in experimental 
design alter this complex. A shorter MLL construct lacking three negative charges 
outside of the helical region accelerates rather than decelerates with increasing salt 
concentration.109 It’s likely that the salt acts as a stabilizer for electrostatic charges 
near the MLL∙KIX complex.109 The longer MLL construct follows the general trend 
that the additional negative charges in MLL accelerate its association with 
Figure 1-7 Sequences for different c-Myb constructs  Different KIX constructs have been used in
studying its binding to KIX. One main difference in these constructs is that the amino terminal of 
KIX tends to form helical structures freely in solution. The leucine residue at 302 written in yellow 





Other activators utilize the same site as MLL with distinctive binding 
affinities and binding modes (Table 1-1). For instance, in differentiation and 
apoptosis a phosphorylated region of c-Jun (residues 47-89) is shown to contact 
KIX with moderate affinity.110 Another TF E2A principally recruits CBP or p300 
through the KIX domain. The first activation domain (TAD1) of E2A (10-26) is 1 to 
2% helical yet binds very quickly to KIX in an induced-fit process.106 E2A contains 
another TAD2(294-407) that binds weakly to the same region within KIX. Another 
partner from a chromosomal translocation fuses the CREB-regulated 
transcriptional coactivator (CRCT1) to mastermind-like 2 (MAML2) coactivator 
and the product CRCT1-MAML2 TAD (150-190) directs the recruitment of CBP or  
p300 through KIX. CRCT1-MAML2 joins the activator club (c-Myb, pKID, MLL) 
Figure 1-8 Cartoon representations of the KIX-MLL complex  KIX is shown in grey and 
MLL is in red. The important residues that make-up the MLL-binding site within KIX are 




who contact the other site of KIX with low affinity (KDs greater than 100 μM).111  
 The human T-cell leukemia virus type 1 (HTVL-1) viral TF, Tax is 
intrinsically disordered with two possible helical regions (residues 60-71 and 83-
89) that can contact the MLL-binding site of KIX.118 Another viral TF, HTVL-1 basic 
leucine zipper factor (HBZ) utilizes the VDGLL (residues 24-28) and LDGLL 
(residues 44-48) motifs to bind with high affinity to KIX.119 27 These viral TFs may 
prefer the MLL-binding site, perhaps, because of its chemical and steric features 
that permit higher affinity interactions. This site also appears more “druggable” 
by its contacts with small molecule partners than the pKID-binding site as 
discussed in section 1.9. However, the endogenous TF∙KIX relationship remains 
under investigation – especially for how they utilize this site.  
1.6 KIX masters intermolecular and intramolecular communication.  
Although the flexibility of IDRs governs its interactions and functions - these 
also depend upon the dynamics of their binding partners. For instance, 
TAD KD (μM) Method used 
MLL19 (2844-2854) 2.8 ± 0.4  ITC112 
MLL (2842–2869) 2.1 ± 0.1  ITC113 
pJun (47-89) 30  NMR titration: 31P chemical shifts110 
E2A-PCET (10-26)  12 ± 2  FP114 
E2A TAD1 (11-24) 5.2 ± 0.9 FP115 
E2A TAD2 (394-420) 21 ± 3 FP115 
CRCT1-MAML2 (150-190) 20 ± 5  ITC116 
HBZ (1-77) 2.3 ± 0.2 Calculated from stopped-flow, KD = koff/kon106 
Tat (1-24) 11 ± 1 NMR chemical shift titrations117 
Table 1-1 Comparing KDs for the TADs at the MLL-binding site  The reported dissociation 
constants (KDs) are shown for different TADs that are known to bind within the MLL-binding 
site of KIX. The KDs were measured as indicated with isothermal calorimetry (ITC), nuclear 
magnetic resonance spectroscopy (NMR), fluorescence polarization (FP) or calculated from 




conformational changes within KIX dramatically alter binding partner preferences 
at the second site leading to downstream effects in the transcriptional outcome.120 
This is shown by the binary KIX∙MLL complex enhancing the affinity of pKID or 
c-Myb at the other site by 1.5 to 2-fold and vice versa. This process known as 
allostery occurs when a ligand at one site affects the function of another site 
through long-range, indirect changes. The cooperative effect offers another level 
of control to regulate PPIs.121 
Allostery occurs through different mechanisms involving structural, 
thermodynamic and dynamic changes. In a purely dynamic process a ligand 
rigidifies its partner and limits its thermal fluctuations.122,123 Entropy drives the 
binding of the second ligand and a slight stiffening or limiting of motion within a 
protein provides favorable energy of a few kcal∙mol-1.124 When the affinity 
increases for the second ligand then its binding mode changes by either how fast 
it associates or how long it resides with its partner. When the binary complex 
stabilizes the flexible and unfolded regions of the main partner or favorable 
intermolecular contacts become more available, the second ligand may associate 
more quickly increasing kon.99 The ternary complex can prolong the residence time 
of both ligands over the binary complex as shown by decrease in koff. This allosteric 
mechanism appears to contribute to the ternary KIX complexes.  
The allosteric effect with pKID depends on the stabilization of the MLL-KIX 
complex so entropy drives the allosteric effect.112 The cooperativity between c-Myb 
and KIX∙MLL occurs through an unfavorable decrease in entropy and a favorable 
increase in enthalpy. Hydrophobic contacts in the middle and C-terminal regions 
of the third helix contribute to binding while some favorable energy come from 
the KIX∙MLL complex pushing residues E666 and E665 closer to the c-Myb 




interactions.43,108 The c-Myb interaction with MLL∙KIX lowers the koff for the 
MLL∙KIX∙c-Myb complex by a factor of two.109 
KIX contains an allosteric network consisting of hydrophobic amino acids 
which MLL and c-Myb or pKID engage to stabilize flexible regions through the α3 
and the L12-G2 loop of KIX (Figure 1-9).108,125 From relaxation dispersion data for 
backbone amide 15N and 13Cα nuclei the KIX∙MLL complex is shown to exist as a 
disparate ensemble with 7% populating a higher energy conformation that 
displays a higher affinity for either c-Myb or pKID than the major lower energy 
state. The two states maintain an equilibrium. As the higher energy state is 
depleted through the formation of the ternary KIX complex additional higher 
Figure 1-9 KIX contains an allosteric network.  The first schematic shows the transition 
from apo KIX (grey) to binary KIX-MLL(red) and finally the ternary KIX-MLL-pKID(blue) 
complex. When MLL binds then pKID binds with a 2-fold higher affinity at the other site 
and vice versa. As shown in the cartoon KIX is flexible with the largest changes in the loop 
regions. These conformational changes contribute to the cooperativity between the two 




energy complexes form.108 This suggests that conformational selection may 
contribute to the positive cooperativity. However, this contribution remains under 
debate because this favorable bound-like excited state should accelerate kon yet it’s 
change is negligible for c-Myb and pKID with KIX∙MLL using stopped-flow 
transient kinetic analysis.106 This excited state may contribute to dynamic and 
structural allostery in which the MLL∙KIX complex reduces the entropic cost for 
the second ligand by stiffening a favorable ternary conformation to decrease koff 
for the ternary complex. However, this requires additional mechanistic and 
structural insight into the allosteric network.  
1.7 These additional binding partners like to hug KIX  
TFs regulate genes by their spatial and temporal presence. They make 
themselves or cellular signals more robust through factors such as competing with 
other TF for coactivators as well as utilizing alternative interactions to remain 
poised for active gene expression.126 The latter may explain why FOXO3a and p53 
contain tandem TADs that manipulate KIX through both binding sites. The 
FOXO3a construct consisting of the carboxyl-terminal segment of CR2 (CR2C) 
connected to CR3 with the (GGGS)3 linker binds to KIX with two possible 
orientations that occur in equal populations.127 However the binding modes are 
distinct. FOXO3a may appear promiscuous, but if one site within KIX is restricted 
then FOXO3a adopts another orientation to encourage the coactivators to remain 
in the vicinity.  
The tumor suppressor p53 also interacts with KIX with tandem TADs in 
two different orientations to each of the binding sites within KIX.128 These resemble 




KIX. Both regions prefer the MLL-binding site although TAD2 outcompetes TAD1.  
The moderate to low affinity (86 ± 18 μM for CR2C-CR3 FOXO3a and 14-27 
μM for full-length p53) may support that these TF need to rapidly switch on and 
off. For active transcription these TF can further stabilize CBP and p300 because 
FOXO3a interacts with TAZ1(340-439) and TAZ2 (1764-1855) while p53 interacts 
with these domains it also associates with NCBD.126,127,129,130 These genes may 
require regulation from multiple transcriptional regulators such as a cooperative 
effort between themselves since promoters contain multiple FOXO3a recognition 
sites.127 In both cases phosphorylation enhances their transcriptional activity. With 
FOXO3a phosphorylated S626 increases its affinity by 1.5-fold for KIX.130 When the 
p53 TAD(13-57) is phosphorylated at Y18 and S20 then its affinity for KIX increases 
15-fold relative to the unmodified form.128 This demonstrates how KIX reacts to 
phosphorylation states to regulate its interactions.  
1.8 Activators and coactivators are involved in diseases 
Transcription regulates the variety and abundance of protein in cells. 
Differences between normal and disease states come from changes in transcription 
rates, messenger RNA degradation, translation and protein degradation, but 
transcription arguably makes the larger contribution to the biological 
outcomes.131,132 Since TFs drive gene expression, their actions govern downstream 
biological activity.133,134 
As highlighted in the previous two sections, KIX interacts with many 
different TF and these convey diverse functions (Figure 1-10). For instance, E2A 
regulates genes for cellular specification and maturation.135 MLL regulates genes 
for hematopoiesis. Likewise, c-Myb regulates definitive hematopoiesis and it is 




many processes. In response to various cellular cues CREB induces genes required 
for proliferation, survival and differentiation. Some of these depend on the 
interactions between CREB(pKID) and CBP or p300, but CREB utilizes other co-
regulators.  
Parsing these transcriptional pathways are important to understand 
physiological processes and diseases. Cancer represents a diseases-state where 
multiple processes are affected. Transcriptional networks are often hijacked which 
alters the concentrations and PPI networks.140 For instance, the MLL chromosomal 
translocation fuses MLL to CBP to constitutively recruit CBP to MLL-regulated 
genes and constitutively express genes leading to overexpression of myeloid and 
lymphoid markers. E2A forms at least two chromosomal translocations associated 
with acute lymphoblastic leukemia. In one translocation, the E2A DBD is replaced 
with PBX-1.135 E2A-PBX1 expression results in rapid proliferation of immortalized 
myeloid cells. This is also replicated by infecting primary bone marrow cells with 
a retrovirus expression E2A-PBX1 which leads to myeloid progenitors with 
sustained exponential growth. The CRTC-MAML2 translocation product activates 
Figure 1-10 KIX has multiple binding partners. The activators that bind to KIX are associated with 
different biological processes as shown. These activators interact with KIX through at least of the 




both myelocytomatosis oncogene (Myc) and CREB-responsive genes to drive 
tumor formations.116 The Myb proteins contribute to cancer through different 
schemes. In some cases, the c-Myb gene remains unaltered, but it is overexpressed. 
Cancer becomes “addicted” to it because it promotes undifferentiated growth. The 
c-Myb proto-oncogene likely contributes to proto-oncogenic activity because upon 
phosphorylation c-Myb may support normal cells through the G1/S phase in the 
cell cycle.141 The tumor suppressor p53 inhibits cell cycle progression, but c-Myb 
can compete with p53 to bind to KIX. This is one possible route for c-Myb’s 
involvement in leukemia.  
Viral machinery hijack transcriptional regulators to replicate, and diseases 
result because of this viral activity. For instance, the virus HTVL-1 is present 
during the progression of adult T-cell leukemia (ATL). The viral TF Tax contacts 
the MLL-binding site of KIX to alter gene expression in cell cycle regulation and 
apoptosis early-on in HTVL-1 pathogenesis.119 Tax also directly stabilizes the DBD 
of CREB at sites within the HTVL-1 promoter. Although Tax hasn’t been shown to 
engage in the allosteric network Tax needs to directly recruit CBP or p300 in the 
absence of pKID.142 As Tax expression varies, HBZ can continue to disrupt gene 
expression. Due to its high affinity HBZ likely monopolizes the MLL-binding site 
of KIX and enhances the binding of c-Myb and pKID to KIX by 6-fold leading to 
proliferation of leukemia cells. Finally, from the virus HIV-1, Tat also competes 
with TF such as MLL, E2A and c-Jun for the MLL-binding site of KIX through its 
TAD (1-24) with moderate affinity.142. The HIV-1 genome is packaged into 
nucleosomes and requires HAT for its gene expression. Since these viruses utilize 
the MLL-binding site of KIX the other TFs such as MLL, E2A and c-Jun must 




contributing to the leukemogenic states.117  
KIX directly corresponds with adverse phenotypes. This has been 
demonstrated with the triple mutation (Y650A, A654Q, Y658A) that disrupts its 
interactions with c-Myb and pKID. Mice homozygous for these mutations in p300 
have defects in hematopoiesis-related processes involving platelets counts, B cells, 
T cells and red blood cells indicative of altered c-Myb-dependent gene 
regulation.143,144 The analogous triple mutant within CBP produce minimal effects, 
possibly reflecting different expression patterns or preference of p300 over CBP in 
hematopoiesis.143 Another mouse model containing the triple mutant within CBP 
aims to test KIX-dependent pKID and c-Myb interactions on long-term memory. 
From behavioral analyses, the mice show specific impairments in long-term 
memory occurring in the hippocampus, but not in the amygdala.145 This 
demonstrates that regions of the brain have different CREB-dependent 
transcriptional requirements. In the hippocampi, the triple mutant reduces several 
genes (Fosb, Dusp1, Icer, Bdnf4) that depend on the KIX-CREB(pKID) interaction.145 
Rubinstein-Taybi syndrome (RTS) results from a genetic alterations in the CBP 
gene.146 The development disorder is characterized by skeletal and cardiac 
abnormalities as well as mental retardation and occurs in 1 out of 125,000 births.147 
RTS develop from the monoallelic mutation of CBP and the loss of KIX-based 
activity likely contributes to the mental retardation as well as other defects.148,149 
Subtle cellular changes affect the fine-tuned control between TF and 
coactivators yet parsing out the individual players remains challenging. In certain 
transcriptional networks TF contribute to an observable phenotype only under 
certain conditions. Some gene networks are more robust so if one or two players 
are lost the system may function.150 These subtle networks make it challenging to 




transcriptional networks are important for normal functions and even when their 
concentrations are tightly controlled. If TF concentration increases in cellular 
models, then TF may sequester coactivators beyond the DNA activating region. 
This squelching effect depends on the concentration of the activating regions and 
the strength at which the TF engages its target. At the same time, imbalances in 
transcriptional regulators can be subtle or lacking because the transcriptional 
complex assembly provides some degree of buffering.151 There is a need to draw 
out the interactions that are important to specific transcriptional processes.  
1.9 Can small molecules effect and probe KIX∙activator complexes? 
KIX∙activator complexes elicit gene activation in response to various 
stimuli, but the specific transcriptional mechanisms remain elusive. Small 
molecules that target these interactions with high affinity can be useful to 
discriminate their phenotypic consequences from endogenous, lower-affinity 
activators.  
Small molecule development for TF and coactivators requires addressing 
many hurdles including their transient and moderate affinity, promiscuity or 
selectivity, and binding surface structures. In terms of structure, a PPI surface 
spans 1,000 to 2,000 Å2 while small molecules cover an average of 300 to 500 Å2. 
Therefore, small molecules must efficiently engage a region within the PPI surface 
to directly modulate the target interaction.  
Structural characterization of binding interfaces aids in small molecules 
design because the atomic level resolution structure provides specific chemical 
features within a binding site. High resolution X-ray crystal structures require 
diffraction-quality crystals which flexible proteins such as KIX and its endogenous 




KIX as well as CBP KIX complexes come primarily from solution NMR techniques. 
In the case of selectivity, the GACKIX motifs in the master coactivators CBP 
and p300 contain over 90% sequence homology so specifically targeting these 
regions with small molecules is difficult. The discovery of specific small molecule 
modulators of activator-coactivator PPIs is rendered especially challenging by the 
level of redundancy in the protein interaction network.152-155 
Small molecule probes need high affinity to efficiently engage the target 
and to indirectly reduce off-target effects. The KIX∙activator interactions are 
optimized for efficient functional output – not necessarily high-affinity complexes. 
For instance, single mutations within CREB such as Y134F or KIX L607F increases 
their affinity for each other which would possibly switch CREB from an inducible 
to constitutive activator demonstrating the importance of endogenous, 
concomitant affinity.95,156 By using phage display peptides containing eight amino 
acids underwent directed evolution to identify sequences that bind with high 
affinity to KIX. Their affinity remains moderate within 16.1 ± 1.1 μM.157 These 
peptides are short and flanking these sequences may improve the affinity and 
biological potency. Peptidomimetic strategies to modulate PPIs are available, 
however for the promiscuous binding between KIX and its partners their 
applicability for this system remains unexplored.  
On the bright side KIX appears amenable to small molecule intervention. 
The pKID-KIX inhibitor, naphthol-AS-E-phosphate (KG-501) was identified from 
a screen using 1H-15N heteronuclear signal quantum coherence (HSQC) spectra to 
monitor shifts in isotopically 15N-labeled KIX (Figure 1-11).158 Structure-activity 
relationship of KG-501 demonstrated that naphthol-ASE is the most active form in 
cell culture and disrupts CREB-dependent genes in AML.159 The AML-treated cells 




potential efficacy. CREB-bound loci also show reduced histone 3 lysine 27 (H3K27) 
acetylation reflecting the loss HAT-based activity from the CREB-CBP 
interaction.159 KG-501 also disrupts c-Myb from CBP and p300 and it has the 
potential to treat leukemia progression because it has promoted differentiation in 
myeloid leukemia cell culture models.160 Two natural products, sekikaic acid and 
lobaric acid natural products, were identified from a fluorescence polarization (FP) 
screen that targeted the KIX∙MLL complex (Figure 1-11).152  
Since these KIX screens have a very low hit rate fragment-based screening 
and design is an attractive method to design small molecules for these “target-rich, 
lead-poor” cases.161 Fragments need to be efficient binders with a higher energy 
per molecular mass unit and molecular weights between 150 to 250 Da.  
Although fragments tend to efficiently bind to a target with a high 
Figure 1-11 Small molecules that bind to KIX   The structures for the small molecules are shown. 
Naphthol-ASE-phosphate and its dephosphorylated derivative inhibit the KIX interactions with 
pKID and c-Myb. Sekikaic acid and lobaric acid are natural products identified initially as 
inhibitors of the MLL-KIX interactions. The fragment core of 1-10 is shown. The 1-10 disulfide was 
identified from an LC-MS Tethering screen. The first crystal structure of KIX was obtained from 




proportion of their atoms their affinities range from mM to 30 μM. Therefore, the 
fragment hits require optimization by either growing or linking chemical features 
on to it. Frequently growing-out the fragments rapidly result in higher affinities 
reaching the low to nanomolar range. Although linking fragments together results 
in a drug-like compound optimizing linkers are more difficult to achieve optimal 
and efficient binding affinity. However, this discussion is premature. First 
fragments need to be identified which is challenging considering their high μM to 
mM affinities.  
 Techniques such as NMR and x-ray crystallography may detect fragments 
that target a specific PPI. Protein-observed fluorine NMR spectroscopy (PrOF 
NMR) is particularly sensitive and has identified fragments that target KIX. Here, 
3-fluorotyrosine (3FY) replaces tyrosine naturally located in the MLL-binding site 
(Y631) and pKID or c-Myb binding site (Y649, Y650, Y658).162,163 Residue-specific 
19F shifts indicates a favorable interaction between a fragment and KIX at a specific 
region and from 508 fragments 3 fragments perturbed the MLL-binding site and 1 
fragment hit the pKID-binding site with KDs ranging from around 1.5 to 7 mM. 
These scaffolds provide a framework to derivatize KIX inhibitors, however 
additional work is required to turn these fragments into probes.163  
From these screens KIX remains a difficult target with a range of hit rates 
(0-0.8%) resulting in ligands with moderate μM to mM affinities.152,163 A site-direct 
strategy known as Tethering* is the next approach in the quest for the optimal KIX 
probe. Just to clarify; the optimal KIX probe would differentiate between p300 KIX, 
CBP KIX and ARC105/MED15 KIX (very selective), and efficiently capture specific 
                                                 
* Tethering was developed by Dr. James Wells and his team at Sunesis Pharmaceuticals and this 
technique was first reported by Erlanson et al., Proc. Nat. Acad Sci. USA 97:9367-9372 (2000).164 




conformations of KIX (potent with Ki or IC50 within 10-7-10-9 M).166 
 Tethering has built a reputation as a method to develop fragments for 
difficult targets.167 This strategy requires a cysteine either endogenous or 
strategically positioned in proximity to the target site of the protein. This target is 
screened against disulfide-containing fragments using a reducing agent to vary 
the stringency of the assay (Figure 1-12). Through the thiol-disulfide exchange the 
fragment with affinity for the target is readily detectable as a covalent mixed 
disulfide using liquid chromatography mass spectrometry (LC-MS).167 
Initially Tethering was used to identify fragments that manipulate 
malleable sites within proteins.167 In one case, the immune response player, 
interleukin-2 (IL-2) appears to reveal a defined hot-spot region only upon binding 
to an inhibitor.168 A fragment-based screen directed in the receptor binding site 
revealed a hot-spot region. The strongest hit from the Tethering screen formed the 
basis of a nanomolar small molecule that binds efficiently through the adaptive 
surface identified in the screen. Since then other Tethering screens have revealed 
both flexible sites that adapt to small molecules and novel allosteric regions.169-172  
For KIX the LC-MS Tethering screen targeted at the MLL-binding site 
Figure 1-12 Disulfide Tethering scheme  The protein target must contain a cysteine which is 
screened against a library of disulfide fragments. The stringency of the assay is controlled with a 
reducing agent such as β-mercaptoethanol as shown. The fragment with intrinsic affinity for the 




resulted in promising fragments that capture conformational features of KIX. The 
KIX L664C mutant tethered to the fragment known as 1-10 forms a stable construct 
amenable to crystallography.173 The fragment sits within the MLL-binding site 
where hydrophobic region including I611, L628, L607, V635, and Y631 hug the 
aromatic ring of 1-10. KIX is highly dynamic so modifying 1-10 based on this 
structure remains difficult since KIX shifts in regions such as the loop between α1 
and α2 to accommodate the ligand. From PrOF NMR the 1-10 fragment interacts 
with KIX with a dissociation constant, KD of 210 μM.162 However, the main 
advantage of these cysteine-reactive fragments is that it targets the cysteine-
containing KIX domain. Therefore, introducing a cysteine within CBP means the 
probes specifically target this coactivator over say p300. While these probes 
provide the first insight on an atomic level additional applications are required to 
delineate exact mechanisms for KIX∙activator interactions in biological processes. 
These probes may be the start since they specifically target the cysteine-containing 
KIX domain of CBP versus p300.  
1.10 What does this thesis offer? 
This thesis focuses on the challenge to understand how conformational 
changes within KIX dictates its interactions, mainly using small molecule probes. 
The site-directed Tethering strategy is initially used to identify fragments that 
capture the conformations and interactions with KIX in vitro. In Chapter 2, a novel 
FP screen is used to identify novel fragments that disrupt the CREB(pKID)∙KIX 
complex. In Chapter 3, transient-state kinetics of these tethered KIX complexes 
examines what contributes to these allosteric effects. These probes are prepared 
for in cellulo studies by converting the reversible covalent inhibitor into a series of 




changes between the fragment and irreversible “warhead” are tested for how they 
react with KIX in vitro (Chapter 4). In summary, this dissertation seeks to identify 
strategies and probes that examine the mechanism of KIX∙activator complexes. 
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 FP Tethering: a screening technique to rapidly identify 
compounds that disrupt protein-protein interactions1,† 
2.1 Abstract 
Tethering is a screening technique for discovering small-molecule 
fragments that bind to pre-determined sites via the formation of a disulfide bond. 
Tethering screens traditionally rely upon mass spectrometry to detect the disulfide 
bond formation, which requires a time-consuming liquid chromatography step. 
Here we show that Tethering can be performed rapidly and economically using a 
homogenous fluorescence polarization (FP) assay that detects displacement of a 
peptide ligand from the protein target as an indirect effect of disulfide formation. 
We apply this method, termed FP Tethering, to identify fragments that disrupt the 
protein–protein interaction between the KIX domain of the transcriptional 
coactivator CBP and the transcriptional activator peptide pKID. 
2.2 Introduction to FP-based Tethering screens 
Protein-protein interactions (PPIs) underpin all cellular processes, and 
dysregulation of PPI networks is strongly correlated with human disease.3 For this 
reason, synthetic molecules that modulate PPIs are highly sought tools. Despite 
                                                 
1Contents of this chapter are reproduced and adapted from a published article:1 J. M. Lodge, T. Justin 
Rettenmaier, J. A. Wells, W. C. Pomerantz and A. K. Mapp, Med. Chem. Commun., 2014, 5, 370 DOI: 
10.1039/C3MD00356F– Reproduced by permission of The Royal Society of Chemistry (RSC). 
 
This research was a collaborative effort. Dr. T. J. Rettenmaier conducted and analyzed the FP-
Tethering screens and the confirmatory LC-MS experiments at the University of California, 
San Francisco. Dr. W. C. Pomerantz contributed to the preliminary screen against the KIX 
N627C mutant and provided peptides for these studies. Dr. M. E. Breen provided the 
fragment, 6D11 and the alkylators for the follow-up studies. These compounds were used for 
the experiments shown in Figure 2-6, and Figure 2-8. 
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their importance, small molecule PPI modulators are difficult to obtain through 
either screening or design.4-6 This is largely due to the intrinsic features of PPIs, 
most of which are comprised of significantly larger surface areas (average ~1,949 
± 760 Å2) than typical protein–ligand interfaces and are often flatter with few 
interaction features.7,8 Indeed, PPIs have often been described as ‘undruggable’ 
due to the challenges associated with identifying small molecules that can 
effectively engage these binding interfaces.9-11 
Tethering is a screening strategy that circumvents many of the difficulties 
associated with PPIs and has been successfully used to discover a range of small 
molecule modulators.12,13 It is a fragment discovery method in which a library of 
disulfide containing fragments (molecular weight < 300 Da)14 are screened under 
reversible conditions against a protein target bearing a native or engineered 
cysteine adjacent to the binding site of interest (Figure 2-1A).15,16 Fragments that 
interact favorably with the protein target bias the equilibrium towards the mixed 
disulfide, which is subsequently detected by liquid chromatography-mass 
spectrometry (LC-MS) (Figure 2-1B).15 resulting fragment molecules can be 
converted to non-covalent inhibitors by growing the fragment or used as covalent 
binders for functional and biophysical studies.17-19 
We previously reported the application of Tethering to discover small 
molecule ligands for the KIX domain of the master coactivator, CBP.20 Several 
fragments identified from this screen proved to be excellent inhibitors of the PPI 
formed between KIX and the transcriptional activator MLL as well as enhancers 
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Figure 2-1 The Tethering methodology for site-directed ligand discovery A) A reversible 
disulfide reaction is set-up such that the mixed disulfide only persists when the ligand makes 
favorable interactions with the protein. Increasing the β-ME concentration results in a more 
stringent assay. B) Comparison between traditional liquid chromatography-mass spectrometry 
(LC-MS)-based Tethering with the novel fluorescence polarization (FP)-based Tethering. With FP 
the signal drops when the peptide is displaced from its partner due to the formation of a mixed 
disulfide. C) Cartoon representation of the KIX domain (grey) bound to two coactivator peptides 
MLL (dark red) and pKID (blue). (PDB ID: 2LXT) Previously, four cysteines lining the MLL-
binding site (left) were screened using the LC- MS. Here, two mutants are shown that lined the 
pKID-binding site. The cysteine at position H602 is well-behaved in comparison to wild-type KIX 
so it was used to test the FP-based Tethering screen.  
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of the complex that KIX forms with the transcriptional activation domain of CREB 
(pKID).2,21 Nonetheless, we noted that some of the fragments that bind to KIX 
efficiently did not affect the interactions between activators and KIX. In retrospect, 
this is not surprising since the screen detects the disulfide formation, not inhibition 
of a PPI. We hypothesized that combining Tethering with a competitive inhibition 
effect would provide a more direct route to PPI modulators (Figure 2-1B). Here we 
show that fluorescence polarization (FP) Tethering is a rapid method for the direct 
discovery of PPI modulators and we use this method for the identification of 
effective inhibitors of the complex formed between KIX and pKID.  
2.3 Results  
FP is a homogenous, mix-and-read method used to directly measure the 
fraction of a small fluorescently-labeled peptide tracer that is bound to a larger 
protein.22 Binding of the tracer to the protein results in high FP signal, but the 
tracer's fluorescence is rapidly depolarized following displacement by an 
unlabeled ligand (Figure 2-1B).23 This type of ligand displacement assay provides 
a way to measure the affinity between the protein target and an unlabeled ligand. 
However, FP ligand displacement assays are less sensitive than X-ray 
crystallography or NMR for detecting the low affinity interactions of fragments, 
which typically occur in the high micromolar to millimolar range.24,25 Since 
Tethering fragments to a target via a disulfide bond enhances their affinity, we 
reasoned that these binding events should be detectable by FP. 
To test this approach, we first used the results from our earlier Tethering 
screen against cysteine mutants of the KIX domain. The KIX domain is a small (90 
residue) three-helix bundle containing two binding sites that can be occupied 
simultaneously by different transcriptional activators (Figure 2-1C).26-30 These two 
binding sites are in allosteric communication, with the binding of MLL in the 
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smaller and deeper of the two sites leading to up to 2-fold enhancement of binding 
with activators such as pKID (the transcriptional activation domain of CREB) at 
the second, more shallow binding site.27,31 Two disulfide fragments isolated from 
the original Tethering screen bind well to the KIX N627C mutant, fragments 1A10 
and 1C11, and also were effective inhibitors of MLL binding when covalently 
associated with KIX N627C.32 Rather than measuring binding inhibition using a 
fully labeled protein, we reasoned a competitive inhibition signal could indicate 
the fragment-labeling of the KIX N627C mutant during the Tethering reaction. The 
inhibition of a fluorescently-labeled MLL peptide was observed in a dose-
dependent fashion as a functional consequence of protein labeling (1A10: IC50 68 
μM and 1C11: IC50 115 μM, see Figure 2-2A). In the presence of 5 mM β-ME and 
the highest concentration (250 μM) of 1A10 used in the FP competition assay 82% 
of the KIX N627C mutant was labeled. The ability to increase or decrease the 
inhibition levels by changing the β-ME concentration affords a control for ruling 
out fluorescent impurities or other false positives.  
Next, 80 disulfide-containing fragments were screened at two different β-
ME concentrations against the KIX N627C mutant (Figure 2-2A). The FP Tethering 
screen identified the same set of ligands that were previously identified in the MS-
based screen (Figure 2-2B). Notably the hits that resulted in the largest inhibition 
of the KIX domain and MLL interaction were also the most potent hits from our 
MS-based screen. These results suggested that the FP Tethering assay was suitable 
for high-throughput identification of fragments that disrupt the interaction 
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Figure 2-2 FP- and MS-based Tethering identified overlapping ligand sets for the MLL-binding 
site.  A) The FP competition assay was tested by varying the concentrations of the fragments,
1A10 and 1C11 and keeping the concentration of KIX N627C mutant, and fluorescently-
labeled MLL peptide constant.2 The polarization signal was plotted against the various
concentrations of the fragment, 1A10 and 1C11 and analyzed by GraphPad Prism 4.00. The
last two traces show the percent of MLL displaced from KIX N627C for the two fragments and
for the 80 small-molecule disulfides. The screen was performed at medium and high
stringency (1 mM and 5 mM β-ME, respectively). The top 4 fragments that were previously
identified by a LC-MS-based Tethering screen are colored in red. B) The structures and
properties of the two fragments were rediscovered by FP-based Tethering.  
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between KIX and its coactivators.  
To test the FP Tethering approach in a pure discovery mode, we targeted 
the second binding site within the KIX domain that is used by pKID in addition to 
the activator c-Myb. This is the considerably more challenging of the two sites, 
with a larger surface area (1,480 Å2) and a less well-defined surface.33 In 
preparation for the screen, we mutated several residues lining the binding site to 
cysteine and determined the integrity of the mutants. The helicity and stability of 
the KIX mutants was assessed by circular dichroism (CD) (Figure 2-3). While the 
thermal stability difference is similar between wild-type KIX and KIX K662C the 
cysteine mutation at K662C disrupts the helical propensity of KIX. 
The affinity for pKID, c-Myb, and MLL tracers were also compared to the 
wild-type KIX protein (Table 2.1 and Figure 2-4). The KIX H602C mutant retained 
its affinity for the tracers and it was thus chosen for the FP Tethering screen. The 
competition assay was developed with 25 nM FITC-labeled pKID and 4 μM of KIX 
H602C. These conditions were sufficient to detect displacement of FITC-labeled 
pKID tracer from the KIX domain by the unlabeled pKID peptide providing a 
signal/background ratio of at least 1.5-fold across the different β-ME 
Figure 2-3 The impact of the cysteine mutants within the pKID-site of KIX on the overall KIX 
structure was assessed by CD. The wavelength scan shows the relative helicity of the KIX 
constructs (on the left). The scan represents an average of five measurements. The melting 
temperature curve was measured monitoring the helicity change at 222 nm (on the right). While 
the melting temperatures have little variations for the KIX constructs, the KIX K662C mutant lost 
approximately 20% of the native helical structure.  
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concentrations. The assay was also precise with coefficient of variation (CV) values 
for the maximum and minimum signals was between 2 to 3% for the bound and 
unbound form of the FITC-pKID tracer following the guidelines that. CV values 
below 15% are acceptable as a measure of precision for the assay.34 
Table 2-1 FP results for wild-type KIX and two cysteine mutants  The equilibrium dissociation 
constants (KD) for the three tracers, MLL, pKID, and c-Myb were compared between two KIX 
cysteine mutants and wild-type KIX using the FP-direct binding assay. Errors reflect the standard 
error (SE) of nonlinear fits in GraphPad Prism. The corresponding curves are shown in Figure 2-4.  
Using this assay, we screened 960 disulfide-containing fragments at three 
different β-ME concentrations against a fluorescent pKID tracer in complex with 
KIX H602C (Figure 2-5A). The Z’ factors were calculated as 0.69 at 0.2 mM β-ME, 
0.63 at 1 mM β-ME, and 0.60 at 5 mM β-ME. Therefore, this the variability of the 
assay’s signal and dynamic range was considered acceptable for a high-
throughput screen (1 > Z’ > 0.5). Fragments that yielded total fluorescence 
KD (μM) pKID c-Myb MLL 
Wild-type KIX 0.54 ± 0.07 1.1 ± 0.2 0.26 ± 0.03 
KIX H602C 0.22 ± 0.02 2.2 ± 0.2 0.24 ± 0.05 
KIX K662C  4.9 ± 0.9 0.52 ± 0.05 0.64 ± 0.04 
Figure 2-4 The FP Tethering screen requires a compatible, cysteine-containing KIX target. A 
couple of cysteine mutants were generated in proximity to the pKID-binding site and the mutants 
were compared to wild-type KIX by FP-direct binding assays with the three different tracers, MLL, 
pKID, and c-Myb. The FP direct binding curves of KIX and the cysteine mutants are shown for the 
three different tracers. All measurements were performed in triplicate and the error bars reflect the 
standard deviation (SD) error of nonlinear fits in GraphPad Prism.  
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Figure 2-5 FP-based Tethering screen to identify new ligands that disrupt the interaction 
between KIX and pKID. A) Overview of the workflow for screening, hit selection, and
validation. B) The percent of pKID displaced from KIX H602C is shown for 960 small-molecule
disulfides at low, medium, and high stringency (0.2 mM, 1 mM, and 5 mM β-ME,
respectively). The curve is black represents the average percent inhibition for the β-ME
screens. C) The percent of KIX H602C that is labeled by the top 10 small molecule disulfides
was measured by LC-MS. The reaction was performed with increasing stringency to assess




intensities (TFI) greater than 150% of the DMSO control wells were flagged as 
fluorescent artifacts and excluded from further analysis. Next the remaining 
fragments were ranked by their percent inhibition of pKID binding across the 
three β-ME concentrations (Figure 2-5B). The average percent inhibition for all the 
compounds was 5 ± 14% at 0.2 mM β-ME, 7 ± 12% at 1 mM β-ME, and 3 ± 12% at 
5 mM β-ME. As expected, the highest stringency of 5 mM β-ME resulted in 
decreased inhibition relative to the lower β-ME concentrations. The two lower β-
ME concentrations, 0.2 mM and 1 mM, deviated from this trend in which the 
lowest percent inhibition fluctuated between 1 mM β-ME and 0.2 mM β-ME for 
the different fragments (Figure 2-5B). 
From the top hits, 10 disulfides were cherry-picked for validation by LC-
MS analysis (Figure 2-5C). These fragments covalently labeled the KIX domain. 
However, 2E10 was likely a false positive given its high percent inhibition by FP 
yet a low degree of labeling by MS. Comparison of labeling across the three β-ME 
concentrations reveals the relative potencies of the fragments. From the ten hits, 
two fragments, 3D4 and 6D11 were chosen for further characterization. The 
fragment 3D4 labeled KIX H602C more effectively than any other fragments and 
maintained a high percent inhibition of pKID even at 5 mM β-ME (31%) (Figure 2-
5D). The fragment 6D11 had the highest average percent inhibition of pKID for 
the three β-ME concentration. Notably, percent labeling did not always correlate 
with inhibition of pKID binding. While fragment 3D4 labeled 70% of KIX H602C 
at 5 mM β-ME, this resulted in 24% inhibition of pKID binding. The larger 
fragment 6D11 labeled KIX H602C only 15% at 5 mM β-ME, but this translated to 
nearly equivalent inhibition (22%) of pKID binding. This finding suggests that 
although 6D11 may exhibit weaker overall potency, it is the more efficient 
inhibitor. Other top hits replaced the diphenylamine moiety in 6D11 for a 
diphenylmethane or 2-chloro-2-N phenylaniline. These changes did not improve 
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their ability to displace the pKID tracer, but their ability to bind to the KIX H602C 
mutant improved slightly. The disulfide fragment library contained several 
variants of the core scaffolds of 3D4 and 6D11 and a comparison revealed that both 
structures are sensitive to substituent placement and identity; this is particularly 
true for 6D11 where modifications of the distal aromatic ring leads to dramatic 
changes in inhibition (Figure 2-7).  
Dose–response curves were determined for 3D4 and 6D11 using LC-MS to 
determine the percent of KIX H602C mutant bound to the fragment (Figure 2-6A 
and 2-6E). The concentration at which 50% of the KIX H602C mutant is bound by 
the fragment (DR50) was lower with the fragment 3D4 than 6D11. This finding was 
consistent with single point LC-MS measurements in which the fragment 3D4 was 
more potent than the fragment 6D11. Finally, we labeled greater than 90% of KIX 
H602C with the fragments, 3D4 and 6D11 and used these protein–ligand 
conjugates for direct binding experiments with the MLL, pKID, and c-Myb tracers. 
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Figure 2-6 Labeling of KIX H602C with 3D4 and 6D11 decreases the affinity for pKID, c-Myb, 
and MLL. A) The dose-response binding experiments were performed with a constant 
concentration of KIX H602C and various concentrations of fragment, 3D4 and 6D11. Each value 
was duplicated in separate experiments except the top concentration of compound (250 μM) which 
was only measured once due to a limited quantity of compound. The extent of KIX H602C tethered 
to the fragments was quantified using LC-MS. The average of the duplicated values is plotted and 
the error bars indicated SD error. B) The FP direct binding curves are shown for MLL, C) pKID, 
and D) c-Myb. KIX H602C was quantitatively labeled with either 3D4 or 6D11 and this tethered 
construct was used to assess the KDs for the three tracers. All FP experiments were performed in
triplicate and the error bars indicate SD error. E) The results are shown for the FP direct binding
assays and dose-response curve. The relative inhibition values were assessed by comparing
the KD values from the labeled KIX H602C to the untethered KIX H602C. Error reflects the SE 
of nonlinear fits calculated in GraphPad Prism. 
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Figure 2-7. 3D4 and 6D11 contain chemical features that supported their discovery in the FP-
Tethering screen in comparison to other fragments.  A comparison of inhibition for 3D4 and 6D11
and related fragments reveals that both scaffolds are sensitive to substituent placement and 
identity. Relative potency values are the inhibition value of each fragment measure under stringent 
(5 mM β-ME) conditions divided by the inhibition value for the parent fragment (3D4 or 6D11).  
59 
 
The equilibrium dissociation constant (KD) of each tracer for the KIX-fragment 
conjugate was assessed by a binding isotherm that accounts for ligand depletion 
(Figure 2-6B-E).35 Surprisingly, 3D4 not only increases the KD for binding to pKID 
and c-Myb but also for MLL, which binds on the opposite face of the KIX domain. 
This finding demonstrates a negative allosteric coupling between the pKID- and 
MLL-binding sites. The fragment, 6D11 was a moderate inhibitor from the FP-
Tethering screen and 6D11 tethered to KIX H02C disrupted pKID from KIX to a 
similar extent as 3D4. This fragment perturbed c-Myb and MLL at the distal site 
to a lesser extent. As probes, these fragments may moderate the assembly of 
activators that share the same binding site within KIX.  
Given that 3D4 and 6D11 disrupts the binding of all three coactivator 
peptides, irreversible covalent analogues would be useful chemical probes for 
studying CBP and p300 biology. However, the conversion of disulfide fragments 
into irreversible co-chaperones presents challenges. The fragments must orient to 
first bind and then react with the cysteine-containing target. Here we used 
different irreversible covalent analogues (Figure 2-8). The disulfides reacted more 
readily with the KIX H602C target than these analogues after one hour in the 
presence of 1 mM β-ME. These irreversible fragments struggled to fully label the 
target KIX H602C even under forcing conditions. As observed in the screen, 
changes within the core 3D4 and 6D11 scaffolds disrupts the fragment’s ability to 
bind or to disrupt the pKID-KIX H602C interaction (Figure 2-7). Therefore, 
additional linkers and alkylator moieties may be required to develop irreversible 
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covalent co-chaperones at the pKID-binding site of CBP KIX.  
2.4 Conclusion 
FP Tethering is an efficient and accessible screening format for identifying 
fragments that disrupt a PPI. This method was successfully benchmarked against 
a previous LC-MS-based Tethering screen on the MLL-binding site of KIX. 
Figure 2-8 The initial 6D11 and 3D4 irreversible derivatives suffer from poor labeling efficiency 
with the KIX H602C target.  The disulfides and their irreversible structures are shown. Two of the 
6D11-based compounds contain ethylenediamine (EDA) linkers. In the graph, the extent of KIX 
H602C bound by the compound was measured by LC-MS after one hour of incubating 5 μM of KIX 
H602C with 100 μM of compound in the presence of 1 mM β-ME. Each value is an average of two 
separate experiments and the error bars represent the SD error.  
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Application of this method in discovery mode against a more challenging surface 
within KIX,36 the broad interface of the KIX∙pKID complex, was also a success. FP 
Tethering lead to 9 fragments confirmed to displace pKID from the KIX domain 
by covalently labeling the protein. These molecules represent promising leads for 
follow-up studies. For instance, 3D4 engages the KIX H602C mutant disrupting 
interactions at both the pKID or c-Myb binding site and the MLL-binding site. 
From the previous screen targeting the MLL-binding site KIX L664C tethered to 
1A10 also known as 1-10 also directly disrupts MLL and allosterically inhibits 
pKID.32 Small molecules appear to readily engage in this negative effect from 
either site within KIX. Previously, KIX L664C tethered to 1A10 was shown to 
induce a negative cooperativity effect.32 This appears to be readily available to 
small molecules, but no known, endogenous KIX-associated ligands induce 
negative allostery within KIX.  
The 3D4 and 6D11 disulfides efficiently labeled KIX H602C, however the 
irreversible derivatives were unable to label KIX H602C to the same extent. With 
this small fraction of labeled KIX H602C the fragments antagonized the binding of 
MLL, pKID and c-Myb between 1-5 relative fold inhibition. While these disulfides 
have potential as effective inhibitors, the probes need to efficiently bind to the 
target. Excess, unbound small molecule would lead to off-target effects in cellular 
environments where other reactive cysteines and free thiols are present such as 
glutathione.  
More broadly, these results suggest that Tethering could be combined with 
any binding assay that is compatible with disulfide-containing molecules and β-
ME37,38 increasingly the accessibility of this important technology. In retrospect, a 
parallel LC-MS Tethering screen would have identified fragments that labeled the 
pKID-binding site. At this stage, we cannot conclude on how Tethering screens 
result in different disulfide fragment hits depending on whether the screen was 
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conducted by LC-MS or FP. Tethering through a disulfide bond significantly 
enhances the affinity of fragments for the protein. One important advantage of 
Tethering is to rapidly identify disulfide fragments for the protein target that 
would not, otherwise, be detectable through standard LC-MS or FP fragment-
based screens. 
2.5 Materials and Methods 
2.5.1 Expression and purification of the KIX domain 
The KIX domain (residues 586-672) of mouse CBP protein fused to a 
hexahistidine tag and short polar linker was cloned into the bacterial expression 
pRSETB vector. All cysteine mutants were generated by using site-direct 
mutagenesis as previously described.32,39 The KIX protein was overexpressed from 
Escherichia coli Rosetta2(DE3) pLysS (Novagen) cells in Terrific Broth (37 0C, 250 
rpm). When the cell density reached an OD600nm ~0.8, protein expression was 
induced with 0.1 mM isoprpyl-β-D-thiogalactopyranoside (IPTG) for 
approximately 12 hours at 25 0C. The cells were harvested by centrifugation and 
stored at -80 0C. The hexahistidine-tagged KIX protein was affinity purified using 
Ni-NTA beads (Qiagen) followed by ion-exchange chromatography (Source S 
column, GE Healthcare) using an FPLC system. The purified protein was stored 
in 10 mM phosphate, 100 mM NaCl, pH 6.8 at -80 0C.  
2.5.2 Synthesis of fluorescent peptides 
Peptides were synthesized using standard Fmoc solid phase synthesis as 
previously described.40 
2.5.3 Fluorescence polarization binding assay  
In 384-well microplates various concentrations of KIX protein were mixed 
in binding buffer (10 mM sodium phosphate, 100 mM NaCl, pH 6.8) with a 
constant concentration of fluorescein isothiocyanate (FITC)-labeled peptides (25 
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nM) and β-mercaptoethanol to a final volume of 10 μL in each well. The samples 
incubated at room temperature for 1 hour. The anisotropy and fluorescence 
intensity were monitored using the Tecan Genios Pro microplate reader at an 
excitation wavelength of 485 nm and an emission wavelength at 535 nm. The 
equilibrium dissociation constants, KD in Eq, 1 were calculated by fitting the 
observed anisotropy values as a function of KIX protein concentration to the 
ligand depletion model assuming single site binding of peptide to protein,  
A = + −  × 
([ ] [ ]) ([ ] [ ]) [ ][ ]
[ ]
   (Eq. 1) 
where [LT] and [PT] are the total concentrations of fluorescent peptide and KIX 
protein, respectively, A is the observed anisotropy, Ab is the maximum anisotropy 
value for the fully bound peptide, and Af is the minimum anisotropy value for the 
free peptide. All nonlinear data analysis was performed with GraphPad Prism 4.0 
software (San Jose, CA). 
2.5.4 Fluorescence polarization Tethering screens 
For the proof of concept screen, KIX N627C (0.5 μM) was mixed in binding 
buffer with FITC-labeled MLL peptide (25 nM), β-ME (1 mM or 5 mM), and one 
of 80 fragment disulfides (160 μM) in a final volume of 30 μL. For the discovery 
screen, KIX H602C (4 μM) was mixed in binding buffer with FITC-labeled pKID 
peptide (25 nM), β-mercaptoethanol (0.2 mM, 1 mM or 5 mM), and one of 960 
fragment disulfides (125 μM) to a final volume of 20 μL. Wells containing DMSO 
instead of the fragment disulfides and those containing only 25 nM of FITC-
labeled pKID were used as controls. 
All plates were shaken at room temperature for 1 hour to reach equilibrium. 
The fluorescence polarization (FP) and total fluorescence intensity (TFI) were 
measured using the Analyst HT Multi-Plate Reader (Molecular Devices) at an 
excitation wavelength of 485 nm and an emission wavelength at 530 nm. 
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Fragments that yielded TFI greater than 150% of the DMSO control were flagged 
as artifacts and excluded from further analysis. FP readings were transformed 
percent inhibition, using the following equation.  
% Inhibition= (FPBound-FPsample) (FPBound-FPfree)⁄ × 100   (Eq. 2) 
The statistical parameter Z’ factor was calculated by 
’ = 1 −  (3 −  3 ) | −  |    (Eq. 3) 
where σmax is the standard deviation of the positive controls (maximum signal), 
σmin is the standard deviation of the negative controls (minimum signal), μmax is the 
mean of the maximum signal or positive controls, and μmin is the mean of the 
minimum signal or the negative controls.34,41 The signal/background (S:B) ratio 
was calculated by   
: =           (Eq. 4) 
and the coefficient variance was calculated from  
% =    100        (Eq. 5) 
where σ is the standard deviation of the assay signal and μ is the mean of the assay 
signal. The acceptable limit is set at less than 15%.34 
2.5.5 LC-MS validation of fragment hits 
KIX H602C (4 μM) was mixed in binding buffer with β-mercaptoethanol 
(0.2 mM, 1 mM or 5 mM) and each fragment disulfide (125 μM) to a total volume 
of 25 μL. The plate was shaken for 1 hour at room temperature to reach 
equilibrium. Each sample was subjected to LC-MS using an LCT Premier ESI-MS 
(Waters) with an inline C4 protein desalting column (Microtrap). Protein masses 
were deconvoluted using the Max-Ent algorithm within the MassLynx software. 
Percent labeling was measured by comparing the peak areas for the labeled versus 
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unlabeled protein.  
2.5.6 Determination of the dose response (DR50) 
A constant concentration of the KIX H602C mutant and fresh β-ME in 10 
mM phosphate buffer, 100 mM NaCl, pH 6.8 were incubated with various 
concentrations of compound (0.2 uM -125 uM) at room temperature for one hour. 
The samples were spun-down and injected onto an Agilent Q-TOF HPLC-MS 
instrument. Protein masses were deconvoluted using the Max-Ent algorithm 
within the Agilent MassHunter Workstation Bioconfirm software. The dose-
response (DR50) values were determined with a normalized response from 1 to 100 
using the equation 
= ( )        (Eq. 6) 
where x is the logarithm of the concentration of the fragment and y is the percent 
of protein bound to the fragment. For the relative inhibition values the following 
equation was used; 
 Relative fold inhibition value =  for labeled KIX H602C
 for untethered KIX H602C
   (Eq. 7) 
2.5.7 Fragment Tethering  
The KIX H602C mutant was incubated with 8 - 10 equivalents of small 
molecule and fresh β-ME in 10 mM phosphate buffer, 100 mM NaCl, pH 6.8 and 
incubated overnight. Excess small molecule was removed and small molecule-
protein complexes were concentrated using 10 kD molecular weight cutoff 
concentrators (Vivascience). The extent of labeling was measured by Q-TOF LC-
MS (Agilent). Protein complexes that were at least 90% alkylated were used for the 
FP binding assays. A control samples was included replacing the small molecule 
with DMSO. 
2.5.8 CD wavelength and variable temperature scans 
For the sample 300 μl of 10 μM KIX protein in 10 mM sodium phosphate, 
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100 mM NaCl, pH 6.8 was used. The CD cuvette was a Spectrosil far UV quartz, 
standard rectangular 1 mm cell with stopper (useable range 170 to 2700 nm, 
Starna® Cells, Inc., 21-Q-1). The CD instrument (JASCO J-175) equipped with a 
modified water-bath to modulate the temperature scanned the samples for the 
wavelength from 260 to 195 nm in continuous scanning mode at 500 nm min-1 with 
1.0 nm bandwidth, accumulation of 5 scans, and data pitch of 1 nm at 200C. For 
data analysis, the sample’s CD signal was corrected by subtracting the buffer’s 
signal for each wavelength. The CD signal was cut-off when the dynode energy 
reached 500 eV or greater. Therefore, the typical scan resulted in analysis from 260 
nm to 195-198 nm. The data was converted to mean residue ellipticity 
(deg∙cm2∙dmol-1) using the following equation: 
[ ] =  
 ∗ ∗
        (Eq. 8) 
where Ψ was the CD signal in degrees, l was the path length in centimeters, c was 
the concentration in decimoles per cm2, and n was the number of amides. This KIX 
construct contained 100 amides. The helical content was determined:  
% ℎ  = 100 ∗ ∗ 
, ∗( . )    (Eq. 9) 
where Q was the ellipticity measured at 222 nm.42 
For the thermal melt, the temperature scan was set to read at 222 nm from 
200C to 950C ramping 1.0 0C∙min-1 and collecting data for each 1 0C. The resulting 
data were subtracted from the data for buffer at 222 nm. The data were fitted using 
the nonlinear regression model ([Inhibitor] versus response using a variable slope 
considering four parameters) using GraphPad Prism 4 software. 
2.5.9 Alkylation experiments 
5 μM of KIX H602C mutant was incubated with 100 μM compound, 1 mM 
β-ME in 10 mM sodium phosphate buffer, 100 mM NaCl, at pH 6.8. After one hour 
1 μL was injected with the 1290 Agilent autosampler onto the 1290 binary pump 
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(Agilent). The protein was eluted off the Proshell 300 SB-C8 column (Agilent) 
using a gradient of 95% water containing 0.1% formic acid (Solvent A) and 5% 
acetonitrile, 0.1% formic acid (Solvent B) at 0.3 ml per min. In the first two minutes 
95% of solvent A was sent to waste. Subsequently the LC stream was directed to 
the MS and solvent B increased over three minutes to 100%. Intact mass analysis 
was measured by electrospray ionization on a quadrupole time-of-flight (Q-TOF) 
mass spectrometer (6545 Agilent Q-TOF). The MS-TOF was set to acquire spectra 
from 400 to 3200 m/z and set-up with an internal reference mass of 922.009798 m/z. 
The MS fragmentor was set to 300 V and the skimmer was at 75 V. After the protein 
eluted, the data was analyzed using the Agilent MassHunter Bioconfirm software. 
The spectra were extracted from the total ion chromatography peak after 
subtracting a background spectra. The raw data mass spectrum of a protein 
appeared as a series of multiply charged ions and these were selected for the 
deconvolution of the protein using the Maximum Entropy algorithm. The percent 
of protein labeled by the small molecules was calculated by dividing the height of 
the labeled protein peak over the total KIX H602C species (the sum of the labeled 
protein, unbound protein, and β-ME bound protein). 
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 Dissecting Allosteric Effects of Activator-Coactivator Complexes 
Using a Covalent Small Molecule Ligand‡ 
3.1 Abstract  
Allosteric binding events play a critical role in the formation and stability 
of transcriptional activator-coactivator complexes. These often involve an 
intrinsically disordered protein that binds to an accommodating partner. The KIX 
domain of the master coactivator CBP/p300 is a conformationally dynamic motif 
that interacts with transcriptional activators at two discrete binding sites that are 
in allosteric communication. The complexation of KIX with the transcriptional 
activation domain of Mixed Lineage Leukemia (MLL) leads to an enhancement of 
binding by the activation domain of CREB (pKID) to the second site. An 
underlying question has been how this positive cooperativity is achieved. A 
transient kinetic analysis of the ternary complex formation aided by small 
molecule ligands that induce positive or negative cooperative binding reveals that 
positive cooperativity is largely governed by a decrease in the dissociation rate 
constant, koff. This suggests that the increased binding affinity for the second 
ligand such as pKID is not due to an allosteric creation of a more favorable binding 
interface by the first ligand, MLL. 
In contrast, negative cooperativity is manifested by alterations in both 
                                                 
‡This chapter are adapted and reproduced from a published article: Wang, N. K., Lodge, J. M., 
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collaboration initiated by Dr. Ningkun Wang who conducted experiments including FP-direct 
binding assays, and stopped-flow kinetics for wt KIX, KIX N627C, and KIX L664C constructs. 
She also prepared the materials (purified protein, and peptides) required for those 




the association and dissociation rate constants, kon and koff, respectively. These 
data lead to a general model for allosteric regulation in transcriptional 
activator-coactivator complexes. 
3.2 Introduction to the cooperativity between activators and coactivators 
Protein-protein interactions (PPIs) underscore all cellular processes, and 
the mechanistic dissection of PPI networks is thus a high priority.1-4 A 
particular challenge is defining the mechanism of PPI formation between 
intrinsically disordered proteins (IDPs) and their dynamic partners where 
allosteric changes play a substantive role.6-8 Allosteric communication between 
distal binding sites is vital for the proper function of regulatory circuits in the 
cell.9,10 The conformationally dynamic KIX domain of the master 
transcriptional coactivator CBP (CREB-binding protein) undergoes a structural 
shift and stabilization upon binding to a cognate ligand such as the intrinsically 
disordered transcriptional activation domain (TAD) of MLL (Figure 3-1).11 The 
interaction of a second ligand, pKID (phosphorylated Kinase Inducible 
Domain of CREB) is enhanced up to 2-fold by the presence of MLL and several 
Figure 3-1 Activator-KIX domain interactions  The KIX domain (grey) regulates 
different functions through interactions with activators from MLL(red) and 
pKID(blue) shown in a cartoon form.  The intrinsically disordered regions of 
transcriptional activators form helical structures upon binding to the KIX domain 
which contains two discrete binding sites.  
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elegant studies have documented allosteric communication between the two 
binding sites.12-16 However, the relatively modest affinities (KDs on the order of 
1-25 μM) of the native complexes and the aggregation propensities of the 
transcriptional activation domains have hampered kinetic dissection of this 
and other complexes.17,18 High concentrations of ligand are required to 
maintain these fully bound complexes at equilibrium. NMR has shown that at 
high concentrations, ligands tend to bind nonspecifically to KIX complicating 
the evaluations between the binary and ternary complexes.19,20 
The coactivator CBP exists across metazoans 21-23 and is a transcription 
hub that interacts with numerous transcriptional activators using several 
discrete domains.24,25 The KIX domain within CBP is a 90-residue motif that 
consists of a three helix bundle along with two 310 helices.14 It interacts with 
more than ten distinct transcriptional activators,25 via two different binding 
sites, with the resulting complexes leading to regulation of key functions such 
as hematopoiesis, cell cycle progression, and memory formation.14,16,26-28 Many 
of the KIX-binding TADs from activators such as pKID, MLL and c-Myb are 
intrinsically disordered regions that assume a helical structure only upon 
binding to interaction partners such as KIX.26,29,30 Conformational changes in 
both the TADs and KIX occur upon binding.11,12,14,16,28 However, the transient-
state kinetic mechanism of two ligands binding cooperatively to the KIX 
domain has yet to be defined, and there is little information on the mechanism 
of how different protein ligands elicit differential degrees of allosteric 
effects.13,15 Further insights into these processes are crucial for defining the 
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communication pathways within CBP interaction networks.  
PPIs between IDPs and their binding partners are complex, affecting 
both the thermodynamic binding affinity of the interaction (dissociation 
constants, KDs) and kinetic properties. Previously, stopped-flow transient-state 
kinetic studies were used to examine complexes between activators and 
coactivators.31 Here we hypothesized that a similar strategy could be applied 
to dissect the allosteric communication between the MLL and pKID binding 
sites of native KIX. As a complementary tool in this effort we use a covalent 
small molecule ligand of the KIX domain, fragment 1–10, that quantitatively 
forms a stable complex at the MLL binding site and in doing so alters the 
conformational dynamics of KIX (Figure 3-2A). This small molecule can 
influence binding at the second site either positively or negatively, depending 
on the site of covalent attachment, thus facilitating transient kinetic studies of 
KIX in its complexes with native binding partners to examine both positive and 
negative cooperativity. We find that the change in the dissociation rate of the 
TAD•KIX complex is the main driving force for changes in overall binding 
Figure 3-2 Comparing the conformations of KIX  (A) Overlay of KIX structures shows 1-10-KIX 
L664C5, with MLL, and both pKID and MLL. Note the structural shift in the loop and terminal 
regions upon ligands binding to KIX. (B) The binding sites of MLL (fire-brick red) and pKID (blue) 
on KIX, with 1-10 depicted in yellow from structure 1-10-KIX L664C. PDB IDs: 4I9O, 2LXS, 2LXT 
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affinities in positive cooperative binding events. These results suggest that KIX 
allosterically regulates its binding events not simply through altering 
interaction interfaces, but also through stabilizing the energetic state of the 
ternary complex. Thus, in this IDP protein complex, dissociation rate mainly 
governs the binding equilibrium.  
3.3 Results 
The goal in this study was to kinetically dissect the continuum of 
cooperativity in KIX ternary complex formation. Toward that end, in addition 
to wild-type (wt) KIX domain in complex with one or both of the native 
transcriptional activation domains of MLL and pKID, we used several KIX 
mutants as well as the cysteine-reactive small molecule ligand for KIX, 
compound 1–10 (Figure 3-2B). Replacement of isoleucine 660 with a valine has 
been shown to disrupt allosteric communication within KIX, providing a 
valuable control for these experiments.11,12 The two additional KIX mutants are 
those in which a cysteine residue replaces either N627 or L664, both of which 
border the MLL binding site. Both the N627C and L664C mutants maintain 
affinity for MLL and for pKID.5,32 Previously, we described the discovery of 
compound 1–10 through a Tethering screen of KIX L664C.5 
This small molecule forms a selective covalent complex through 
formation of a disulfide bond with the cysteine residue and, in doing so, 
occupies the MLL binding site. Furthermore, equilibrium binding experiments 
with the 1–10–KIX L664C complex demonstrated that 1–10 tethered to a 
cysteine residue at position 664 allosterically inhibits pKID binding. Parallel to 
the KIX L664C screen we carried out a Tethering screen of N627C and 
compound 1–10 emerged as a molecule that selectively tethers to that cysteine 
with high efficiency as well32; the binding properties of the 1–10–KIX N627C 
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complex are defined below. An advantage of 1–10–KIX L664C and 1–10–KIX 
N627C complexes is that they can be generated quantitatively in a disulfide 
exchange reaction and then purified, enabling a single species to be used in 
kinetic assays.  
3.3.1 Equilibrium Binding Measurements Define Extent of Cooperativity for Each 
Complex.  
Dissociation constant measurements of wild-type KIX and mutants 
either in complex with excess MLL or fully labeled with small molecule 1–10 
Figure 3-3 Bar graph of relative KD values of pKID•KIX complexes normalized to the 
KD of pKID and free KIX constructs  The KD values were obtained from fluorescence
anisotropy assays performed in triplicate. The KIX structure (PDB ID: 4I9O) with the
corresponding mutated residue depicted in a black sphere is shown under each KIX
construct. Bars below the dotted line reflect positive cooperativity whereas bars above
the line reflect negative cooperativity. Errors reflect the standard error (SE) of
nonlinear fits in GraphPad Prism propagated for normalization to free KIX constructs.
*0.01 < P < 0.05, **P < 0.01; P values are calculated by GraphPad Prism.  
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were carried out to define the extent of cooperativity for each of the complexes 
(Figure 3-3 and Figure 3-4). As expected, KIX I660V precomplexed with excess 
MLL exhibited no cooperative binding to pKID. However, KIX N627C either 
precomplexed with excess MLL or fully labeled with small molecule 1–10 
reproduced the cooperative binding behavior observed in the wild-type 
protein. In contrast, when 1–10 was fully tethered to KIX L664C, negative 
Figure 3-4 Anisotropy binding curves of complexes of KIX wt, KIX I660V, KIX N627C, and KIX 
L664C binding to pKID  All measurements were performed in triplicate and the error bars
indicate the standard deviation (SD) error of the three measurements. The KD values and SE
are shown in the table and they were calculated in GraphPad Prism.  
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cooperativity was observed, with a more than twofold loss of pKID affinity.  
3.3.3 Transient-State Kinetic Analysis of KIX Complexes. 
Subsequently, we examined the transient-state binding kinetics between 
KIX and pKID by fluorescence stopped flow in the presence and absence of the 
peptide and small molecule ligand at room temperature (Figure 3-6A). The 
association rate is determined from the changes in fluorescence intensity after 
rapidly mixing fluorescently labeled pKID with KIX complexes and the 
dissociation rate is measured from changes in fluorescence intensity when the 
labeled-pKID•KIX complexes are mixed with an excess of unlabeled pKID 
peptide. Fluorescein is tagged at the amino terminus of the pKID peptide, a 
construct that has been used in previous studies33-35 to show allosteric effects 
consistent with results from isothermal calorimetry (ITC) assays using 
unlabeled pKID.15 One rapid association phase was observed upon mixing 
pKID with varying concentrations of KIX complexes and the observed 
association rates exhibit a linear dependence on the KIX complex concentration 
(Figure 3-5). The slope from the linear regression fit is the rate constant (kon) of 
the association step. The value of kon for pKID binding to free KIX wt (kon = 14 
± 1 μM−1∙s−1) is of the same magnitude as values obtained by NMR relaxation 
dispersion in the literature (6 μM−1∙s−1)26, confirming that this is a viable method 
for studying the transient-state interaction between pKID and KIX. We did not 
observe an additional rapid conformational change step (approximately 200 s−1) 
reported in the literature due to time resolution constraints of the stopped-flow 
instrument (dead time ∼2 ms). The calculated association and dissociation rate 
constants measured for the various pKID•KIX complexes are summarized in 
Table 3-1, and Figure 3-6.
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Figure 3-5 Stopped-flow binding kinetics for the observed association rates  For
measuring the association rate constant excess KIX complex of varying concentrations
is rapidly mixed with a constant amount of FITC-pKID peptide (final concentration
25 nM) at 25 °C, and the change in fluorescence intensity is measured in real time. The
dependence of kobs on the concentration of excess KIX for formation of pKID•KIX
complexes (wild-type KIX, KIX I660V, KIX N627C, and KIX L664C), which suggests
this association step is a bimolecular interaction. The linear regression of each slope
approximates the association rate constant (kon) of this interaction. Each kobs value is
an average of two separate experiments; each experiment is an average of five to eight
traces. The error bars represent the SD of the two kobs values.  
Table 3-1 Association and dissociation rate constants of pKID∙KIX complexes  Association 
rate constants are slopes of linear regression fits. Errors reflect the SE of nonlinear fits in 




Figure 3-6 Comparing the Kon and Koff between pKID and KIX complexes  (A) The set-up for
measuring the association rate constant. An excess KIX complex of varying concentrations is
rapidly mixed with a constant amount of FITC-pKID peptide (final concentration 25 nM) at
25 °C. (B) The trace is shown for the change in fluorescence intensity in real time. (C) Bar
graph of kon between pKID and KIX complexes. The error bars represent SD of the average of
two values from separate experiments. *0.01 < P < 0.05, **P < 0.01; P values are calculated by
GraphPad Prism. (D) The schematic shows the experimental set-up for measuring the
dissociation rate constant of pKID from KIX pre-complexed with FITC-pKID. This complex
was rapidly mixed with an excess of unlabeled pKID peptide. (E) Dissociation traces of pKID
from KIX complexes by competition of excess amounts of unlabeled pKID peptide. The red
lines represent the fitted curve. All spectra in (B) and (D) were obtained by excitation at 493
nm and emission collected with a 510 (LP) filter. All spectra are an average of 5-8 separate
traces. (F) Bar graph of dissociation rate constants of pKID dissociating from KIX complexes.
The error bars represent SD of the average of two values from separate experiments. *0.01 <
P < 0.05, **P < 0.01; P values are calculated by GraphPad Prism.  
82 
 
The kinetics for the binding of pKID to the various KIX complexes show a positive 
correlation between the change in the affinity of KIX for pKID (KD) and the 
dissociation rate of pKID from the KIX•pKID complex (koff). Specifically, N627C 
shows positive cooperativity upon addition of either MLL or 1–10, increasing the 
binding affinity of pKID to KIX by nearly twofold, whereas the value of koff 
similarly decreases almost two-fold from 7.3 s−1 to 4.1 s−1 with no observed effect 
on the kon, which is in a constant range between 14 μM−1∙s−1 and 17 μM−1∙s−1. 
Therefore, in this system, positive cooperativity is primarily determined by koff. 
KIX L664C previously showed negative cooperativity upon tethering to 1–10.5 
Whereas an increase in koff contributes to this allosteric change as well (from 8.7 s−1 
to 13.8 s−1), there is also a decrease in kon values from 23 μM−1∙s−1 to 6 μM−1∙s−1. The 
control KIX variant, KIX I660V, in which the allosteric network is interrupted, 
shows no significant change in either the association or dissociation rate constants 
with and without the presence of MLL.  
3.3.2 Testing for stabilizing effects with KIX mutants   
The allosteric mechanism was shown to depend upon the structural 
stability of the domain in molecular dynamics simulations by Law, S.E. et al.36 They 
identified a combination of six mutations at two residues within the helix α3 that 
were predicted to increase KIX’s helicity and the affinity for c-Myb mimicking the 
allosteric effect from the MLL-KIX interaction. A few of these mutants were 
generated and their overall helicity was assessed by circular dichroism (CD). From 
these experiments, the helicity appeared to moderately decrease and subsequently 
pKID and c-Myb did not show an enhanced affinity for KIX over wild-type KIX 
(Figure 3-7 and 3-8). Previously at lower pH c-Myb was shown to increase its 
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affinity for KIX due to more favorable enthalpy.28 By decreasing the pH from 6.8 
to 5.5 the affinity of c-Myb for some of these mutants increased by 2-fold (Figure 
3-9). However, this enhancement was attributed to a favorable enthalpic 
contribution while these mutants were proposed to reduce the entropic cost.28,36,37 
Finally, the predicted helicity changes were minimal (4.2% for KIX S670N to 1.2% 
Figure 3-7 Mutants aimed to stabilize KIX and induce positive cooperativity  The position of the 
chosen residues are shown as S670 and K667. These mutants were assessed for their change in 
helicity by CD and their relative change in KD for c-Myb and pKID by FP-direct binding assays. 
Figure 3-8 Analyzing the helicity of KIX mutants  The selected mutants were scanned by CD and 
the helicity was determined from the molar ellipticity at 222 nm. 
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for KIX S670L).36 Consequently, the mutants may have induced subtle changes that 
were not readily observed with these CD and FP-direct binding assays. Finally, 
double and triple mutants may contribute to the stability of the third helix and this 
increase in the stability and helicity of KIX may detected more readily.  
3.4 Discussion on cooperativity 
Taken together, these data provide insight to the mechanism of ternary 
activator-coactivator complex formation (Figure 3-10a). In the case of positive 
cooperativity, the consistent kon values and the correlation of relative koff and KD 
values (Figure 3-10b) suggest that this cooperativity is achieved not by lowering 
the energy barrier for association but by increasing the energy barrier for 
dissociation. This indicates a scenario where the binding of one ligand to KIX does 
not significantly change the interaction interface for the second ligand, but when 
both ligands bind to KIX, this ternary complex occupies an energy minimum that 
Figure 3-9 Equilibrium binding results for KIX S670N and S670K against c-Myb  The pH of the 
buffer was changed from pH 6.8 to pH 5.5. The binding curve measurements were performed in 
triplicate and the error bars represent the SD of all three measurements. The KD values and SE 
errors are shown in the table and they calculated with nonlinear fits in GraphPad Prism 7.0. 
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is more stable than that of the binary complex. Therefore, the major effect of 
positive cooperativity is to stabilize the ternary complex (Figure 3-10c). That koff 
plays a major role in the cooperative binding of two activators to KIX is reasonable 
considering that our measured kon values (0.7-2.4 × 107 M-1s-1, Table 3-1) are close 
to the predicted maximal diffusion rate of 107-109 M-1s-1 for proteins in a cellular 
environment.30,38-40 Thus when cellular regulation requires an allosteric increase in 
protein-protein binding affinity, there is little room for increase in the association 
rate constant (kon). Alternatively, the dissociation rates (koff) are not governed by 
diffusion limits and can be significantly altered, providing access to a large range 
of binding affinities. The dissociation rates of transcriptional activators from DNA 
or small molecule ligands from proteins41,42 have been shown to govern the 
residence time of proteins and ligands in particular functional states and/or 
Figure 3-10 Summary for the kon and koff analysis  (a) A mechanism scheme for pKID association
with KIX complexed with peptide (in purple, MLL) or small molecule (in cyan, 1–10) ligand,
where the kon is a bimolecular process. The orange star on pKID depicts the position of the
fluorescein label, which is not at the primary site of interaction. (b) Cooperativity correlation plot
of relative kon vs. KD (Left) and koff vs. KD values (Right) (normalized to values for free KIX binding
to pKID for each KIX construct). These plots illustrate that there is little correlation between kon
and KD values whereas koff values linearly correlate with KD values exhibiting an R2 value of 0.8.
(c) A schematic energy diagram of the proposed mechanism of positive cooperativity through
stabilizing the final ternary complex (resulting in increase of koff). (d) A schematic energy diagram
of the proposed mechanism of negative cooperativity through stabilizing the initial binary
complex (resulting in both decrease in kon and increase in koff). 
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locations. It is possible that in this case the residence time of various TADs with 
the coactivator CBP is used to regulate the degree of transcriptional activation 
and/or histone acetyl transferase activity in cellular pathways.  
The analysis of negative cooperative binding with KIX (1-10 tethered to KIX 
L664C) reveals a more complicated scenario. In this instance both kon and koff are 
affected, with kon decreasing 4-fold and koff increasing 1.6-fold (Table 3-1). In a case 
when negative cooperativity is required in physiological regulation, there is ample 
room for the decrease of kon from diffusion-controlled limits. We noted from the 
chemical perturbation data that the residues perturbed by 1-10 upon tethering to 
KIX L664C are similar to those altered by the binding of sekikaic acid, a natural 
product small molecule that also allosterically decreases pKID binding affinity43. 
In the case of both 1-10 and sekikaic acid, the residues 608-611 and 629-631, which 
flank the loop region in helices α1 and α2, exhibit significant alterations. As we 
have identified two small molecule ligands of KIX, 1-10 and sekikaic acid, that 
both show negative cooperativity with pKID binding through standard screens, it 
is possible that negative allosteric regulation of KIX binding occurs with native 
ligands, a scenario currently under investigation.  
As demonstrated here, mutants and small molecules that lock the allosteric 
network within KIX are useful to understand the binding mechanisms for these 
conformationally dynamic complexes. The proposed mutants that promote 
positive cooperativity would also aid in understanding its function. They were 
chosen based on their ability to increase the overall helicity as shown by the 
calculation of KIX.36,44,45 Because the allosteric enhancement depends on the 
stability of KIX these mutants were expected to enhance the binding affinity for c-
Myb or pKID. From our work, so far, this helicity and enhanced affinity was not 
observed. However, the predicted changes were subtle - enhancing the overall 
helicity of KIX by no more than 4.2%. Therefore, the mutants may require different 
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experimental techniques to judge their effects. Previously other NMR and top-
down electron capture dissociation of gas-phase structures of KIX led to the 
proposal that this third helix is more stable the first two.46-48 This may reflect how 
the stability of this helix is important for the formation of KIX-activator complexes.  
3.5 Conclusion 
The transient kinetic experiments described here were significantly 
influenced by the availability of a covalent small molecule ligand for KIX. Not only 
do covalent ligand-protein complexes offer the advantage of an isolable, 
homogeneous sample for study, they enable us to access a continuum of 
cooperativity modes, significantly expanding the breadth of the analysis. Given 
the ease with which such covalent small molecules can be discovered via 
Tethering, we anticipate the broader use of such ligands in mechanistic studies of 
conformationally dynamic protein complexes that comprise critical cellular 
functions.49-51 
3.6 Methods and supplemental experimental information 
3.6.1 Preparation of protein and peptides 
Cloning, expression and purification of the KIX domain of CBP (residues 
586-672) and the KIX mutants were carried out as previously described.52,53 
Fragment 1-10 was tethered to KIX mutants by incubating 10 equivalents of 1-10 
in 50 mM phosphate buffer at pH 6.8 overnight.5 Excess small molecule was 
removed by illustra NAP-5 desalting column (GE Healthcare). The column was 
equilibrated with 10 ml of buffer and 0.25 or 0.5 ml of the sample was added, and 
eluted with 0.7 or 1.5 ml into storage buffer (10 mM Sodium Phosphate, 100 mM 
NaCl, 0.01 % NP-40, 10 % glycerol, pH 6.8) by gravity flow. The extent of tethering 
was verified by Q-TOF LC-MS (Agilent Technologies). When at least 95% of the 
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KIX cysteine mutant was labeled by the small molecule, the sample was flash 
frozen in liquid nitrogen and stored at -800C. Peptides were synthesized by Fmoc-
based solid phase synthesis methods, purified by HPLC, and verified by LC-MS 
as previously described.53 The sequences were as follows: 
(unlabeled) pKID: Ac-βA-TDSQKRREILSRRPS(Phos)YRKILNDLSSDAPG 
FITC-pKID:  FITC-βA-TDSQKRREILSRRPS(Phos)YRKILNDLSSDAPG 
FITC MLL19:   FITC-βA-ADAGNILPSDIMDFVLKNTP 
FITC c-Myb25: FITC-βA-KEKRIKELELLLMSTENELKGQQALW 
3.6.2 Fluorescence anisotropy assays 
The fluorescence anisotropy assays were performed in triplicate with a final 
sample volume of 10 μL in a low volume, non-binding, black, 384-well plate 
(Corning), and read using a Tecan Genios Pro plate reader with polarized 
excitation at 485 nm and emission intensity measured through a parallel and 
perpendicularly polarized 535 nm filter. FITC (Fluorescein isothiocyanate)-labeled 
peptides were diluted in storage buffer to a concentration of 25 nM. Then 10 μL of 
the peptide solution was added to a series of 50 μL solutions of various KIX 
concentrations in storage buffer to obtain the final concentrations of up to 20 μM. 
The samples were incubated for 30 min at room temperature before the degree of 
fluorescence anisotropy was measured (Tecan Genios Pro).  Anisotropy data were 
corrected for the change in fluorescence intensity using Equation 1, where “fB”is 
the fraction bound, “R” is the ratio between fluorescence intensity of 100% bound 
ligand and free ligand, “r” is the measured anisotropy value, “rF” is the anisotropy 
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value of free ligand and “rB” is the anisotropy value of 100% bound ligand. 
=
( )
        Eq. 1 
A binding isotherm that accounts for ligand depletion (assuming a 1:1 
binding model of peptide to KIX) was fit to the observed anisotropy values as a 
function of KIX concentration to obtain the apparent equilibrium dissociation 
constant, KD: 
= + ( − )×
[( ) ( )
      Eq. 2 
where “a” and “x” are the total concentrations of fluorescent peptide and KIX, 
respectively, “y” is the observed anisotropy at any KIX concentration, “b” is the 
maximum observed anisotropy value, and “c” is the minimum observed 
anisotropy value. Each data point is an average of three independent experiments 
with the indicated error (standard deviation). Data analysis was performed using 
GraphPad Prism 5 software. 
An analogous experiment with varying molecular equivalents of MLL to 
KIX was also carried out to determine that at least 4 molecular equivalence of MLL 
to KIX is required to elicit maximum degree of positive cooperativity. 
3.6.3 Fluorescence stopped-flow kinetic assays 
Stopped-flow experiments were performed on a KinTek model SF-2001 
stopped-flow equipped with a 75W Xe arc lamp in two-syringe mode. FITC was 
excited at 493 nm and its emission was monitored at wavelengths > 510 nm using 
a long-pass filter (Corion). 
All kinetic traces reported are an average of five to eight independent 
determinations. All traces displayed a monophasic association and fit to a single 
exponential equation (Eq. 3). Below, the single exponential function was fit to the 
transient kinetic time courses, F(t) as in Eq. 3, to obtain the fluorescence amplitude 
(A) and the observed rate constant, kobs; F(0) is  the initial fluorescence intensity and 
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t is the time.:  
( ) = [1 − exp(− )] + (0)       (Eq. 3) 
Analysis of the time courses was performed using Kintek software, and the 
reported errors are the asymptotic standard errors. The dependence of the 
observed rates on KIX concentration was analyzed using GraphPad Prism 4.0 
software.  
Control Experiments: 25 nM of pKID-FITC was rapidly mixed with either KIX 
storage buffer (10 mM Sodium Phosphate, 100 mM NaCl, 0.01 % NP-40, 10 % 
glycerol, pH 6.8) (Figure 3-11a) to control for potential photobleaching of the 
fluorophore or 0.1 mg/ml of BSA in KIX storage buffer (Figure 3-11b) to control for 
effects of nonspecific binding and crowding of protein. Both control experiments 
revealed no change in fluorescence intensity over 120 seconds.  
Figure 3-11 Stopped-flow traces of control experiments: (a) 25 nM pKID-FITC rapidly mixed
with KIX storage buffer; (b) 25 nM pKID-FITC rapidly mixed with 0.1 mg/mL BSA in KIX
storage buffer. Both spectra were obtained by excitation at 493 nm and emission was collected
with a 510 (LP) filter. Both spectra are an average of five to eight separate traces. 
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Association Experiments: 25 nM (final concentration after mixing) of pKID-FITC 
in KIX storage buffer was rapidly mixed with varying concentrations (0.1-5 μM, 
final concentration after mixing) of KIX complexes (free protein, pre-complexed 
with 4 equivalents of MLL peptide, or pre-tethered with 1-10) in KIX storage buffer 
at 25°C. The measured time domains (0.1 and 1 second or 0.05 and 0.5 second) 
were selected to enhance the data analysis as they were closest to the predicted 
best time-frame by the fits in the Kintek software.   
Dissociation Experiments: 25 nM (final concentration after mixing) of pKID-FITC 
in KIX storage buffer was pre-equilibrated with 500 nM KIX complex (final 
concentration after mixing) and rapidly mixed with 12.5 μM (500 molar 
equivalents, final concentration after mixing) of unlabeled pKID peptide in KIX 
storage buffer at 250C. The results are summarized in Table 3-1. The Y-intercepts 
from (kobs vs KIX concentration) approximately correlate with the off-rates fitted 
in the dissociation experiments. Three of the Y-intercept values had a larger error 
of fitting, rendering them with too high a degree of uncertainty to compare with 
experimental dissociation values. 
3.6.4 CD analysis of KIX mutants  
For the sample 300 μl of 10 μM KIX protein in 10 mM sodium phosphate, 100 mM 
NaCl, pH 6.8 was used. The CD cuvette was a Spectrosil far UV quartz, standard 
rectangular 1 mm cell with stopper (useable range 170 to 2700 nm, Starna® Cells, 
Inc., 21-Q-1). The CD instrument (JASCO J-175) equipped with a modified water-
bath to modulate the temperature scanned the samples for the wavelength from 
260 to 195 nm in continuous scanning mode at 500 nm min-1 with 1.0 nm 
bandwidth, accumulation of 5 runs, and data pitch of 1 nm at 200C. For data 
analysis, the sample’s CD signal was corrected by subtracting the buffer’s signal 
for each wavelength. The CD signal was cut-off when the dynode energy reached 
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500 volts or greater. Therefore, the typical scan resulted in analysis from 260 nm 
to 195-198 nm. The data was converted to mean residue ellipticity (deg∙cm2∙dmol-
1) using the following equation: 
[ ] =  
 ∗ ∗
        (Eq. 4) 
where Ψ was the CD signal in degrees, l was the path length in centimeter, c was 
the concentration in decimoles per cm2, and n was the number of amide bonds (100 
amides in KIX). The helical content was determined using the following 
equation54: 
% ℎ  = 100 ∗ [ ] ∗  
, ∗( . )    (Eq. 5)
 For the thermal melt, the temperature scan was set to read at 222 nm from 
200C to 950C ramping 1.0 0C∙min-1 and collecting data for each 1 0C. The resulting 
data were subtracted from the data for the equivalent scans of buffer only at 222 
nm. The data were fit using the nonlinear regression model response using a 
variable slope considering four parameters) using GraphPad Prism 7 software 
(La Jolla, CA). 
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 Covalent chemical co-chaperones for the CBP KIX domain§ 
4.1 Abstract 
As part of the coactivator CBP, the KIX activator-binding domain regulates 
diverse processes from development to cognitive function. It has been an attractive 
target for small molecule probes to understand how context-dependent activators-
KIX complexes regulate cellular functions, especially in diseases ranging from 
leukemia to memory disorders. However, the dynamic and transient PPIs formed 
by KIX are difficult targets for small molecules. An additional complication is that 
activator-binding motifs such as KIX are found in multiple coactivators, making 
specificity difficulty to attain. In this study, we demonstrate that the strategy of 
Tethering can be used to rapidly develop highly specific covalent modulators of 
the dynamic PPIs between activators and coactivators. These serve as both 
orthosteric and allosteric modulators, enabling the tunable assembly or 
disassembly of the activator-coactivator complexes formed between the KIX 
domain and its cognate activator binding partners. These molecules maintain their 
function and selectivity even in human cell lysates and in bacterial cells and thus 
will ultimately be highly useful probes for cellular studies.
                                                 
§ This chapter was a collaborative effort. Dr. C.Y. Majmudar, and Dr. W.C. Pomerantz 
constructed the KIX cysteine mutants. Dr. C.Y. Majmudar and Dr. W.C. Pomerantz ran the LC-
MS Tethering screen at the University of California, San Francisco with Prof. J.A. Wells and Dr. 
J.D. Sadowsky. Dr. J.C. Clayton synthesized the irreversible 1-10 small molecules referred to as 1-
10a-f. Dr. C.Y. Majmudar helped conduct experiments to assess their effect on KIX N627C and 
these results are shown found in in Table 4-1. Dr. C.Y. Majmudar helped plan and run the 
selectivity experiments in Figure 4-3. Dr. J.C. Clayton helped prepare samples for the selectivity 
experiments in Figure 4-7c. Dr. J.C. Clayton helped with the cell viability experiments found in 
Figure 4-9 and Dr. C.H. Doss supervised these experiments. 
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4.2 Introduction  
KIX is one of several conformationally dynamic domains found in the 
master coactivators CBP and p300.1,2 It interacts with more than 15 transcriptional 
activators at two distinct interfaces.2 NMR studies of KIX bound with native 
transcriptional activation domains (TADs) have shown that the endogenous 
partners such as MLL and c-Jun interact at a relatively deeper and smaller site (an 
area of approximately 900 Å2)3,4 while the transcriptional activation domains of 
CREB (pKID) and c-Myb interact with a shallower and larger surface on the 
opposite side.5 The two interfaces are allosterically connected such that binding of 
the transcriptional activation domain of MLL enhances the interaction of c-Myb or 
pKID at the other binding site by approximately 2-fold.4,6 This allosteric 
enhancement is thought to play a key role in recruitment of p300 or CBP to gene 
promoters.4,7,8 
The activator-KIX complexes participate in fundamental processes such as 
hematopoiesis and memory formation.9-11 The discovery of small molecule 
modulators for those processes has been of high priority in the selection, screening 
and top-down approaches to find KIX inhibitors.12-16 One early success was 
Naphthol AS-E, a molecules that disrupts oncogenic responses in cancer cell 
models with the CREB-KIX and MYB-KIX complexes as its intended targets.12,17,18 
As this examples illustrates, small molecules that target KIX have the potential to 
delineate activator-coactivator functions on a phenotypic level. However, even the 
most specific modulators for KIX have limited selectivity due to the level of 
redundancy in the protein interaction network.15,19,20 The binding surfaces that 
coactivators use to interact with activators are often similar. For example, the 
activator p53 interacts with the GACKIX motif as well as three other domains in 
CBP and p300, illustrating fundamental similarities in these binding surfaces. 21-25 
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Finally, the GACKIX motif within CBP has been found in at least four eukaryotic 
coactivators, including the closely related p300 but also in unrelated 
transcriptional regulators, such as ARC105/MED15, and RECQL5.26-28 Therefore, 
the unusually specific inhibitor sekikaic acid, a natural product that exhibits high 
specificity for the KIX domain, has the undesirable potential to target other 
coactivators with this motif in a cellular setting.15 This severely limits the utility of 
these probe molecules to dissect individual activator-KIX interactions and to 
understand their role in normal and pathological processes.27 Probes that also 
complement an interface in KIX are likely to accommodate other regions within 
co-regulators. 
 
Recently we reported that the covalent fragment discovery strategy of 
Tethering yields covalent chemical co-chaperones for KIX that stabilize distinct 
conformations of this plastic motif and, in doing so, modulate its ability to form 
binary and ternary complexes.29 While useful for structural and in vitro biophysical 
Figure 4-1 Irreversible Tethering scheme  The standard Tethering scheme involves in the 
formation of a mixed disulfide with the target when the fragment favorably interacts with the 
regions surrounding cysteine residue. By replacing the fragment’s disulfide with an alkylating 
moiety, the probes are compatible with the reducing environment of a cell.  
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studies, these molecules react with KIX via disulfide exchange under reversible 
conditions and are thus not usable in more complex environments such as those 
of cells and cell lysates. Here we show, that despite the shallow and poorly defined 
binding surfaces in GACKIX, irreversible covalent co-chaperones highly selective 
for their cognate binding site can be readily accessed by replacement of disulfides 
in the Tethering hits with more reactive moieties (Figure 4-1). Further, the co-
chaperones show high selectivity for their cognate binding site, even in the 
presence of many potential reactive partners. Finally, changes in the thiophile 
enable tuning of the assembly behavior of KIX, leading to allosteric enhancement 
or inhibition of binding with a subset of partners. 
4.3 Results and Discussion   
4.3.1 Converting 1-10 into irreversible analogues 
The KIX domain does not contain well-defined pockets for small molecules, 
but rather binding surfaces that are relatively featureless. These KIX binding 
surfaces adapt upon interacting with their binding partners so the conversion of 
the disulfide fragments into irreversible probes can be challenging. The 
irreversible probes need orient the fragment at the selected point of Tethering and 
effectively modulate the cysteine-containing KIX domain interactions. 
We sought a fragment that is well-established to impact the KIX 
interactions. The fragment 1-10 has previously been shown by the Mapp lab to act 
as an effective modulator of GACKIX-activator interactions by both disrupting 
MLL binding and enhancing interactions between KIX and pKID by 2-fold. Thus, 
1-10 was chosen as the scaffold for irreversible inhibitor development (Table 4-1). 
To initiate the investigation, the disulfide moiety of 1-10 was replaced with three 
distinct thiophiles with or without a glycine linker to produce 1-10a-f. These 
molecules were then assessed for dose-dependent alkylation of the KIX N627C 
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mutant and, as shown in Table 4-1, the DR50 values varied significantly with the 
nature and linkage of thiophilic group. The least effective reactive group in this 
series is the ,-unsaturated amide, with the labeling of the protein occurring only 
under forcing conditions. Both the -chloro amide and the vinyl sulfonamide 
series were effective labelers, with DR50 values ranging from 4.6 - 150 M after one 
hour.  
Any impact of these fragments on KIX N67C interactions was considered 
Table 4-1 Evaluating the 1-10 irreversible probes  The structure of the 1-10 disulfide and the 
irreversible derivatives are shown. The DR50 values were determined by varying the concentration 
of compound and after one hour evaluating how much of KIX N627C was labeled using LC-MS. 
The fold inhibition values were obtained from FP experiments by comparing the dissociation 
constants (KDs) for the unlabeled (DMSO) KIX N627C construct with the KDs for the labeled KIX 
N627C- 1-10 alkylator complex for both the MLL and pKID tracers. All FP measurements were
performed in triplicate and errors reflect the standard deviation (SD) error.  
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unique because the labeling KIX N627C with the alkylator, iodoacetamide (IAM), 
had minimal impact on the affinity of the endogenous ligands (Figure 4-2). When 
covalently attached to KIX each of these structures, 1-10a-d, competitively blocked 
MLL from interacting with its cognate binding site analogous to the parent 
disulfide 1-10. More remarkable are the effects at the distal binding site, with 
fragments 1-10b and 1-10c allosterically inhibiting the binding of pKID and 1-10d 
enhancing the binding nearly 2-fold, comparable to the effects observed with the 
native ligands MLL, pKID and c-Myb. E2A binds to the MLL-binding site of KIX 
and the alkylators 1-10a, 1-10c, and 1-10d also disrupt this interaction, but to a 
lesser extent than MLL (Figure 4-3). These alkylators also have negligible effects 
on c-Myb which binds to the pKID-site. Therefore, the linker and alkylation 
moiety, appears to differentially impact the assembly state of KIX.  
4.3.2 Assessing target engagement of two 1-10 irreversible probes 
A further examination of the reactivity of the covalent modifiers revealed a 
remarkable degree of selectivity for the MLL-binding site within KIX. None of the 
Figure 4-2 Effect of the alkylating agent, IAM on KIX N627C  The interactions between KIX 
N627C labeled by IAM and its endogenous partners, MLL and pKID remained unaffected by FP 
direct binding assays. All measurements were performed in triplicate and the error bars
indicate SD of the three measurements. The KD values and SE are shown in the table above
from the nonlinear fits in GraphPad Prism 7.0. 
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molecules (1-10a-f) react with the KIX domain in the absence of a cysteine residue 
(native KIX). In addition, covalent modification selectively occurs only in the MLL-
binding site, even when cysteine residues are introduced around other activator 
binding sites. Figure 4-4A shows covalent modifiers 1-10a and 1-10d, both of 
which are reactive electrophiles, only form covalent bonds with KIX when a 
cysteine is present at the cognate (MLL) binding site even when cysteines are 
introduced in other activator binding sites within KIX. In a more complex 
environment E. coli expressing KIX N627C protein was dosed with the irreversible 
probes for one hour and the resulting purified protein was analyzed by Q-TOF 
LC-MS to detect the extent of labeling by the irreversible probes (Figure 4-4B). 
Covalent modifier 1-10a required high (250 M or more) concentrations for 
effective labeling to occur, suggesting high cross-reactivity with other protein or 
small molecule thiols and/or a slower reaction with the KIX N627C target. In 
contrast, molecule 1-10d covalently labeled KIX at concentrations as low as 15.6 
Figure 4-3 Other TADs and their interactions with alkylated KIX N627C  The FP-direct binding 
assays were conducted with KIX N627C bound to either 1-10a, 1-10c, and 1-10d against the E2A 
and c-Myb tracers which share binding sites with MLL and pKID, respectfully. Each value 
represents an average of three separate measurements and the error bars show the SD error of 
nonlinear fits in GraphPad Prism 7.0 software. The table shows the relative change in KD from the 
unlabeled (DMSO) KIX N627C control versus the alkylated KIX N627C complexes and the error 
reflects the SD error. 
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M, close to the in vitro DR50 value and displays strong selectivity for the KIX 
domain. The affinity of the core scaffold of 1-10 (no electrophilic moiety) has been 
measured at approximately 250 M; thus, it is unlikely 1-10d at concentrations 
under 10 M will produce effects due to non-covalent binding interactions.  
The concern surrounding irreversible probes is that they may target critical 
cellular components in mammalian cells, prolonging adverse effects due to their 
reactivity. We assessed the cell viability of these alkylators in Hela cells (Figure 4-
5). The 1-10a α-chloro and 1-10c sulfonamide derivatives were more toxic at 
concentrations approaching 100 μM while the corresponding glycine-linked 
versions, 1-10b and 1-10d were tolerated after three hours. This demonstrates that 
Figure 4-4 Selectivity of 1-10 irreversible alkylators for KIX N627C  A) 1-10a and 1-10d show 
preference for the KIX N627C mutant located near the MLL-binding site. N644C is located in the 
loop and the remaining mutants, K662C, H651C, Q609C and K606C are located within the pKID-
binding site. The error bars represent standard error of the average of two separate experiments.  
B) The 1-10 alkylators were dosed into E. coli during the expression of KIX N627C protein and after 
nickel affinity purification, the extent of labeling was assess by LC-MS and each reaction was 
repeated three times. The error bars represent standard error from three separate experiments. 
*0.01 < P < 0.05, **0.05 < P < 0.001,***0.001 < P < 0.001, ****P < 0.001; P values are calculated by 
GraphPad Prism  7.0. 
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cells handle these probes well, perhaps due to the lack of nonspecific and toxic 
targets.  
Finally, we wanted to visualize the potential targets of these probes in a 
cellular environment. We did this in cells by adding the purified KIX N627C 
mutant to HEK293T lysate and then dosed in the biotinylated 1-10d probe. Biotin-
containing components were pulled-out of the lysate using neutravidin resin and 
analyzed by western blot with streptavidin-HRP (Figure 4-6). Once again, the 1- 
10d alkylator displayed significant selectivity for the target.  
4.4 Conclusion 
The purpose of targeting the KIX domain is to understand what roles its 
interactions with activators complexes play in transcriptional events. However, it 
is difficult to distinguish the role of the KIX domain in CBP versus p300 function 
due to their significant homology (90%). From our results, the irreversible 1-10 
derivatives displayed a preference for the cysteine-containing KIX N627C mutant. 
Figure 4-5 Cell viability for the 1-10 alkylators  A WST-1 cell proliferation assay was used 
to measure the viability of Hela cells in the presence of the 1-10 alkylators. Each 
measurement was duplicated with the values representing the average of all the 
measurements and the error bars represent the standard error. 
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They selectively enhance or disrupt interactions between KIX N627C and its 
activators only when the cognate cysteine residue is present. Since the binding of 
these probes are irreversible, nonspecific targets can drastically weaken their 
fitness as cellular probes.30-34 Our preliminary evidence shows that 1-10d engages 
the KIX N627C target with no prominent, off-targets in different complex 
Figure 4-6 Visualizing specificity with the biotinylated 1-10d probe  The structure of the 
biotinylated 1-10d probe is shown above. It was added with purified KIX N627C (25 nM) and 100 
μg of HEK293T lysate. Any biotin-containing proteins purified on neutravidin agarose beads were 
visualized by western blot using chemiluminescence with Streptavidin- HRP. The bands within 




Other covalent fragment screens start their search for alkylator-containing 
fragments rather than disulfide fragment.35-37 Our data reveal that the reactivity of 
the fragment regulates it ability to both engage KIX and to modulate interactions 
with KIX. If we ran the same LC-MS screen against a library containing the 
acrylamide-based fragments instead of disulfide fragments then 1-10 with intrinsic 
affinity for KIX may have been missed due to its suboptimal reactivity with KIX 
N627C (DR50 >500 μM). By starting with the disulfide fragments the screen depends 
upon reaching equilibrium conditions while the stringency of the screen is 
controlled through the concentration of reducing agent.38 Then a favorable 
fragment resides with its target and makes it less dependent on the kinetics or 
reactivity of its tail. However, the conversion from the mixed disulfide to the 
irreversible thiolphile still requires optimization. Based on our data one fragment 
from the reversible disulfide Tethering screen provided a framework to produce a 
range of irreversible modulators.  
The next step is to apply these probes in a cellular system; however the 
cognate cysteine mutation is required to achieve selective target engagement. A 
similar irreversible Tethering scheme has previously been adapted to target an 
oncogenic cysteine mutation (G12C) within Ras that impairs GTP hydrolysis.39 The 
purpose of those irreversible probes was also to selectively target the cysteine 
mutant form of Ras over the wild-type in cancer cells. In our method, an additional 
step is required to introduce the target cysteine mutant. For now, we have showed 
for the first time that Tethering can produce selective irreversible probes for PPIs.  
4.5 Methods 
4.5.1 Protein Expression and Purification 
As previously described40, the DNA sequence encoding the KIX domain 
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from mouse CBP  residues 586-672 was cloned into the bacterial expression 
pRSETB vector with an additional hexahistidine tag and a short polar linker fused 
to the N-terminus of KIX resulting in protein with the sequence (tag and linker 
residues are shown in lower case):
mrgshhhhhhgmasGVRKGWHEHVTQDLRSHLVHKLVQAIFPTPDPAALKDRR
MENLVAYAKKVEGDMYESANSRDEYYHLLAEKIYKIQKELEEKRRSRL 
The cysteine mutants at N627, R644, K662, H651, Q609, and K606 of CBP 
and R67 and H70 of MED15 KIX were generated using site-directed mutagenesis 
as previously described.41  
The CBP KIX protein was expressed in Rosetta2(DE3) pLysS Escherichia coli 
(Novagen). Cells were grown to an OD600nm of 0.8 - 1.0 (37 0C, 250 rpm), induced 
with 0.25 mM IPTG for 4 hours at 25 0C, harvested by centrifugation, and stored at 
-80 0C. The His6-tagged CBP KIX protein was affinity purified using a batch 
method with Ni-NTA beads (QIAGEN) following the manufacturer’s instructions 
and eluted with 400 mM imidazole. KIX was polished up with ion-exchange 
chromatography on a Source S column (GE Healthcare) in 50 mM phosphate 
buffer, 1 mM DTT, pH 7.2 eluting with the NaCl gradient from 0 to 1 M. Purified 
protein was buffer exchanged into 10 mM sodium phosphate, 100 mM NaCl, pH 
6.8 using a PD-10 column (GE Healthcare) and stored at -80 0C. 
The MED15 KIX cDNA encoding the amino acids 1 through 78 was 
synthesized by GenScript USA, Inc. and cloned into the pET-15b plasmid 
(Novagen, EMD Millipore) using the Nde1 and Xho1 cloning sites. The resulting 
recombinant ARC105/MED15 KIX protein sequence contained the N-terminal 
hexa-histidine tag and a thrombin cleavage site as shown in lower case letters; 
mgsshhhhhhssglvprgsHMDVSGQETDWRSTAFRQKLVSQIEDAMRKAGVAHS
KSSKDMESHVFLKAKTRDEYLSLVARLIIHFRDIHNKKSQASV 
The ARC105/MED15 KIX (1-78) protein was also expressed in 
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Rosetta2(DE3) pLysS Escherichia coli (Novagen) except after the cultures reached 
an OD600nm between 0.6-1 and then the temperature of the incubator was dropped 
to 20 0C. After one hour KIX expression was induced through the lac operon with 
the addition of 125 μM IPTG for 12-18 hours at 200C, 250 rpm. The cells were 
harvested by centrifugation for 15 minutes at 6,000 rpm in an Avanti Beckman 
Coulter High-speed Centrifuge with a JLA 8.1000 rotor or at 7,903 xg in a SorvallTM 
LYNXTM Superspeed Centrifuge with a Fiberlight F6-6x1000 LEX Carbon Fiber 
Rotor (ThermoFisher Scientific), collected in a 50 ml falcon tube, and stored at -
800C. 
For purification of the MED15 KIX cysteine mutants, a bacterial cell pellet 
expressed in one liter of terrific broth was thawed on ice and then suspended in 
approximately 25 ml of lysis buffer (50 mM sodium phosphate, 300 mM NaCl, 5 
mM imidazole, 1 mM β-ME pH 7.2, cOmpleteTM, EDTA-free Protease Inhibitor 
Cocktail Tablet (Roche)). The cells were lysed by sonication at 50% amplitude on 
ice using a 6 mm tip with pulsing cycles of 3 seconds on and 6 seconds off for at 
least 3 minutes of total pulsing time. The soluble lysate was collected by 
centrifugation for 30 minutes at 9,500 rpm (9,299 x g) in an Allegra X-22R 
centrifuge (Beckman Coulter) with a C0650 fixed angle rotor, and then incubated 
with 2 ml of suspended Ni-NTA agarose resin (Qiagen) for 1 to 2 hours rotating 
on a rotisserie-style tube revolver (Fisher Scientific). The resin was washed 5 times 
by adding 5 ml of wash buffer (50 mM sodium phosphate, 300 mM NaCl, 30 mM 
imidazole, 1 mM β-ME, pH 7.2), spinning down the resin at 2,500 x g for 2 minutes, 
and gently pouring off the buffer. The nickel-bound protein was eluted by 
incubating the resin with 1 ml of elution buffer (50 mM sodium phosphate, 300 
mM imidazole,1 mM β-ME, pH 7.2) for 30 minutes to one hour, and collecting the 
elution for a total of 4 ml of elution buffer per ml of Ni-NTA agarose resin. The 
elutions were concentrated to about at least 5 ml and diluted up to 12 ml with 10 
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mM sodium phosphate, 100 mM NaCl, 10% glycerol, 0.01% NP-40 pH 6.8. Then 
600 μl of 10x thrombin cleavage buffer was added (20 mM Tris-HCl pH 8.4, 150 
mM NaCl, 2.5 mM CaCl₂) with 10 μl of Thrombin (Restriction grade, Novagen® 
69671). The protein incubated overnight on the rotisserie at 40C. Then this protein-
cleavage cocktail incubated with 2 ml Ni-NTA agarose resin for one hour to 
remove remaining histidine-tagged KIX protein. The cleaved protein was isolated 
by pouring off the flow through from the resin and washing the resin once with 5 
ml of 50 mM sodium phosphate buffer at pH 6.8. This protein was further purified 
on the AKTA FPLC Purifier (GE Healthcare) with the strong cation exchanger 
Source 15S media (GE Healthcare) packed to a 17-ml column volume. After 
loading through the 50-ml super loop the column was washed for 1.5 column 
volumes with buffer A (50 mM sodium phosphate, pH 6.8 1 mM DTT). The protein 
was eluted from the column with a gradient of 0% to 60% of buffer B (50 mM 
sodium phosphate, pH 6.8, 1 mM DTT, 1 M NaCl) over four column volumes. 
Major peaks typically eluted around 20% and 30% of buffer B with thrombin-
cleaved KIX observed as the major species in the first peak and any remaining 
thrombin-tagged KIX eluting in the second peak.  
Using a 3 kDa MWCO Amicon Ultra-15 Centrifuge Filter Units (EMD 
Millipore) the ARC105/MED15 KIX was concentrated and buffer exchanged by 
adding 5 to 10 ml of buffer (10 mM sodium phosphate, 100 ml sodium chloride, 
10% glycerol, 0.01% NP-40 pH 6.8) after each spin at 3,500 rpm, 4 0C for 15 minutes 
in a swinging bucket rotor. The buffer was added in increments to the filter until 
the final added buffer volume was at least three times the final volume of protein. 
The protein was flash frozen in liquid nitrogen as 250 to 500 μl aliquots and stored 
at -80 0C. The concentration of the protein was measured using absorbance at 280 
nm on a NanoDrop 1000 Spectrophotometer (Thermo Scientific). The extinction 
coefficient for ARC105/MED15 KIX was measured using ProtPram with the 
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following equation  
ɛ =  (# )×ɛ( ) +  (# )×ɛ( ) + (# )×ɛ( )   (Eq. 1) 
where # is the number of amino acid residues present in the sequence and ɛ is the 
extinction coefficient. The extinction coefficients for tyrosine, tryptophan and 
cysteine measured in water are ɛ(Tyr) is 1,490 M-1 cm-1, ɛ(Trp) is 5,500 M-1 cm-1, 
ɛ(Cys) is 125 M-1 cm-1. The background absorbance for the protein was subtracted 
for the absorbance value at 340 nm and the buffer absorbance at 280 nm. From the 
absorbance at 280 nm the concentration of KIX was calculated using Beer’s Law 
 ( ) =  ɛ× ×           (Eq. 2) 
where l is the path length and c is the concentration in M (mol L-1). When necessary 
the sample was diluted in buffer to maintain an absorbance below 1.0 unit. The 
ARC105/MED15 KIX protein was verified by Q-TOF LC-MS (Agilent) analysis and 
the purity of the protein was assessed by SDS-PAGE.   
4.5.2 Peptide Synthesis and Purification  
All peptides were synthesized by standard N-9 Fluorenylmethoxycarbonyl 
(Fmoc) solid phase synthesis methods42 as previously described.40 The peptide 
sequences written as single letter amino acid abbreviations are as follows: 
MLL  βA-DAGNILPSDIMDFVLKNTP-CONH2 
pKID  βA-DSQKRREILSRRPS(Phos)YRKILNDLSSDAPG-CONH2 
c-Myb  βA-KEKRIKELELLLMSTENELKGQQALW-CONH2 
E2A  βA-KEKRIKELELLLMSTENELKGQQALW-CONH2 
The abbreviation, βA represents beta-alanine and S(Phos) is phosphoserine. The 
fluorescent fluorescein isothiocyanate (FITC) tag was added at the amino-
terminus of the peptide before the β-alanine residue. The C-terminus of the 
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peptides contained an amide group (-CONH2). 
4.5.3 Determination of the dose response (DR50) 
For the DR50 values, various concentrations (500-0.2 μM) of the fragments 
were incubated with 5 μM KIX mutant protein (at 1 mM β-ME) for 45 minutes at 
RT and incubated at 40C for at least 15 minutes prior to analysis. The percent of 
protein tethered to fragment molecules was determined by Q-TOF LC-MS 
(Agilent).44 The concentration of fragment molecule required for 50% maximum 
Tethering (DR50) was determined by data analysis in GraphPad Prism software 
4.00, fitting to Equation 3, where x is the log of fragment molecule concentration 
and y is the normalized response from 1 to 100 (percent of protein tethered to 
fragment molecule) (Figure 4-7a).  
= ( )          (Eq. 3) 
4.5.4 Alkylation reaction of KIX 
The KIX N627C mutant was incubated with 5 to 10 equivalents of small 
molecule in 10 mM phosphate buffer, 100 mM NaCl, pH 6.8 overnight at room 
temperature. Excess small molecule was removed and small molecule-protein 
complexes were concentrated using 10 kDa molecular weight cutoff concentrators 
(Vivascience). The extent of labeling was measured by Q-TOF LC-MS (Agilent). 
Protein complexes that were at least 95% alkylated were flash frozen in liquid 
nitrogen and stored at -80 0C.  
4.5.5 Fluorescent anisotropy assays  
The fluorescent anisotropy was measured in triplicate with a final sample 
volume of 10 μl in a low volume, non-binding, black, 384-well plate (Corning). For 
each experiment 25 nM of fluorescently labeled peptide tracers, FITC-MLL and 
FITC-pKID were incubated with various concentrations of the small molecule-KIX 
mutant complexes in binding buffer (10 mM phosphate, 100 mM NaCl at pH 6.8) 
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for 30 min. at RT. The plates were read using a Tecan Genios Pro plate reader with 
polarized excitation at 485 nm and emission intensity measured through a parallel 
and perpendicularly polarized 535 nm filter. A binding isotherm that accounts for 
ligand depletion (assuming a 1:1 binding model of peptide to KIX) was fit to the 
observed anisotropy values as a function of KIX to obtain the apparent equilibrium 
dissociation constant, KD:  
A = + −  × 
([ ] [ ]) ([ ] [ ]) [ ][ ]
[ ]
   (Eq. 4) 
where [LT] and [PT] are the total concentrations of fluorescent peptide and KIX 
protein, respectively, A is the observed anisotropy, Ab is the maximum anisotropy 
value for the fully bound peptide, and Af is the minimum anisotropy value for the 
free peptide. All nonlinear data analysis was performed with GraphPad Prism 4.0 
software (San Jose, CA). The KDs and FP direct binding curves for KIX N627C and 
the irreversible probes against the MLL and pKID tracer are shown in Figure 4-7.  
When the total intensity changed due to a difference in signal between the 
fluorophore’s bound and free species then the anisotropy values needed to be 
corrected.45 The anisotropy, r was corrected with an average of free and bound 
fluorophore: 
= × + ×         (Eq. 5) 
where fF and fB were the fraction contributions of the free and bound forms of the 
fluorophore.46,47 The fraction of bound peptide, fB was calculated from 
=
( ) ( )
        (Eq. 6) 
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where R = IB/IF was the ratio of total intensities for the bound and free peptide 
species.  
4.5.6 Labeling KIX cysteine mutants  
5 μM of cysteine mutants at KIX N627C, R664C, K662C, H651C, Q609C, and 
K606C KIX as well as R67C and H70C MED15 KIX stored in 10 mM sodium 
phosphate, 100 mM NaCl pH 6.8 were incubated with 100 μM of small molecule 
in DMSO (at 1 mM β-ME) for 1 hour at RT. The extent of labeling was measured 
Figure 4-7 Summary of DR50 and FP experiments to compare the effect of the irreversible probes 
with KIX N627C a) The dose response curves are shown for the different 1-10 alkylators. b) The 
dissociation constants, KD for MLL and pKID are shown for alkylated and unbound (DMSO) KIX 
N627C. The error reflects SE from the nonlinear fit in GraphPad Prism 7.0. c) The FP direct binding 
curves correspond to the KD values above. All measurements were performed in triplicate. The
values represent the average and the error bars represent the SD error. 
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by Q-TOF LC-MS (Agilent). Each labeling reaction was duplicated.  
4.5.7 Alkylation reaction in growing E. coli 
The protein expression system for the KIX N627C protein was expressed, 
as described above. Three hours after induction with 0.25 mM IPTG the culture 
was concentrated by centrifugation in which the cell pellet from 50 ml of culture 
was suspended in 1 ml of media. For a 1 ml alkylation reaction, 10 μL of compound 
in DMSO was added to concentrated cells to obtain concentrations of 100 μM, 250 
μM, 50 μM, and 12.5 μM. The mixtures were incubated for 1 hour at 25 0C (250 
rpm). The cell pellets were washed three times with 10 mM phosphate, 100 mM 
NaCl at pH 6.8 and stored at -80 0C. Purification was carried out as previously 
described.48 The elutions were buffer exchanged into 10 mM phosphate, 100 mM 
NaCl at pH 6.8 and concentrated using 10 kilodalton molecular weight cutoff 
concentrators (Vivascience). The samples were analyzed by Q-TOF LC-MS 
(Agilent). The extent of labeling was determined by comparing the peak intensity 
of small molecule-KIX N627C complex versus unlabeled KIX N627C. 
4.5.8 Cell viability assay 
Hela cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum albumin (FBS). In a 96-well plate 4,000 
cells were plated per well. The next day they were treated for three hours with the 
indicated concentrations of compound and the control vehicle was dosed with 1% 
v/v DMSO. After three hours, the media was swapped with fresh DMEM 
containing 10% FBS with 10% WST-1 reagent and the plate was read at an 
absorbance set to 440 nm after one to two hours and the data was normalized 
against the DMSO (1% v/v) vehicle control.  
4.5.9 Neutravidin pull-down assay with the biotinylated 1-10 probe 
HEK293T cells were maintained in DMEM supplemented with 10% FBS. 
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The cells were lysed in 750 μl of lysis buffer (150 mM NaCl, 50 mM Tris (pH 8.0), 
0.1% Nonidet P-40 (NP-40)) containing halt protease inhibitor cocktail (Thermo 
Scientific) and soluble lysate was isolated by centrifugation (12,000 rpm, 4 0C, 15 
min.) HEK 293T lysate (100 ng total protein) and 25 nM of purified KIX N627C 
were incubated with DMSO or various concentrations of the biotinylated 1-10d 
probe (5 μM, 1 μM, 200 nM, 40 nM and 8 nM) at RT for 1 hour. Following 
incubation with NeutrAvidin agarose resin (50 μL, Thermo Scientific) for 1 hour 
at 4 0C the beads were washed twice with 1 ml of wash buffer (10 mM phosphate, 
100 mM sodium chloride, 10% glycerol, 0.1% NP-40, pH 7.2) and the resin-bound 
complexes were eluted by boiling in NuPAGE® LDS Sample Buffer (Invitrogen) 
containing DTT. The samples (15 μL) were resolved on 12% SDS polyacrylamide 
gel by electrophoresis. The proteins were transferred onto a PVDF membrane and 
incubated with streptavidin conjugated to hydrogen peroxidase (HRP) enzyme 
(ab7403, Abcam) at 1:10,000 dilution in 10 mM PBS, 0.2% Tween-20. The 
membrane was developed using Amersham ECLTM Prime Western Blotting 
Detection Reagent (GE Healthcare) and captured on X-ray film.  
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 Conclusions and Future Directions 
5.1 Abstract 
The GACKIX activator-binding motif plays a key role in the transcription 
by interacting with different activators to regulate the expression of genes. The 
functions of activator∙GACKIX complexes are diverse and include cellular growth, 
hematopoiesis, synaptic plasticity, and lipid homeostasis. Chemical tools are 
sought to dissect the individual functions of activator∙coactivator complexes and 
to provide a potential therapeutic model for diseases as diverse as leukemia and 
Alzheimer’s disease. This small domain has been found in CBP and its homolog 
p300 as well as the other unrelated coactivators such as ARC105/MED15. 
Therefore, selective small molecules that distinguish between these KIX domains 
such as CBP versus p300 remains a challenge. The site-directed strategy known as 
Tethering was applied to match orthogonal disulfide-containing fragments with 
the cysteine-modified KIX domain. These probes were designed to selectively 
target CBP KIX versus p300. Finally, the activator-KIX complexes are transient and 
defining so how KIX responds to the demands of multiple activators remains 
unclear. Chemical and biochemical tools were also used to impact the 
conformations of KIX. These KIX constructs enable us to define how the ternary 
complex depends on the stabilization of the ternary complex. Additional work 
remains to develop additional probes for these activator∙coactivator complexes 
and to understand their function in cells. 
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5.2 Conclusions  
This dissertation focuses on the development of analytical tools and 
chemical probes for the study of the interactions between the KIX domain of CBP 
and its activator binding partners including c-Myb, MLL, and pKID. This work 
began by developing orthosteric modulators for the MLL- and CREB(pKID)-
binding site of KIX. Effective small molecule inhibitors (500 Da or less) for PPIs 
may have a daunting task when they must compete with large peptides (~2,000 
Da) to disrupt the interactions. Therefore, PPIs were initially viewed as 
“undruggable”1,2 – a researcher may have preferred to look for the proverbial 
needle in a haystack than find small molecule PPI inhibitors. In the last decade, 
small molecule development for PPIs has gained traction from being 
“undruggable” to often being “difficult”. Prior to this work small molecules that 
target CBP KIX lacked potency being within the mid-micromolar range. Since the 
KIX domain is highly conserved especially between the coactivators CBP and p300 
these probes also remain limited in their ability to selectively distinguish CBP KIX 
versus p300 KIX prompting the need for alternative attack strategies. This 
dissertation work demonstrated how the Tethering strategy developed site-
selective probes for CBP KIX (Figure 5-1).  
In Chapter 2 small molecules were identified using a novel fluorescence 
polarization (FP)-based Tethering screen to identify inhibitors of the 
CREB(pKID)∙KIX interaction.3 A liquid chromatography mass spectrometry (LC-
MS) Tethering screen identified the disulfide fragment known as 1-10 which 
bound within the MLL-binding site to the KIX N627C mutant and directly 
inhibited MLL binding. The 1-10 disulfide displayed unique capabilities 
unforeseen for this fragment. The KIX N627C tethered to 1-10 mimicked the KIX-
MLL complex by engaging the allosteric networking to increase its affinity for 
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pKID by two-fold. However, 1-10 tethered to KIX L664C disrupted interactions 
with pKID. In addition to the I660V KIX mutant that nullified the allosteric 
network these KIX constructs provided a framework with which to understand 
how the allosteric alterations impact the formation from a binary KIX-MLL to the 
ternary KIX-MLL-pKID complex using transient kinetic stopped-flow 
experiments (Chapter 3). In Chapter 4 the 1-10 disulfide was converted into 
irreversible compounds to produce compatible cellular probes. The strategy 
involved the addition of electrophiles with or without a glycine linker to the 1-10 
fragment. The linkers and electrophilic moieties with 1-10 ranged in their abilities 
to engage the target and impact both sites within KIX N627C. For instance, the 1-
10 vinyl sulfone had a slight disruption with the pKID interaction. While the 1-10 
glycine-linked vinyl sulfonamide enhanced the pKID interaction with the KIX 
N627C mutant 2-fold. These two derivatives disrupted the formation of the MLL 
complex to the same degree. These results show that subtle changes in contacts 
Figure 5-1 The Tethering-based approach to develop selective probes for CBP KIX  Eukaryotes 
contain at least four GACKIX motifs in different transcriptional regulators as shown on the far left: 
RecQL5 (green), p300 (purple), CBP (grey), and MED15 (blue). By identifying reversible, disulfide-
containing fragments and converting them into irreversible covalent probes, these probes are 
expected to selectively target the cysteine-containing KIX domain of CBP over the other KIX-
containing proteins in cellular models. PDB IDs: 2LXT, 2GUT, 2K0N, 4BK0 
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between KIX and its ligand alter it allosteric capabilities.  
5.3 Future directions  
5.3.1 Expanding on the Tethering screen  
In Chapter 2 a novel FP-Tethering screen was developed to directly target 
the pKID-binding site of KIX. Different screening platforms can broaden the 
applicability of Tethering to other systems. For instance, a fluorescence resonance 
energy transfer (FRET)-based screen should also work as a homogenous and high-
throughput Tethering screen.4 FRET occurs through nonradiative (dipole-dipole) 
energy transfer from a donor to an acceptor fluorophore when they are around 1-
10 nm apart. Time-resolved FRET (TR-FRET) reduces auto-fluorescent artefacts 
because of the time delay of the signal. The FP Tethering screen must remove 
fluorescent artefacts that were more than 150% of the total fluorescent intensity of 
the controls, but these artefacts are less likely to occur with a TR-FRET signal. A 
high-throughput screen utilized both FP and FRET (F2) signals to produce a robust 
screening strategy.5  
The fragments identified from these assays depend on the screening 
platform (Figure 5-2). They could expand to evaluate the interactions between KIX 
and its other partners. For instance, c-Myb shares an overlapping site with pKID. 
Therefore, running two parallel FP screens against pKID and c-Myb could 
measure how fragments impact these interactions. A similar type of FP screen 
identified fragments that target an interaction between BRCA1 and a 
phosphorylated peptide expect the same peptide was labeled with either 
fluorescein or rhodamine.6 The main advantages of the dual-fluorophore screen is 
to validate hits reducing common artefacts including false positives from 
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fragments with intrinsic fluorescence.6  
With this dual FP scenario, the assay with c-Myb requires optimization. The 
affinity of KIX and c-Myb is high (KD 1.1 ± 0.2 μM, as shown in Chapter 2), and 
detrimental is its low dynamic range (~30 anisotropy units) and high signal-
background ratio (S:B) using the minimal recognition motif of c-Myb (25 amino 
acids) with an amino-terminal fluorescein tracer. Therefore, this assay requires 
optimization starting with changes in the c-Myb tracer. A longer 32-amino acid c-
Figure 5-2 Site-directed Tethering scheme  Fragments with intrinsic affinity for the KIX cysteine 
mutant (cysKIX) are identified through the formation of a stable mixed disulfide. LC-MS based 
Tethering screens directly measure the formation of fragment-cysKIX complex by a shift in the 
mass of cysKIX. The added mass is equivalent to the mass of the fragment. FP-based Tethering 
screens require a fluorescently labeled peptide. When the fragment binds to cysKIX the FP signal 
drops due to the displacement of the peptide from cysKIX. A dual FP Tethering screen is proposed 
to measure the orthosteric and allosteric effect of a favorable fragment-cysKIX complex. 
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Myb construct improves its affinity for KIX (KD 0.23 ± 0.06 μM by ITC).7 Finally, 
changing the fluorescent dye can potentially improve the robustness of this assay. 
Fluorophores with high extinction coefficients are considered bright (high 
maximum of absorbance and extinction coefficient), but the emission efficiency 
(quantum yield) of the dye depends on the environment. For a dual FP screen, the 
same peptide labeled with the red-shift tetramethylrhodamine (TAMARA) 
fluorophore exhibited a larger FP dynamic range then the green-shift fluorescein 
dye. Therefore, the FP assay against c-Myb could rapidly improve with minor 
changes.6  
Small molecule probes for KIX often either allosterically disrupt or enhance 
interactions at the second site. However, few screens detect the impact of 
fragments at both sites.8,9 While examining different fluorophores, an assay could 
focus on both sites within KIX. This assay could, for instance, involve MLL-labeled 
with a red-shift rhodamine fluorophore and a green-shift fluorescein-labeled pKID 
peptide. The two dyes must act independently and they shouldn’t interfere with 
the native interactions between the peptides and KIX. The plate reader also needs 
compatible optical filters to run two different tracers in the same screen. This type 
of FP assay that rapidly detects binding events at both sites in the primary screen 
can lead to potentially interesting allosteric modulators (Figure 5-2).  
So far, the LC-MS and FP-based Tethering screens have been used (Figure 
5-2).3,10,11 Both screens have advantages and disadvantages. For instance, the LC-
MS screen directly detects favorable fragment-complexes but it is time-consuming 
and expensive. The FP screen is rapid, but it requires a fluorescently-labeled 
partner. The drop in a FP signal should represent the same events observed in the 
LC-MS screen – a fragment binds to the cysteine within KIX. Practically, the FP 
screen ranks the most active or best inhibitors for the target complexes while the 
LC-MS screen provides the efficient binders. The FP Tethering screen was tested 
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against a pKID tracer with KIX H602C. Perhaps, in hindsight a parallel LC-MS 
analysis would provide a comparison for the fragments that result from using 
these two different platforms. The parallel Tethering screens require additional 
time for the LC-MS analysis, however by reading the FP signal first the same 
samples can then be directly injected onto the LC-MS system. This process reduces 
the material consumption if the reagents and buffers are compatible with both FP 
and LC-MS analysis.  
The pKID-binding site has a large surface area and lower affinity 
interactions then the MLL-binding site so it has previously been described as less 
amenable to small molecules.8 Therefore, it is likely advantageous to target other 
cysteines within the pKID-binding site. The caveat of Tethering as a site-directed 
approach is that identifying effective small molecules may require extensive 
screens probing at different regions of the interface. Since KIX is conformationally 
flexible, it may appear featureless and broad, but it could contain cryptic small 
molecule binding regions. These sites only appear in the presence of a ligand. 
Computational models are available to predict the locations of these sites, but 
additional screens would be needed to test these potential sites.12 Once identifying 
cryptic sites, the fragments would efficiently bind to this region – a characteristic 
that would certainly overcome the current limitations of developing irreversible 
probes for this pKID-binding site. When converting the fragments, 6D11 and 3D4, 
into irreversible probes, their binding efficiencies were poor in comparison to the 
disulfide fragments (Figure 5-3). Even with less than half of KIX H602C labeled by 
these derivatives they retained their ability to disrupt the interactions with KIX. 
Unfortunately, as probes they need to efficiently recognize their target otherwise 
they react with other free thiols in cells. Therefore, designing probes from 
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fragments that engage the target and elicit a desirable function improve on the 
development of irreversible probes.  
5.3.2 Developing covalent probes  
In Chapter 4 covalent probes were developed to target the engineered 
nucleophilic thiol cysteine mutant of KIX N627C. This conversion requires 
optimization with different reactive groups to improve the efficiency of covalent 
bond formation which leads to functional and efficient probes (Figure 5-4).13 For 
instance, electrophiles, such as vinyl amide, α-chloro ketone and vinyl 
sulfonamide derivatives range in reactivity.14-16 The alkylators need to balance this 
so they efficiently engage the target above all other free thiols.17-19 An assay that 
measures the reactivity of the alkylator and the reversible affinity of the fragments 
ranks the function of the irreversible probes.20 This involves a time-dependent 
assay that measures the irreversible inhibition (kinact) with the reversible binding 
Figure 5-3 Development of irreversible probes for KIX  The disulfide fragments, 3D4 and 6D11 
bind to KIX H602C within the pKID-binding site. Examples of irreversible probes based on these 
fragments are shown with their activity from KIX H602C. The disulfide 1-10 was converted into a 
series of alklyators with two derivatives shown. PDB ID: 2AGH 
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affinity of the fragment (Ki).21  
Other reversible covalent electrophiles would reduce intrinsic reactivity of 
the electrophile with the aim to minimize any off-target effects. While other 
cyanoacrylamide groups were explored with 1-10 their complexes were 
undetectable by LC-MS. However, these covalent modifications are advantageous 
because if they react with other free thiols the bond is rapidly reversible. Therefore, 
these reversible electrophiles may be useful to develop cellular probes from the 
disulfide fragment (Figure 5-3).22,23  
This leads to the main concern that the covalent probes need to undergo 
extensive selectivity assessments.24 In cells, irreversible alkylators may react with 
glutathione and target reactive cysteines in proteins.25 For instance, 518 human 
kinases have an accessible reactive cysteine.22 Therefore, providing rapid assays 
against the reactive cysteines within cellular models would reduce the 
investments required to test these probes. Activity-based probes such as attaching 
biotin to the probe also identify any off-targets. After cells are treated with this 
compound then biotinylated protein targets are isolated. Western blots 
quantitatively show if other biotin-containing proteins are isolated using a 
Figure 5-4 Examples of reactive warheads On the left, the blue box 
encloses irreversible functional groups. In the yellow box, functional 




detection reagent such as streptavidin conjugated to horseradish peroxidase.26 If 
these biotinylated proteins are isolated, digested into peptides then any potential 
targets of the biotin-tagged probe can be identified through a LC-MS-based 
proteomics experiment.27,28 For downstream cellular analyses when probes cause 
a biological response in cells then more confident hypotheses are drawn because 
any potential non-specific targets of a probe are known and minimal or ideally, 
non-existent.29  
5.3.3 Alternative method to identify probes for homologous domains 
In Chapter 4 the irreversible Tethering strategy led to the development of 
probes to selectively target the KIX domain within CBP versus other coactivators 
such as p300. The ‘bump in the hole’ strategy represents another method that 
designs selective probes against highly similar domains. With the bump-and-hole 
approach, a binding site is reconstructed using site-directed mutagenesis. Then a 
fragment with intrinsic affinity for the domain is modified with large, bulky 
groups that accommodate the modified target over the apo protein.24 Compatible 
modifications are made between the protein and fragment until a specific probe 
results for the mutant protein. For more difficult targets this requires “larger” 
holes (more dramatic mutations); but these mutations must also conserve the 
structure and function of the protein domain.30-32 This technique has adapted a BET 
bromodomain inhibitor, I-BET762/JQ1 selective for BET bromodomains 
possessing a distinct leucine or alanine mutation versus the entire BET subfamily.33 
This method could also produce selective probes for the KIX domain. For instance, 
the initial fragments such as 3D4 and 6D11 bind to region near the cysteine mutant 
KIX H602C. By mutating around this region in KIX and altering the fragments 
selective small molecules may be developed for KIX. Additionally, in CBP KIX 
nearby the 602 residue is a serine, but in p300 KIX this residue is an asparagine so 
132 
 
the modifications to the fragments 3D4 or 6D11 could exploit this difference to 
selectively target one KIX motif over another (Figure 5-5).34   
5.3.4 Venturing to probe the cooperativity imparted by KIX 
In Chapter 3 the ternary complex formation from the binary MLL-KIX to 
MLL-KIX-pKID was examined using different constructs of KIX that conveyed no, 
negative, and positive cooperativity and transient state kinetics.35 Allostery is a 
complex process that involves changes in how a partner binds in the absence and 
presence of a second ligand.36 The mutants and covalent probes produce 
homogenous populations of KIX and these complexes are useful to understand 
how the second partner binds to an otherwise nonnative, but functional form of 
KIX. Therefore, identifying additional ligands and mutants that target 
conformations of KIX could be used to aid in our understanding of the underlying 
allosteric mechanism of KIX and its partners.  
Fragments that bind to KIX alter the conformational states by either 
stabilizing or destabilizing KIX. These changes shift the thermodynamic 
equilibrium between the bound and native state of KIX which are detectable by 
measuring the melting temperature (Tm) through “thermal shift” or “thermofluor” 
Figure 5-5 Bumb-and-hole approach  A proposed scheme with KIX (grey surface) H602C binds to 
a the known ligand, 6D11 represented as blue sticks that binds to KIX H602C. This ligand binds in 
proximity to a single amino acid difference between CBP and p300 (orange region) and this 
difference could be used to generate a selective small molecule. PDB ID: 4I9O 
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DSF assays. It detects the unfolding process through a fluorescence signal of an 
environmentally sensitive fluorescent dye. SYPRO® orange, for instance, emits 
light from the hydrophobic surface of protein and it is quenched as the protein 
unfolds exposing the dye to aqueous solution.37 The melting temperature, Tm 
reflects the temperature when 50% of the protein remains folded. This is measured 
from the point of inflection of the fluorescence signal against the temperature. DSF 
is a high throughput technique heating as fast as 2 degrees C per minute and it is 
used to identify ligands that stabilize proteins. The material consumption is 
moderate requiring a volume of 10-20 μl for a 384-well plate. Multiple fragments 
can be screened per well. This combinatorial screening approach reduces 
nonspecific interactions due to competing fragments. If the Tm shifts, then the 
compounds from the well are separated out in a secondary screen. This reduces 
the intensive material consumption and time required for DSF screens.  This type 
of screen may provide novel fragments for the coactivator domain targets because 
it primarily detects stabilization or destabilization of the target. This can later show 
how these effects impact binding events and functions.38  
In Chapter 3, mutations within the third α-helix of KIX attempted to 
stabilize its structure and to increase the affinity of KIX for c-Myb. Structurally, 
KIX is marginally stable and this stability is hypothesized to regulate its function 
and ability to induce cooperativity between the two activator-binding interfaces.39-
41 Stability results by limiting the dynamics or thermal fluctuations within the 
protein, but specific factors remain difficult to isolate and to predict. Large 
structural shifts result in minimal stability changes while small, subtle changes 
may significantly stabilize a structure.42 Therefore, stable conformational states of 
KIX that impact its interactions remain difficult to capture. An artificial selection 
technique could experimental identify mutations that stabilize it. For instance, a 
shotgun mutagenesis library can be made with a parental protein expression 
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vector that is randomly mutated to create a library of clones with each well 
representing an individual point mutation.43 Two or three mutants are generated 
per position often reflecting a conservative and more drastic change. In a well-
based format, the mutants are processed through the cloning process to purified 
protein. Then the protein can either be screened by a thermal melt assay or by a 
binding assay. In a high-throughput binding assay the protein expressed with a 
tag (hexahistidine or biotin) is easily isolated on compatible plates. This format 
enables a rapid screen with methods such as surface plasmon resonance or 
biolayer interferometry that require an immobilized protein to measure its affinity 
against different binding partners.44  
Alternatively, an endogenous screen in cells detects robust mutants that 
maintain function and cell viability.45 For this type of screen a CRISPR/Cas9 
platform introduces double-stranded breaks (DSB) using library of guide RNAs 
(sgRNA) to target regions across the target gene.46,47 The breaks induce the non-
homologous repair pathway which produces small insertions or deletions (indels) 
at the DSB.48 While these indels initially appear random they are reproducible 
across experimental replicates, and cell lines. Viable genes are sequenced and then 
the protein is re-assessed in vitro for how these mutations effect the function or 
structure of the target protein. Due to subtle changes within KIX this type of screen 
would likely benefit from a robust signal such as designing a reporter (FRET or 
luminescence) assay within the cells.4,49 The mutational robustness of KIX may 
reflect how it selects its partners. For instance, CBP and p300 KIX bind to a variety 
of activators while ARC105/MED15 KIX selectively bind to sterol response 
element binding proteins (SREBPs) to regulate metabolism.50 This type of in cellulo 
screen may reveal how the GACKIX motif evolves to selectively bind to activators 




5.3.5 Examining coactivators and its complexes 
The PPIs between activator and coactivators are reduced to a minimal 
transcriptional activation domain (TAD) from the activator and the coactivator 
domain partner to study them using biochemical methods in vitro. In the full-
length coactivator, domains are separated by flexible regions that allow them to 
function independently. 51 Little evidence is available to understand how the 
domains orient in the full-length coactivator and whether a domain’s interactions 
are regulated by the others.52 The domains within CBP/p300 have been extensively 
characterized so it is time to link these complexes together starting with more 
extensive structural characterization of the coactivators. The first hurdle it to 
isolate these large proteins and insect cells enable the expression of large, 
challenging proteins (Figure 5-6).53 The initial structural characterization of the 
coactivator can proceed through techniques such as electron microscopy (EM)54 
and ion mobility mass spectrometry (IM-MS). With IM-MS collisional cross-
Figure 5-6 Structural characterization of the coactivator, CBP or p300   Above represents the 
domains of CBP and p300. The respective positions of these domains are taken from the protein 
sequence and individually the structures for the domains have been characterized. The overall 
structure for the coactivators has not yet been characterized. The general steps for protein 
expression in insect cells are outlined. This type of procedure is useful to successfully isolate large 
and/or complex proteins.   
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section analysis measures the average rotational orientation or size. This large 
coactivator makes it difficult to reconstruct a model, but could be aided with EM 
structures and the expansion of computational tools. Perhaps, by using an 
ensemble of known ligands, these extensive experiments and computational 
predictions can show how these domains orient with respect to one another. 
Additional mass spectrometry tools including cross-linking, electron capture 
dissociation and other bottom-up approaches can analyze peptide cleavages to 
reconstruct structures.55 This type of molecular detail provides insights into how 
the coactivator functions as a hub to interact with hundreds of activators.56  
5.3.6 Expanding into cellular systems 
The long-standing goal is to understand how these activator-coactivator 
complexes function in a cellular environment. For in vitro experiments, highly pure 
proteins, peptides, and small molecules are mixed in buffered solutions for 
binding interaction studies. In cells, these PPIs occur in heterogenous and crowded 
environments yet detecting PPIs in these complex environment remains 
challenging. Additional methods are expanding the ability to probe these PPIs in 
cellulo. As previously stated the covalent probes are tested for their ability to bind 
to the target. These probes often affect the conformational stability of KIX which 
also modulates its interactions. The cellular thermal shift assay (CTSA) is 
analogous to the DSF assay described in section 5.3.3, but it measures the relative 
stability of a protein extracted from cells. In this approach, cells are heated causing 
unstable protein to precipitate. Then the target protein is isolated from the soluble 
fraction and quantified by immunoblotting. Probes that target the protein or 
mutations within the protein are introduced into cells and their effects on protein 
stability are measured through the thermal shifts (the amount of protein against 
the increasing temperature). The limit for this technique is the ability to selectively 
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isolate the target protein, usually through a specific antibody. KIX is a small 
domain making up 12 kDa of the total 265.2 kDa of the coactivator CBP. Therefore, 
it is unlikely that immunoblotting for CBP detects the stability differences within 
the KIX domain and even less likely that a specific antibody can detect the KIX 
domain of CBP over p300. However different probes that target other domains 
within CBP or p300 can be used in combination with the probes for KIX and then 
the stability differences may be substantial enough to detect. Mass spectrometry 
techniques may also be developed to quantify stability differences of these 
coactivators.  
This represents how transcriptional regulators are difficult to study in cells 
because the individual complexes make small, but critical contribution to 
transcriptional processes. These complexes are also dynamic meaning they are in 
constant flux drifting on-and-off their interacting partners. Therefore, these 
interactions are harder to detect from a heterogenous cell population. In a cellular 
system, for instance, the changes in biomolecules from proteomics, lipidomics and 
metabolomics are detected globally through LC-MS-based analyses. At the 
genome level, a population’s genome is sequenced either at localized regions or 
on a large scale through deep sequencing. Finally, gene transcripts are quantified 
through target-based approaches (quantitative PCR) or the complete gene 
expression profile is monitored through RNA sequencing (RNAseq). Each of these 
techniques has their advantages and limitations. The main disadvantage is that 
these measurements represent averages from large population of different cells so 
the subtle differences in transcriptional processes are undetectable. By analyzing 
each cell individually these networks and their effects may be drawn out.  
Single-cell approaches simplify the molecular processes but they are 
difficult to conduct due to their small scale. For instance, amplification of genomic 
regions through PCR on minute samples are prone to introduce error from one 
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genomic sample than from multiple samples. However, improvements have been 
made. Microfluidics, for instance, is contributing to these methods through the 
development of droplet microfluids and single-cell printers that gently isolate cells 
for downstream analysis. Flow cytometry and cell microscopy are coming together 
to rapidly monitor specific fluorescently-tagged proteins on a smaller scale. Mass 
cytometry is also a quantitative approach to rapidly detect cellular features. From 
the point-of-view from one cell, there are fewer spatial and temporal 
configurations that the target domain can adopt. In the future, the single cell 
analysis may aid our understanding of how these individual activator-coactivator 
interactions function.  
5.4 Final remarks  
In conclusion, this work has developed selective probes for the CBP KIX 
domain – a highly homologous domain across other transcriptional regulations 
including its homolog p300. From these studies, 1-10, for instance can be a useful 
probe to study the KIX interactions on both MLL-and CREB(pKID)-responsive 
genes. The probes developed in this dissertation provide the framework to 
develop potent and selective probes for other highly homologous targets.  
This work also delved into how dynamic coactivator domain regulates its 
interactions through an allosteric network. The activation of transcription has been 
shown to depend on the binding mechanism between activator-coactivator 
complexes and subtle transitions convey important functional responses. For 
instance, this work demonstrated that positive cooperativity may result from an 
extended interaction time with CBP/p300 possibly resulting in an increase in the 
transcriptional output. However, additional work is required to understand how 
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PPIs such as KIX and its activators function in cells (Figure 5-6). 
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Appendix I Unfinished business: Addressing the cellular requirements 
for the irreversible Tethering strategy 
I.1 Abstract 
The concerted effort between DNA-bound activators and coactivators 
mediate the activation of specific genes. However, these individual activator-
coactivator interactions and their contributions to transcription remain unclear. In 
Chapter 4 we developed irreversible probes to selectively target the KIX domain 
of CBP and its interactions with activators including MLL, CREB (pKID), and c-
Myb. Probes that selectively target a KIX N627C cysteine mutant were developed 
using an irreversible Tethering scheme, but the cellular systems must contain the 
mutation within KIX to use these probes in cellulo. We proposed to introduce or 
generate this mutation using the CRISPR/Cas9 genome editing techniques.  
I.2 Introduction 
The human genome is as important as the regulation of its genes. Genome 
engineering tools that directly and specifically target regions of the genome are 
valuable to understand details about gene expression and regulation.1 In 2012 a 
CRISPR/Cas9 system modified specific regions of the genome in mammalian 
cells.2-4 The type II Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR) Type II system involves the co-expression of the CRISPR-associated 
endonuclease (spCas9) from Streptococcus pyogenes and guide RNA (gRNA).5,6 The 
Cas9 ribonuclease in complex with a guide RNA strand specifically recognizes 
DNA through a protospacer motif (PAM) and creates a double-stranded break 
(DSB).2,7-10 Homology directed repair utilizes a single-stranded template to 
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generate the desired insertions, deletions, or mutations directly into the target 
region.9,11-13 We proposed to generate the necessary KIX cysteine mutant using this 
technique.  
I.3 Results  
Single guide RNAs (sgRNAs) were designed to induce a DSB as close to the 
cysteine mutant as possible within CBP or p300 KIX.5 They cleaved their target 
DNA based on an in vitro Cas9-sgRNA cleavage assay (Figure II-1). However, the 
                                                 
5 As the DSB moves further than 7 bases away from the mutation site the efficiency of HDR starts 
to decrease.  
Figure I-1 In vitro endonuclease cleavage assay to target the KIX gene  a) The scheme of this assay 
involves incubating Cas9 with the RNA to form the ribonucleotide-protein complex and then 
adding the DNA with the target sequence. b) The endonuclease reactions were visualized on a 2% 
agarose gel. The PCR products amplified from the HEK293T genome contained the target 
sequences for the CBP and p300 KIX gene. For p300 KIX both sgRNAs cleaved the target sequence 
but sgRNA 2 was more efficient than sgRNA 1. For the CBP KIX sgRNA 1 recognized and cleaved 
the target. The sgRNA 2 likely degraded because its band was missing at 100 bp. 
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cleavage wasn’t evident in cells either by the visualizing the amplified DNA 
regions with the DNA gel and T7 endonuclease I (T7EI) cleavage assay or by 
Sanger sequencing.9,14,15 To monitor Cas9 delivery into cells N- and C-terminal 
enhanced green fluorescent protein (eGFP)-tagged Cas9 constructs were 
introduced using commercially available lipid-based transfection reagents 
(Lipofectamine 2000, Thermo Fischer Scientific) or through electroporation.16-18 By 
flow cytometry the eGFP constructs entered a small fraction of cells providing a 
strong signal, but cell viability was poor. While the eGFP constructs retained their 
ability to cleave their targets in vitro their efficiency was lower than the untagged 
Cas9 endonuclease (Figure I-2). Therefore, this process requires additional 
Figure I-2 Comparing the cas9 constructs using the in vitro endonuclease 
cleavage assay  The three different Cas9 proteins (without eGFP, an amino-
terminal eGFP and carboxyl-terminal eGFP) incubated with sgRNA2. The DNA 
target was an amplified region of the CBP KIX gene and added to the Cas9-sgRNA 
complexes. The Cas9-tagged eGFP constructs cleaved the target DNA, but Cas9 
alone was more efficient. 
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optimization in both its design and implementation.  
I.4 Discussion and Future Directions 
Most notably, the sgRNA design is critical to the success of the genome 
editing experiment. The Cas9 and sgRNAs are generally more efficient at targeting 
the first couple of exons within a gene.19 Two sgRNAs can also work in tandem to 
cut at different regions of an exon and increase the efficiency of knocking out the 
gene. These types of experiments have also been designed. With this scenario upon 
targeting the first exons of CBP or p300 the respective coactivator would be 
reintroduced using a mammalian expression vector encoding the coactivator and 
KIX cysteine mutant. Other RNA-guided nucleases have also been applied for 
genome engineering purposes. These nucleases are designed to vary how or where 
the target is cleaved and they are often driven by different protospacer adjacent 
motif (PAM) preferences. While more prediction tools are being developed, 
difficult DNA targets are successfully cleaved by comparing many different 
guides to find the most efficient or fragile DSB region. For spCas9 the guide 
sequence is around 19 bases and the target strand must contain the sequence, NGG 
on the 3’ side where N is any base pair and G is guanine.4 The PAM for 
Acidaminococcus and Lachnospiraceae Cpf1, for instance, is TTN on the 5’ side of the 
target where T represents thymine. Cpf1 also generates a staggered cut with a 5’ 
overhang. These types of cleavages are also seen with transcription activator like-
effector nucleases (TALENs) and they allow for precise genome edits. With blunt 
DSB the cells must be dividing to introduce the mutation through HDR and some 
tinkering with these cells increase the editing efficiency such as using NHEJ (Ku) 
pathway inhibitors or synchronizing cell division and timing the delivery of the 
Cas9-sgRNA components. With the overhangs, the desired edit occurs through 
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non-homologous repair end joining (NHEJ) throughout the cell cycle.   
As we observed spCas9 is fussy about its delivery and function in 
mammalian cells. It is a bacterial enzyme so it is not designed for the complex 
mammalian cell. The first improvements to Cas9 have made it more specific. Cas9 
has a very high affinity for DNA (dissociation constant, KD of 1.2 ± 0.1 nM) and it 
remains localized to DNA searching for a matching sequence.13 Mutations within 
Cas9 reduce its high affinity for the DNA target to decrease off-target cleavages. 
When Cas9 lingers in the nucleus the number of off-target effects increase. To 
reduce these potential off-target cleavages, mammalian expression vectors for 
Cas9 contain an inducible promoter to limit the expression of Cas9. Finally, a more 
soluble Cas9 protein increases the nuclease activity in cells as claimed by different 
companies through undisclosed modifications. Excitement surrounded the 
discovery of Cpf1 because it is significantly smaller and easier to introduce into 
mammalian cells.20-22  
Finally, the validation of the mutation as well as off-targets are important 
to properly and responsibly employ these genome-editing strategies. Since these 
approaches have rapidly evolved over the last few years the validations fall to the 
discretion of individual research groups and their peer reviewers. Some argue that 
modified cells should be verified by deep sequencing of the entire genome and/or 
of the expressed genes (RNA-seq) while others find this excessive. So far, the 
minimal requirements are to provide sequencing results for the genomic regions 
that are related to any genotypic and phenotypic conclusions from the study. 
Straight-forward assays detect insertions or deletions (indels) triggered by RNA-
guided DNA nucleases use the T7 endonuclease I or analogous Surveyor nuclease 
which cleave mismatches or bulges in double-stranded DNA.15 A robust and clean 
PCR product from the region of interest is critical to obtain reliable results. Simple 
sanger sequencing of the PCR product also validates the presence of indels. High 
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throughput cloning kits such as the T-Blunt PCR Cloning Kit (SolGent) or TOPO® 
TA kit (Invitrogen) insert the regions of interest into a vector, these insertions are 
screened through colonies, and positive colonies can then be sequenced.  
Although CRISPR/Cas9 genome editing techniques extend into organisms, 
they are broadly used in mammalian cell culture. Mycoplasma testing results is 
one quality-control standard that may be required by peer-reviewed journals. 
Mycoplasma is a well-known contaminant found in cell cultures which can go 
unnoticed due to its small size. Their infection of cells led to misconstrued results 
in certain pathways.23-26 Therefore, researcher must test their cells for mycoplasma 
when they submit research containing data from cell models.  
As these genome engineering techniques advance it will likely become 
easier to directly generate the cysteine mutation and to also target other co-
regulators with our irreversible tethering strategy. 
I.5 Materials and Methods 
I.5.1 Protocol for Cas9 purification  
A pET-based plasmid containing the spCas9 gene from Streptococcus 
pyogenes (Addgene pMJ806, plamsid #39312, deposited by Dr. Jennifer Doudna’s 
Lab)2 was transformed in the E. coli strain RosettaTM (DE3) pLysS competent cells 
(Novagen, Merck Millipore) by means of heat-shock or with Mix & Go Z competent 
cells (Zymo Research). For heat shock transformations 1 to 0.1 μg of plasmid was 
mixed with 50 μl of competent cells. The cells were incubated on ice for 10 minutes, 
placed on a heat block set at 42 0C for 45 seconds, and set on ice for another 2 
minutes. For recovery, the cells were incubated with 950 μl of SOC shaking at 250 
rpm, 37 0C for 1 hour. For Z-competent cells 1 to 0.1 μg of plasmid was incubated 
with 50 μl of with Mix & Go Z-competent cells on ice for 30 minutes. Then 500 μl 
of SOC was added and the transformation mixture incubated for 1-2 hours at 37 
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0C with shaking at 250 rpm. The cells were collected by centrifugation at top speed 
(14 rcf) for 1 minute in a benchtop microcentrifuge. The cell pellet was suspended 
in 100 μl of SOC, they were plated on a LB agar plate containing 25 μg ml-1 
kanamycin, and the plate incubated overnight (16 to 18 hours) at 37 0C.  
For expression of Cas9 protein, 50 ml of LB containing 25 μg∙ml-1 kanamycin 
and 34 μg∙ml-1 chloramphenicol was inoculated with one white colony in a 250-ml 
baffled flask (Bellco Glass Inc.) and grown overnight at 37 0C, 250 rpm. The culture 
was visible cloudy after 18 hours and 10 ml of this starter culture was used to 
initiate growth in a 2 L baffled flask containing 1 L of Terrific broth (24 g yeast 
extract, 12 g tryptone, 4% glycerol, 100 mM potassium phosphate buffer) and 25 
μg∙ml-1 kanamycin and 34 μg∙ml-1 chloramphenicol. The cultures incubated at 37 
0C, 250 rpm until the OD600nm reached between 0.6-1 then the temperature was 
reduced to 20 0C. After 1 hour, a final concentration of 125 μM IPTG was added to 
induce protein expression and left to shake for 12-18 hours. The cells were 
harvested by centrifugation for 15 minutes at 6,000 rpm in a swing bucket rotator 
(Beckman Coulter, JLA 8.1000). The cell pellet was transferred to a 50-ml falcon 
tube and stored at -80 0C.  
The pellet was thawed on ice and resuspended in lysis buffer (50 mM Tris-
HCl, pH 8.0, 1 M NaCl, 20 % glycerol, 10 mM TCEP) containing cOmpleteTM, 
EDTA-free Protease Inhibitor Cocktail Tablet (Roche). The cells were lysed on ice 
by sonication (3 seconds pulse-on, 6 seconds pulse-off at 6 W output) for 10 
minutes or until the solution appeared clarified and homogenous. The soluble 
lysate was obtained by centrifugation at 20,000 g for 30 minutes and incubated 
with Nickel-NTA agarose resin (Qiagen) at 4 °C for 1 hour to capture His-tagged 
Cas9. The resin was washed with 20 resin volumes of wash buffer (50 mM Tris-
HCl, 1 M NaCl, 20 % glycerol, 5 mM imidazole, 10 mM TCEP pH 8.0 at 40C). Cas9 
was eluted with 50 mM Tris-HCl (pH 8.0), 0.1 M NaCl, 20 % glycerol, 10 mM TCEP 
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and 500 mM imidazole.  
Alternatively, the hexahistidine-tagged Cas9 protein was isolated using an 
AKTA Pure 25 L FPLC (GE Healthcare Life Sciences) system with a HisTrap HP 5 
ml (GE Healthcare Life Sciences) column. After sonicating and spinning down the 
cellular debris the soluble lysate underwent a second round of sonication and 
clarification to chew up remaining debris and nucleic acid. This also made it easier 
to pass the lysate through a 0.45 μm filter. After loading the sample with the S9 
sample pump onto the FPLC column, it was washed with lysis buffer until the 
absorbance was stable (± 0.1 mAu) at the baseline for two minutes or until the total 
wash volume reached 50 ml. The protein was eluted with a gradient of 0% lysis 
buffer to 100% elution buffer (50 mM Tris-HCl, 250 mM NaCl, 20 % glycerol, 10 
mM TCEP, 300 mM imidazole, pH 8.0) over 12 column volumes. The peak 
fractions were simultaneously concentrated and buffer exchanged into TEV 
cleavage buffer (20 mM HEPES∙KOH, pH 7, 150 KCl, 10% glycerol, 1 mM DTT, 1 
mM EDTA) using a centrifugal filter (10 – 30 kilodalton molecular weight cut-off, 
Amicon Ultra Millipore). The protein concentration was estimated by measuring 
the absorbance at 280 nm and diluted to 1 mg∙ml-1 with the TEV cleavage buffer 
and 0.5 mg TEV protease was added per 50 mg of protein. The cleavage progressed 
overnight or at least 18 hours, with gently mixing at 4 0C. The protein was spun-
down at 3,000 x g for about two minutes because slight precipitation was visible. 
The soluble, filtered Cas9 was loaded onto the FPLC equipped with a the 5-mL 
HiTrap SP HP column (GE Healthcare)6 and washed with buffer A (20 mM 
HEPES-KOH, 5% glycerol, 100 mM KCl, pH 7, 1 mM DTT). The bound protein 
                                                 
6 Alternative FPLC methods were used during the ion exchange purification step. A 5-ml HiTrap 
Q HP column was placed on top of the cation exchange column and removed after washing out 
the unbound protein. Alternatively, for cation exchange the Source 15S Tricorn (17 mL column 
volume, GE Healthcare) resulted in pure protein using a similar run.  
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eluted using a gradient from 0 to 60% buffer B containing 1 mM KCl over 12 
column volumes (60 ml). Cas9 typically eluted by 50% of buffer B. Cas9 elutes out 
as two prominent peaks and some fractions contained nucleic acids and other 
contaminants. When the ratio of the absorbance at 260 nm and 280 nm 
(Abs260nm/Abs280nm) was less than 0.6 then these fractions were pooled. The 
concentration of protein was determined from the absorbance at 280 nm using the 
extinction coefficients (ɛ) below. Aliquots were flash frozen in liquid nitrogen and 
stored at -80 0C. Properties of the Cas9 constructs are as follows: 
eGFP-Cas9-NLS  MW 187169.91 Da 
   ɛ = 142340 M-1cm-1 
Cas9-NLS-eGFP MW 187169.91 Da 
   ɛ = 142340 M-1cm-1 
Cas9-NLS  MW 160448 Da 
   ɛ = 120450 M-1cm-1 
NLS denotes the nucleoplasmin nuclear localization sequence and eGFP is 
the enhanced green fluorescent protein. The NLS single amino acid code is 
KRPAATKKAGQAKKKK. It was inserted at the carboxyl-terminus of the spCas9 
gene using standard Phusion site-directed mutagenesis following the 
manufacturer’s instructions (Thermo Fischer). The eGFP tag was taken from the 
pMCSG18 plasmid (courtesy of Dr. R. Pricer) and incorporated into the pMJ806-
Cas9 vector with the In-Fusion HD cloning kit following the manufacture’s 
protocols (Clontech Laboratories Inc., Mountain View, CA). 
I.5.2 Preparation and purification of RNA 
The sgRNA was prepared following the GeneArtTM Precision gRNA 
Synthesis Kit (Invitrogen, ThermoFisher Scientific) with modifications. First the 
DNA template was assembled by PCR assembly to create the gRNA DNA with 
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the T7 promoter. Primers were designed based-up the variable 18-20 DNA 
sequence upstream of the PAM.2 The forward primer includes the T7 promoter 
sequence followed by the first 16-20 nucleotides of the target sequence and the 
reverse primer includes the first 15 nucleotides of the crRNA/tracrRNA constant 
region DNA sequence followed by 19-20 nucleotides of the target sequence reverse 
complement. An example of the variable primers is as follows; 
gRNA forward 5’- TAATACGACTCACTATAGCAACTGTCGGAGCTTC -3’ 
gRNA reverse 5’- TTCTAGCTCTAAAACCGTAGAAGCTCCGACAGTT- 3’
The red letters represent the 20-nucleotide target sequence. The primers 
were ordered as desalted and dry standard DNA (Sigma) on 0.025 μmole scale and 
resuspended in sterile, DEPC-treated water to make stocks. The DNA template 
was generated following the GeneArtTM Precision gRNA Synthesis Kit (Invitrogen, 
ThermoFisher Scientific). The PCR product didn’t require purification. 
For the in vitro transcription, the reaction was prepared in the following 
order; 2 μl nuclease-free water, 8 μl of NTP mix (100 mM each of ATP, GTP, CTP, 
UTP), 6 μl of DNA template (~ 0.5 μg), 2 μl of 10x T7 reaction buffer, 2 μl of T7 
RNA Polymerase mix (HiScribeTM T7 High Yield RNA Synthesis Kit, NEB). It 
incubated for 4 hours at 37 0C and the template DNA was digested with 1 μl of 
DNase I (1 U/μl, NEB) for 15 minutes.  
For the RNA purification, a modified solid-phase reversible immobilization 
(SPRI) method was developed with Sera-Mag SpeedBeadsTM Carboxyl Magnetic 
Beads (50 mg/ml, Fisher #09-981-123).27 The beads were prepared in advance by 
washing 100 μl of beads three times with 1 ml TE buffer (10 mM Tris-HCl, 1 mM 
EDTA pH 8.0) mixing well after each addition and isolating the beads on a 
magnetic stand prior to removing the supernatant. After the final wash the beads 
were resuspended in 100 μl of TE and stored in 5 ml of a PEG-NaCl solution (10 
mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0, 1 M NaCl, 20% (w/v) PEG-8000, 0.05% 
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Tween 20) in the dark at 4 0C for up to 3 months. For gRNA purification, the T7 
RNA reaction was brought up to 150 μl with 70% ethanol and incubated with 100 
μl of the modified beads and incubated for 5 to 10 minutes at RT. The beads were 
collected on a magnetic stand for 2 minutes, and the supernatant was removed 
and white particulate appeared on the beads. The beads were washed twice with 
500 μl of 70% ethanol. The beads were left to air dry for 15 minutes and the RNA 
was eluted with 20 μl of nuclease-free water. It was then denatured at 95 0C for 5 
to 10 minutes and allowed to refold slowly at room temperature for one hour. The 
RNA was stored at -200C and the concentration was determined using the 
absorbance at 260 nm. After one month, the quality of the RNA was checked using 
the in vitro cleavage assay.28,29 
I.5.3 In vitro cleavage assay  
The HEK 293T cells were released with trypsin, quenched with 8 ml of PBS, 
collected at 200 xg for 2 minutes, and washed twice with 10 ml of PBS. For the 
DNA extraction, 50 μl of Quick Extraction solution (Epicenter, Madison, WI) per 
50,000 to 2 x106 total cells and incubated for 20 minutes at 65 0C, 20 minutes at 95 
0C, and stored at -20 0C. The concentration of DNA was determined using 
Nanodrop (Thermo Fisher Scientific, Waltham, MA). The PCR reaction was set-up 
by mixing 2 μl of extracted DNA (50 to 150 ng total genomic DNA), 25 μl of 
AmpliTaq Gold® 360 Master Mix (Applied Biosystems by Life Technologies, 
Carlsbad, CA), 1 μl GC Enhancer, 1 μl of 10 μM forward primer, 1 μl of 10 μM 
reverse primer, and water to bring the final volume to 50 μl. The PCR reaction was 
carried-out in a thermocycler set to run at 95 0C for 5 minutes, 30 cycles (95 0C for 
30 seconds, 65 0C for 45 seconds, 72 0C for one minute) and one cycle at 72 0C for 5 
minutes. The annealing step varied depending on the melting temperature DNA 
primers. The PCR reaction was clean-up using a silica-based column following the 
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manufacture’s protocol (Qiagen, QIAprep® miniprep kits).  
For the cleavage assay a 1:1 ratio of Cas9 protein (5 μM) was mixed gently 
with sgRNA in the presence of 2 mM MgCl2 and incubated for 10 minutes at room 
temperature. The cleavage reaction started with the addition of the DNA target 
(50 - 100 ng) and proceeded for up to one hour at 37 0C and its was quenched 
quenching with 1 mM EDTA. Cas9 was digested with 1 μl of Proteinase K (New 
England Biolabs) for 20 minutes at room temperature. The samples were mixed 
with 6xNEB loading dye (2.5% Ficoll®-400, 11 mM EDTA, 3.3 mM Tris-HCl, 
0.017% SDS, 0.015% bromophenol blue pH 8.0 at 25 0C). The control sample 
without sgRNA and cleavage samples ran on 2% agarose TBE DNA gel containing 
0.5 μg/ml of ethidium bromide dye in TBE buffer (Tris-boric acid-EDTA buffer: 
100 mM Tris base, 100 mM boric acid, 2.5 mM sodium ethylenediaminetetraacetic 
acid) for 30 minutes at 120 volts or until the loading dye ran along at least half of 
the gel. The DNA was visualized under UV light.30 
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Appendix II Where bacteria grow, phage strive to be.  
II.1 Abstract 
For biochemical, genetic, and molecular research laboratories bacteria are 
manipulated to generate biological products including proteins and DNA. In these 
settings bacteriophage (from Greek meaning “bacteria eater”) infections are a 
lurking problem. Bacteriophages outnumber bacteria 10 to 1 and infect 
approximately 1023 to 1025 bacteria cells per second in aquatic environments.3-7 
Therefore, any laboratory growing bacteria for research or industrial purposes is 
an attractive environment for phage. Unfortunately, pathogenic phage that target 
bacteria such as Escherichia coli can be detrimental to the progress in these 
laboratories especially when the phage infection goes unnoticed.8 Even small 
isolated infections resulting in low-to-no protein expression may lead researchers 
to spend time optimizing their constructs, expression conditions, or they may 
examine the toxicity of the recombinant protein. Meanwhile the phage is rapidly 
multiplying.9 The purpose of this communication is to define symptoms of phage-
infected bacteria in research laboratories and to recommend preventative and 
decontamination procedures.  
II.2 The physical features of bacteriophages 
The basic definition of bacteriophage is a virus that uses bacteria to replicate 
itself. Phages are extremely small ranging between 50 to 200 nanometers (nm) in 
length and the width of the head is between 50-90 nm.8 Therefore, they are only 
visualized using specialized techniques such as transmission electron 
microscopy.3 The majority of phages consist of a head attached to a tail. The head 
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or capsid protects its genome from the environment. The tail acts as a transport 
tube to pass its genetic material into the host cell.10,11 The phage genomes range in 
size, structure, and genetic material from either single-stranded or double-
stranded DNA or RNA. The genetic material contains genes for transcriptional 
regulation, replication machinery, lysis and structural capsid proteins. However, 
this description is grossly abbreviated. Bacteriophages are predicted to be the most 
abundant organisms (>1030 phages) on Earth in diverse environments including the 
deep sea, acidic hot springs, alkaline lakes, polar lakes, sewage, and the Sahara 
Desert.12-15 As of 2007 >5,000 phages have been structurally characterized and 
approximately 100 new phages are identified each year.16 Phage and bacteria 
influence the diversity of each other through antagonistic coevolution.17 Phages 
present selective pressures on bacteria. Bacteria mutate or evolve slightly faster 
than phage so bacteria develop resistance or defense against infection. However, 
phage counteract and develop mechanisms to circumvent the bacterial defenses.  
Bacteria are provided with certain fitness factors from phage.1,18,19 For 
instance, prophage find that bacteria should survive stressors such as antibiotics – 
it is in their best interest.20 Phage can pass on antibiotic resistance genes through 
specific transduction.21 Transduction affects bacterial genes through a process 
known as lateral gene transfer (LGT) whereby genetic material is incorporated 
from an unrelated organism.22 When foreign genetic material enters into a 
bacterium, the genes are incorporated into the recipient’s genome and the 
expression benefits the bacterium. LGT requires the right conditions to work. The 
genetic elements risk integrating into essential genes producing inviable 
bacterium. Lateral gene transfer plays a role in antibiotic resistance, but these 
elements are often mobile.1,23 The genome sizes of prokaryotes are limited; as 
bacteria acquire genes non-essential genes are lost.24 This also means that bacteria 
may evade infection from one type of phage, but loose immunity against a 
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previous type of phage.  
II.3 The life cycle(s) of bacteriophages  
Phage survive and propagate through six general steps (Figure II-1). For 
infection most phages target bacteria with receptor binding proteins located on 
their tails that chemically complement surface receptors such as polysaccharides 
and lipopolysaccharides on bacteria.25,26 Once hitting their target, phages adsorb to 
host cells, and eject their genomic material into the bacterium.27,28 This 
transduction process is the rate-limiting step for phage infection and so far phage 
Figure II-1 Phage life cycle is generally described in six steps for phage that are temperate and 
virulent. 1) Adsorption. Phage recognize their target through receptors 2) Injection. They inject 
genetic material into the bacterium host. 3) Lysogeny. Depending on the phage type and 
environment they may conserve their genetic material in a dormant state. 4) Replication. During 
the lytic cycle phage hijack, bacterial transcriptional machinery. 5) Assembly. New phage particles 
form. 6) Lysis. As they assemble, enzymes breakdown the bacterial cell wall and release new 
progeny.     
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have lacked the ability to improve upon their strategy.      The next step in a phage 
infection depends on whether the phage is virulent or temperate. For lytic phages, 
they proceed to produce phage progeny and then escape from the bacteria cell to 
start new infections. Once the phage genetic material is inserted into the cell, the 
bacterial machinery is hijacked to replicate phage genomic material and to 
produce phage proteins. New phage particles assemble and build-up in the cell. 
Enzymes such as lysozyme degrade the peptidoglycan layer of bacterial cell wall. 
The proteins responsible for lysis are usually expressed in the late-stage of the 
infection and eventually cause the cell to burst and to release new phage particles. 
Filimentous phages (M13, Pf3) are unique because they can escape the bacteria 
through the cell membrane leaving them intact.29 Phages with complex, double-
stranded DNA genomes (>15 genes) such as T1 have holin-endolysin systems.30 
Holin is a hydrophobic protein that inserts into the bacterial membrane forming 
lesions.31 Endolysin is a peptidoglycan hydrolase that attacks the cellular wall. In 
the presence of holin and endolysin bacteria cells lyse within seconds. The burst 
size (30-300 phages) and latent time (20-100 minutes) required for lysis depends 
on the type of phage and the environment.32,33 For instance, T-odd phages have 
latency phases from approximately 15 to 45 minutes and burst sizes of 100. The 
phage fitness depends upon the lysis time and burst size which phage tries to 
balance. For instance, phage with fast lysis times release few particles. They can 
potentially infect more bacteria, but only if they efficiently recognize and infect 
their target. For T1 phage about 1% of the new particles successfully infect a 
competent bacterial cell.  
Temperate phages proceed through a lysogenic cycle. After adsorption, it’s 
genetic material exists as a plasmid or incorporates into the host’s chromosome 
resulting in a prophage. Lysogenic bacteria pass the prophages on to daughter 
cells. The prophage may lose the ability to excise from the bacterial genome 
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resulting in cryptic prophages. The cryptic phages are acquired more slowly than 
the differentiation of bacterial strains because bacteria from the same strain can 
contain different sequences within prophage sequences. The prophage decay into 
cryptic phages occurs through mutations within essential genes or introduction of 
stop codons.1 Not all phages such as the ecoliphage T7 generate prophage. 
Lysogeny is a dormant state often viewed as a long-term survival 
mechanism.34 When the bacteria experience adverse conditions including 
exposure to UV, chemicals, or stress then the dormant phages enter the hostile, 
lytic cycle. During an initial phage infection, when the bacteria colonies are 
numerous so the lytic life cycle allows the phage to propagate rapidly. However, 
as the bacteria population decreases the phage have fewer hosts. Instead of 
eradicating the bacteria and risking extinction themselves, phage enters the 
lysogenic life cycle for self-preservation.  
The transition from lysogenic to lytic cycles is an important process. 
Lysogenic phage needs to transition to the lytic cycle so they often hijack the 
bacterial SOS genes. The SOS genes are responsible for the bacterial response to a 
crisis such as DNA damage. Lysogenic phage uses SOS to excise itself from the 
bacterial genome and cell. Recently phages have also been shown to communicate 
amongst themselves reporting on the infection environment. Specifically, the 
Bacillus subtilis is prone to infection by a phage virus known as phi3T.35 The phi3T 
phage encodes a protein AimP that is enzymatically cleaved to release a 6-residue 
peptide fragment. This fragment known as arbitrium is released from the bacteria 
cell and taken-up by a neighboring bacterium through the oligopeptide permease-
transporter protein. As the levels of arbitrium increase in bacteria then the 
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probability of the phage entering the lysogenic cell cycle increases.35  
II.4 How to identifying a phage infection? 
Of course, good laboratory hygiene is the best preventative against phage 
infection. Bacteria cultures should be conscientiously contained, bleached, and 
promptly disposed of (Figure II-2). The most common sources of contamination 
include pieces of equipment that contact bacterial cultures at any time including 
such as pipettes, incubators, filters, room aeration systems, buffers, culture flasks, 
and electroporation devices. Phage -infections are observed more frequently in 
warm, humid climates rather than in dry, cold ones. In areas with significant rain, 
airborne pathogens are grounded so phages infections are less common in rainy 
Figure II-2 Preventing phage infections  Above is an example where flasks and tubes containing 
residual bacteria cultures have been left in a sink for an extended period in a high-risk area due to 
past known phage-infected bacteria cultures. 
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environments.8      Even with good hygiene phage infections occur. They depend 
upon bacteria to propagate so it takes only one phage particle to create a wide-
spread infection.36 Extensive and chronic phage infections result in slower bacterial 
growth rates and significant lysis of cells. If the population of infected bacteria cells 
is low, then the bacteria cultures grow at an expected rate and appear normal. As 
the cells lyse and release latent phage, the culture rapidly turns clear due to the 
bacterial cell lysis. Even if only a few bacteria cells are infected the percentage can 
rapidly increase to 100% within 30 minutes depending on the nature of the 
infection.8 A distinctive foam on cultures develops due to the presence of bacteria 
proteins. A healthy, aerated bacterial culture also develops foam; however, the 
foam dissipates after the culture rests for a few minutes. Phage-infected bacteria 
cultures also decrease their production of carbon dioxide, and maintain constant 
alkaline pH rather than decreasing in pH.9 Sting-like material is visible in the 
culture. When infected cultures are harvested the bacterial pellets appear small, 
loose, and sloppy (Figure II-3). Some infections may result in minimal lysis, but 
disrupt the metabolism of bacteria causing slower growth rates and decreasing 
protein production. With some prophages the bacteria grow more slowly and 
decrease production of desired materials. These infections are problematic because 
they are difficult to attribute to phage infections. Researchers may question the 
health of their competent bacteria stocks or the protein-expression plasmid 
constructs to the slow growth and to the low protein production, respectively. 
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Alternatively, phage may provide bacteria with additional fitness factors and the 
lysogenic bacteria grows faster. On solid agar plates, bacterial lawns may form 
phage plaques.37,38 Although bacteria may harbor phage visible formation of 
plaques is depends on the type of phage, the adsorption rate, lysis timing, and 
burst sizes.39-41 
II.5 Cleaning-up after phage    
In general phage is difficult to destroy. The capsid proteins protect the 
genomic material and even without the capsid the genomic material can infect 
competent E coli cells. Phage range in structure and genomic material so some 
phages are easier to eradicate than others. Phage such as ecoliphage T1 survive 
Figure II-3 Indicators of a phage infection  The RosettaTM (DE3) pLysS E. coli (Novagen, 
Merck Millipore) cells were grown in 1 L of terrific broth for 24 hours and collected at 7,900 
xg for 15 minutes. The cellular debris sloshing off the side of the tube and from the pellet 
indicates lysis due to phage-infected bacteria 
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many years in dry, hot environments. Working with bacteria next to a Bunsen 
burner is controversial as a sterile technique to prevent phage infections. Some 
phages survive the brief exposure to heat and the updraft from the burner makes 
phage such as desiccated T1 airborne. Ultra-violet light irradiation is the most 
powerful method to destroy the phage’s genetic material. Otherwise heat 
treatment (200 0C for at least 8 hours) is an effective treatment to destroy common 
phages.  
As previously, mentioned phages are extremely small. Therefore, sterile 
filtering liquids through a 0.2 μm pore-size filters aren’t effective methods to 
eliminate phage from media and other biological solutions.8 These filters are useful 
to separate phage from bacteria which can’t pass through these filters.   
Disinfectants can destroy phage by penetrating the capsid and damaging 
the genomic material, however they should be used with caution. Since phages 
vary in structure and genomic material their sensitivity to disinfectants vary.42 
Some phages are prone to aggregation so a fraction of them survive chemical 
treatments. Basically, any biocide needs to be tested for its effectiveness against 
the phage-of-interest. For instance, tailed phages from the Myoviridae and 
Siphoviridae family containing double-stranded DNA ranging in 50 kbp or 25-170 
kb, respectfully range in their susceptibility to disinfectants. Treatment of 75% 
ethanol is effective against Myoviridae-type phage, but harmless against 
Siphoviridae phage.43 The chlorine-releasing disinfectant agent, sodium 
hypochlorite at 25000 ppm is ineffective at destroying either Myoviridae or 
Siphoviridae. However, sodium hypocholorite does appear to target Pseudomonas 
aeruginosa PAO1 phage F116, Lactobacillus casei and Lactobacillus paracasei phages 
at <5ppm or 800 ppm, respectfully. Virkon (1%) rapidly inactivated Myoviridae and 
Siphoviridae upon contact and destroyed them within 10 minutes.43 Virkon is the 
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most effective disinfectant for broad-spectrum deactivation of viruses.  
Phage infections may also be inhibited with chemical treatments.44,45 
Vitamins including vitamin E and K at 10-5 M has shown to provide >90% 
inactivation. Ascorbic acid is also selectively toxic to phage, but not bacteria by 
forming single-stranded breaks in DNA-containing phage such as ecoliphage T7 
after 20 minutes of exposure.46,47 
Since phages are limited to recognizing features on the membrane of 
bacteria for infection bacteria strains may be varied to prevent pathogenic phage 
from taking over production. Dairy industries often vary the type of bacteria used 
to make cheese and other cultures.48 Therefore, phage with specific receptor 
binding proteins are unable to infect the new type of bacteria. For research 
laboratories, strains of bacteria are available that harbor deletions of 
outermembrane proteins recognized by T1 and T5 phages including deletions of 
FhuA or tonA. The FhuA deletions confers resistance to T1, T5, and f80. For instance, 
T1, T5, and ɸ80 coliphages recognize FhuA, an outer membrane ferrichrome iron 
receptor of E. coli to adsorb to the host so without this receptor phage cannot bind 
to E. coli. The tsx deletions confers resistance against phage T6 and colicin K. These 
bacteria have been genotyped and tested so they are arguably well-suited for 
industrial and research purposes.49 
Very dense bacteria cultures likely contain genetic heterogeneity due to 
bacteria mutation rates. At least endogenous bacteria mutation rates are faster 
than phage so phage must adapt to bacterial defenses. Mutant bacteria propagate 
and during a phage infection they may survive. Bacteria survivors often contain a 
point mutation on the cell wall or in structural proteins which disrupt phage’s 
ability to recognize and to infect them. These mutations are often random.50  
These viable mutants may be used to prevent further phage infection, 
however with unknown mutation(s) the bacteria may have other unknown and 
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potentially undesirable properties. This solution also tends to only work 
temporarily. Although bacteria tend to evolve more quickly, phage also evolve 
with their tail fiber genes adapting with highly variable genes and higher mutation 
rates.51-53  
Although this strain should be confirmed by genotyping through pulse 
field gel electrophoresis (PFGE) with restriction enzymes to confirm that the strain 
has not undergone major deletion or rearrangement in comparison to the parent 
strain.54,55Bacteria that come into contacted with weakened phage particles by 
exposing the phage to UV can defend themselves. They either incorporate 
segments of the phage genome to induce their immune-response CRISPR/Cas 
systems. The number of bacteria with these immune responses are limited. They 
also divert energy from producing the desired proteins and biomaterials in high 
quantity.  
Other measures have been developed to prevent phage infections. Bacterial 
strains harboring temperate, lytic phages prevent infection because bacteria 
infected with a lysogenic phage are resistant to infection by the same phage. 
Prophages have superinfection exclusion systems whereby proteins are anchored 
or associated with the bacterial membrane to prevent other phage components 
from accessing the bacterium.  However, the protein production and growth rates 
of these prophage-containing bacteria remain compromised. Although some E. 
coli containing prophages may grow more quickly than non-lysogenic E. coli. Also, 
bacterial growth conditions require optimization to prevent the development of 
lytic phage. Growing bacteria at 37 0C means their growth rates are high (~2 
doublings per hour) during an exponential growth phase. Slower growth at 20 0C 
is less likely to induce lysogenic phage into the lytic cycle. Slower bacterial growth 
also reduces the production of lytic phage.  
In small laboratories containing phage infections should be straight-
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forward if protocols are established and followed to disinfect areas that bacteria 
may encounter. In contrast a phage infection can be catastrophic to the production 
at large bioprocessing plant. A phage-based detection assay may aid in detecting 
small phage infections and preventing the spread of infections. Although some 
methods require the use of the bacterial host to propagate the virus.  
II.6  The good qualities of bacteriophage      
The phage and bacteria arms race is the oldest and, in my opinion, a 
fascinating antagonist co-evolution story which is in constant development 
(Figure II-4). Despite detesting the phage’s disruption on bacteria, the coexistence 
of bacteria and phage has greatly improved our environment by impacting areas 
such as pharmacy, biotechnology, food production, and genome engineering.  
Biotherapy and human health.    Phage were first observed by Frederick 
Twort when he observed that an unknown agent was disrupting bacterial growth. 
Then Felix d’Herelle in 1915 reported on an “anti-microbe” that was destroying 
dysentery bacillus in patients. 56 Early work with phage looked at its potential as a 
Figure II-4. Bacteria are infected by phage, but they adapt strategies to fight off phage 
infection. Meanwhile phage develop mechanisms to circumvent bacterial defenses. The 
antagonistic coevolution relationship between phage and bacteria is referred to as the 
phage-host arms race which started > 3 billion years ago.1,2 
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therapy; however, phage therapy posed efficacy, selection, and immunogenic 
challenges. Meanwhile broad spectrum antibiotics were developed that eradicated 
most pathogenic bacteria. Although phage therapy has been used in Eastern 
Europe, other Western countries remain skeptical. They are after all viruses and 
pose many challenges and risks. For instance, virulent phages trigger lateral gene 
transfer and may release toxins triggering autoimmune responses. With the rise of 
antibiotic resistant infections, the development of phage-based therapies has 
revitalized with new phages being identified and tested.57-59 Phages kill one species 
or a strain of bacteria limiting their effectiveness.60 By modifying phage therapy 
approaches, phage strategies have the potential to kill or to weaken antibiotic-
resistant bacteria.59 For instance, the phage ɸAPCEc03 targets a broad range of E. 
coli strains infecting 9 out of the 16 tested strains. Phage ɸAPCEc0 targets two 
bacterial genera including three E. coli strains and a Shigella sonnei strain, 
responsible for diarrheal diseases. A phage cocktail including ɸAPCEc03 and 
ɸAPCEc0 isolated from human fecal samples targets a broader spectrum of 
bacteria and completely disturbs E. coli growth in a biofilm by 4-fold after 24 hours. 
Phage-based therapies have been inefficient because bacteria survive the infection 
likely due to bacteriophage-insensitive mutants (BIMs). After 48 hours E. coli 
began to recover in the presence of phage cocktail such as ɸAPCEc03 and 
ɸAPCEc0. 61 In this case combining the ciprofloxacin antibiotic the phage cocktail 
efficiently reduces E. coli growth and limits the emergence of antibiotic- and 
phage- resistant cells. Over the last few years the emergence of novel antibiotics 
phage therapy has the potential to increase the effectiveness of the existing 
antibiotics. In another case the vancomycin-resistant enterococci bacteria are 
difficult to control in hospitals, but this bacterium is selectively targeted by phage. 
However, pathogenic bacteria also become resistant to the phage overtime. An 
effective antisense therapy efficiently targets vancomycin-resistant infections by 
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targeting vancomycin-resistant genes in bacteria.60  The treatment is difficult to 
deliver. Phage provide a structure to deliver to carry genetic material into bacteria. 
These synthetic biology approaches would use phage-based treatments as a 
supplement to antibiotics. The phage constructs target or deliver bacterial factors 
that enhance an antibiotic’s effectiveness and prevents antibiotic-resistance. These 
therapies require additional improvements such as producing non-replicative 
phage to prevent the release of toxins and autoimmune responses. The selectivity 
and delivery may also become more effective by displaying various phage tail 
proteins.62 Finally, these therapies require testing different strains and bacterial 
gene targets before applying them as human-based strategies.60 
The co-existence of phage and bacteria is also important to the human 
microbiota. The heathy human microbiome contains up to 1013 bacteria per gram 
and consequently phage effect the bacterial environment either negatively by 
challenging bacteria or positively by providing bacteria with fitness factors. 
Healthy adults contain the well-known Siphoviridae, Myoviridae, Podoviridae, and 
Microviridae as well as many diverse, and novel viruses.63 Diet and environment 
form the diverse phageome. The microbiota starts developing at birth with the 
mother.  
Differences in the microbiota exist in patients with chronic diseases such as 
Crohn’s disease, irritable bowel syndrome and ulcerative colitis. The phageome 
differs dramatically between healthy and unhealthy individuals. Crohn’s disease 
patients have a 24-fold higher proportion of virion-like particles than healthy 
patients in mucosa biopsies. The phage varies between locations too so the ileum, 
colon, and bowel contain different populations. Probiotics and diets promote a 
healthy microbiota, but not everyone responds to this treatment.  Selective 
pressures exerted by natural occurring phages may be the missing factor for these 




Diagnostics.     The phage-host system is rapid and sensitive so they are 
exploited to detect the presence of bacterium for diagnostic purposes.64 These 
assays provide the presence and identity of bacteria. For instance, phage is 
manipulated so during an infection they are biotinylated in vivo. If the 
streptavidin-coated beads capture biotinylated-phage particles then the specific 
bacterium is present in a complex sample are detected by isolating the phage 
particles on streptavidin-coated beads. This platform is highly efficient since the 
rapid phage bursts increase the limit detection (102 CFU ml-1 with the model T7 
and E coli).65 Typical phage-system assays for bacteria use plaque assays involving 
bacterial isolation and cultivation that require 24-36 hours to complete.  
These diagnostic tools are especially useful to detect possible attractive 
bioterrorism agents. Category A bacterial pathogens include Yersinia pestis and 
Bacillus anthracis undergo a rapid clinical course with high mortality rates. The B. 
anthracis spores are inhaled or ingested by contaminated food or water supply. 
Anthrax symptoms are similar to other ailments, but the disease progresses 
rapidly. If not treated within 24 hours, it is fatal. Y. pestis comes in different forms; 
classical bubonic (lymph nodes), pneumonic (lungs) and septicemic (blood 
vessels).66 Recombinant reporter phage assays provide rapid and specific 
approaches to potentially save lives. A recombinant “light-tagged” reporter phage 
assay uses phage-specific for Y. pesitis and B. anthracis with integrated vibrio haveyi 
luxAB genes into their genome. When the reporter phage recognizes the target, it 
confers a bioluminescent phenotype to recipient cells. The signal is rapidly 
measured in a microplate luminometer and by using 96-well microtiter plate the 
assay becomes high-throughput.67 This assay is also used to detect whether an 
antibiotic effectively kill the bacterium.68 
Phage display applications.      Filimentous phage (M13 or fd) and T4, T7, 
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and lambda phage inspired the development a biotechnique known as phage 
display.69 Variable peptides or protein epitopes are expressed on the viron’s 
surface by inserting the corresponding DNA sequence into the phage’s genome. 
Then these phage particles are screened against a target protein. The nonspecific 
binders are washed away and the selected markers are identified by amplifying 
the marker region. Drug discovery, antigen delivery, biomarkers, epitope regions 
and other applications have advanced using phage display. Most notably drugs 
have been successfully developed using phage display including Humulin®(Lilly) 
for diabetes, Vasotec®(enalapril maleate, Merck Shar & Dohme) for hypertension, 
and Prialt® (ziconotide acetate, Elan Pharms) for severe chronic pain.69  
Food production.     Unlike the biological research and industries where 
phage wreak havoc on bacterial-based production bacteria can disrupt food 
production at any stage from the farm to the consumer. These bacteria appear in 
livestock, on equipment and surfaces, and on raw meats and fresh produce. 
Consumers are at risk of exposure to more than 200 known diseases of which many 
are attributed to bacteria including Salmonella, Campylobacter, pathogenic E. coli 
and Listeria monocytogenes.70  Different products have been approved by the FDA 
that contain natural phage cocktails to target harmful bacteria. For instance, in 
2005 AgriphageTM (OmniLytics Inc.) treats bacterial spot caused by Xanthomonas 
campestris or bacterial speck caused by Pseudomonas syringae on crops. In 2006 
ListShieldTM was formally approved to prevent L. monocytogenes in certain foods 
containing meat and poultry. In 2011 EcoShieldTM was first used to target E, coli 
O157:H7 on red meat began before it was ground into hamburgers. SalmoFreshTM 
can be applied to poultry products and other foods to eliminate Salmonella entrica. 
Although “general designated as safe” the concern remains that resistant strains 
emerge over time so phage cocktails are varied and modified in an effort to 
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proactively address potential resistant bacteria.   
Genome engineering.     Bacteria contain a unique immune system to fight 
off phage. A distinct clustered regularly interspaced short palindromic repeats 
(CRISPRs) loci were discovered in E. coli along with CRISPR-associated (Cas) 
proteins. The CRISPR/cas family is diverse. Mainly a bacterium acquires new 
spacers that match genetic regions of foreign phage or plasmid DNA. The spacers 
are clustered by 21 to 48-bp DNA repeats of similar length. Then upon another 
infection the CRISPR/Cas system recognizes the invading DNA or RNA sequence 
and destroys it with an endonuclease. The Cas9 proteins are highly selective and 
efficient at targeting DNA sequences so they present a powerful opportunity to 
manipulate biological systems at the DNA level.71  
The CRISPR/Cas genome engineering applications was first applied by the 
dairy industry where they need to prevent phage-induced destruction of their 
products such as cheese and yogurt. Bacteriophage insensitive mutants (BIMs) 
from the Streptococcus thermophiles lactic acid bacteria are analyzed to replace 
existing bacteria strains and to prevent a hostile phage takeover in the cheese and 
yogurt production. Naturally occurring BIMs contain CRISPR loci as a defense 
against phage and continue to be used to aid the dairy industry. Since the 
CRISPR/cas system has fascinated the scientific community in the last five years, 
the applications and potential for this system have been already extensively 
reviewed.  
II.7 Conclusion 
In some laboratories phage is hated and its presence force researchers to 
clean-up or find other ways to combat its’ bacteria-killing nature. Phage and 
bacteria have co-existed for a long time and neither is likely to become extinct. 
Therefore, we should embrace them and learn how to live around them because 
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we have certainly lived a better life with both of them.  
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